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Summary 
Barrett's oesophagus is a complication of gastro-oesophageal reflux disease and is 
the single most important predisposing factor for the development of 
adenocarcinoma of the oesophagus. New molecular markers are needed for early 
diagnosis and to monitor disease progression. 
Telomerase is a ribonuclear protein with reverse transcriptase activity, which 
uses its own RNA component as a template for the addition of telomeric repeats 
to the end of chromosomes. Telomerase activity has been studied during the 
neoplastic progression of Barrett's oesophagus using a TRAP based ELISA 
technique, which found telomerase to be reactivated early during . disease 
progression. A non-isotopic method of in situ hybridisation for the detection of the 
RNA component of telomerase has also been successfully developed. 
Plasminogen activation is an inducible extracellular proteolytic system involved 
in the regulation of cellular interactions and invasion. The components of the 
urokinase-type Plasminogen Activator system have been fully investigated 
during the progression of Barrett's oesophagus to adenocarcinoma utilising 
immunohistochemistry and ELISA techniques. Changes in the expression of this 
invasive phenotype were found to occur late during disease progression in 
malignant tissues. 
Two-oesophageal cell-lines have been characterised using molecular biological 
techniques to detect a range of molecular markers to produce ex vivo models of 
oesophageal adenocarcinoma and oesophageal squamous cell carcinoma. In order 
to assess the effects of bile salts and acidity on oesophageal tissues these cell- 
lines were then utilised as ex vivo models. Exposure to acidic conditions both 
alone and with bile salts altered the morphological appearance of the cells and 
disrupted adhesion molecules in the cellular membrane. 
Investigations into both telomerase reactivation and the plasminogen activator 
system have provided new information concerning the nature and timing of 
molecular changes during the Barrett's metaplasia/dysplasia/ adenocarcinoma 
sequence. 
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1 Introduction 
1.1 What is Cancer 
The term cancer refers to more than 100 forms of disease. Almost every tissue 
throughout the whole body can spawn malignancy; some can even yield several 
types of tumour. Normal healthy cells within the body live in a complex 
interdependent way regulating one another's rates of proliferation, thus ensuring 
each tissue maintains a size and architecture appropriate to the body's needs. 
Cancer cells in contrast violate these cellular controls resulting in uncontrolled 
proliferation and the formation of cellular masses. A mass of cancer cells within 
otherwise normal tissue is called a tumour. If the tumour remains at this original 
size and does not invade surrounding tissues it is described as benign, whereas a 
malignant tumour spreads to blood vessels and other parts of the body. Tumours 
composed of malignant cells become more aggressive as time passes and become 
lethal as other tissues and organs are disrupted which are essential for the 
survival of the overall organism. Cancer cells may also possess the ability to 
migrate from the site where they initially grew, invading nearby tissues and 
forming masses in distant sites in the body. This spread of cancer cells beyond 
their original site is called metastasis (Weinberg 1996 and Campbell 1993). 
The cancerous cells within a tumour are descended from a common ancestral cell 
that at one point many years before initiated a program of inappropriate 
proliferation. The malignant transformation of a cell occurs through the 
accumulation of mutations within two classes of genes. In normal cells these 
genes control the sequence of events leading to the proliferation of the cell. Proto- 
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oncogenes code for protein products that encourage cell growth, division and 
adhesion in normal cells. Mutated forms of these genes in cancer cells are known 
as oncogenes. Changes in the genes that inhibit cell division are also involved in 
the formation of cancer cells. These genes are called tumour suppresser genes, 
because they code for proteins that normally prevent uncontrolled cell growth. 
Collectively mutations in these two classes of genes account for much of the 
uncontrolled cell proliferation in human cancers (Weinberg 1996 and Campbell 
1993). 
The cells of malignant tumours are abnormal in many ways besides the lack of 
self-control over cell proliferation. They may have unusual numbers of 
chromosomes, their metabolism may be deranged, they may cease to function in a 
constructive way and the surface of the cells may change (Campbell 1993). The 
formation of a tumour occurs in stages through the accumulation of 
abnormalities from the single genetically altered cell through hyperplasia where 
the cells look normal, but proliferate too much. Later in addition to proliferating 
too much the cells begin to appear abnormal and are termed dysplasic. Cells that 
have formed a mass, but have yet to break through the tissue boundaries are 
described as a cancer in situ. Once the accumulated genetic abnormalities allow 
the cells to invade the underlying tissues or blood vessels a malignant tumour is 
present (Weinberg 1996). 
16 
1.2 Barrett's oesophagus 
In 1950 Norman Barrett, an influential British surgeon, published a report in 
which he described the oesophagus as "that part of the foregut, distal to the 
pharyngeal sphincter, which is lined by squamous epithelium. " (Barrett 1950). 
Today, an oesophagus lined with columnar epithelium rather than the normal 
squamous epithelium is called Barrett's oesophagus. Barrett's oesophagus is a 
complication of chronic gastro-oesophageal reflux disease and is the single most 
important predisposing factor for the development of adenocarcinoma of the 
oesophagus and gastric cardia. For the rest of this thesis a columnar lined 
oesophagus (CLO) will be refered to as Barrett's Oesophagus. 
1.3 The Oesophagus 
The oesophagus is a segment of the alimentary canal that conducts food from the 
pharynx to the stomach and is approximately 25cm in length. It is lined by 
stratified squamous epithelium and has a submucosa containing the oesophageal 
glands (Hopwood 1989). The normal oesophageal mucosa has a basal layer that 
comprises of proliferating cells and differentiated superficial squamous cells in 
the upper portion of the stratified squamous epithelium. Peristalsis squeezes a 
bolus of food along the narrow oesophagus. Swallowing is initially a voluntary 
skeletal muscle contraction followed by involuntary waves of contraction by 
smooth muscle (Campbell 1993). 
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1.4 History 
Norman Barrett was not the first to describe the columnar lined oesophagus. 
Tileston, a pathologist reported several patients in 1906 who had "peptic ulcer of 
the oesophagus" and noted "the close resemblance of the mucous membrane 
about the ulcer to that normally found in the stomach. " (Tileston 1906). Over the 
next few decades various other people described patients with similar peptic 
ulcers and gastric type columnar epithelium. In 1950 Barrett argued that the 
columnar lined tissue was not the oesophagus, but a tubular segment of the 
stomach that had been tethered in the chest by a congenitally short squamous 
lined oesophagus (Barrett 1950). 
In 1953 Allison and Johnstone argued convincingly that the columnar lined 
structure Barrett had called the stomach was in fact the oesophagus. They 
pointed out that the structure "often contained squamous epithelium islands, had 
submucosal glands and a muscularis propria characteristic of the oesophagus" 
(Allison and Johnstone 1953). Barrett finally agreed that the columnar lined 
structure was in fact oesophagus and suggested the condition be called "lower 
oesophagus lined by columnar epithelium. " (Barrett 1957). 
Over the following four decades concepts regarding the criteria for the diagnosis 
of Barrett's oesophagus have undergone major changes and have therefore lead 
to confusion for both clinicians and investigators alike (Spechler 1996). 
Soon after Norman Barrett's original description Morson and Belcher reported an 
association of adenocarcinoma with the columnar lined distal oesophagus 
(Morson 1952). A causal relationship between Barrett's oesophagus and 
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oesophageal adenocarcinoma was proposed by Alder and is now generally 
accepted (Alder 1963). 
1.5 Epidemiology of Barrett's oesophagus 
Adenocarcinoma of the oesophagus is largely a disease of white males of average 
age 60 years, with ongoing reflux as a risk factor (Skinner 1983 and Cameron 
1997). Analysis of cancer incidence data from 1976-1987 in the United States 
revealed steadily rising rates of adenocarcinomas of the oesophagus and gastric 
cardia. The increases among men during this period exceeded those of any other 
type of cancer (Blot 1991). Powell and McConkey carried out a similar study in 
the UK, which also found the incidence of oesophageal adenocarcinoma was 
increasing from 0.7 to 2.0 per 100,000 between 1962 and 1981 (Powell 1990). By 
1990 adenocarcinomas accounted for nearly half of all oesophageal cancers 
among white men (Pera 2000). 
The prevalence (proportion of existing cases in a specified population at a given 
point in time) and incidence (number of newly diagnosed cases) of Barrett's 
oesophagus are hard to quantify. To estimate these values correctly endoscopic 
surveillance of the total population would need to be carried out. Therefore 
prevalence and incidence values are usually calculated for patients undergoing 
endoscopy for gastro-oesophageal reflux symptoms, which are common in 
patients with Barrett's oesophagus, but some patients will have few or no 
symptoms of reflux. Therefore the true number of cases could be underestimated 
(Cameron 1997 and Altorki 1997). 
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Gastro-oesophageal reflux symptoms are common. It has been reported that 4-9% 
of adults experience daily heartburn and 10-15% of people have heartburn at 
least once a week (Cameron 1997). In one study, the prevalence of Barrett's 
oesophagus was 12% for patients undergoing endoscopy for symptoms of gastro- 
oesophageal reflux (Winters 1987). 
Cameron and Lomboy carried out a study between 1976 and 1989 to investigate 
the development of Barrett's oesophagus. It found that the prevalence of Barrett's 
oesophagus increases with age to reach a plateau by the seventh decade with the 
estimated median age of development of the disease being 40 years. Unlike 
prevalence it was found that the mean length of columnar epithelium did not 
increase with age (Cameron 1992). Evidence suggests that Barrett's oesophagus 
is normally present for more than 20 years before it is diagnosed and sometimes 
this happens only when adenocarcinoma is already present (Cameron 1997). 
Patients with Barrett's oesophagus are predominantly white. The disease is rare 
in black and Asian populations and the ratio is estimated to be between 10: 1-20: 1 
(Phillips 1991). 
1.6 Etiology of Barrett's oesophagus 
The rise in oesophageal adenocarcinoma over the short two-decade time frame 
from 1962 to 1981 (Powell 1990) is a strong argument for environmental factors 
as etiological agents, which could interact with genetic characteristics that define 
personal susceptibility. Because of the strong link between Barrett's oesophagus 
and oesophageal adenocarcinoma and the link between Barrett's oesophagus and 
gastro-oesophageal reflux disease, the risk factors of reflux disease have been 
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implemented as possible explanations for the rise in oesophageal 
adenocarcinomas. 
Familial occurrence of Barrett's oesophagus and oesophageal adenocarcinoma 
occurring in successive generations has been reported. It has even been 
suggested there is an autosomal dominant inheritance for Barrett's oesophagus 
in some families (Fahmy 1993). A study of families of patients with Barrett's 
oesophagus, oesophageal adenocarcinoma and reflux disease was carried out in 
1997 and found that there may be a genetic predisposition to the development of 
reflux in families of patients with Barrett's oesophagus and oesophageal 
adenocarcinoma. For uncomplicated reflux oesophagitis, environmental factors 
appear to be more important (Romero 1997). 
Substantial clinical and experimental evidence supports the importance of pepsin 
and acid reflux in causing oesophageal mucosal damage. The oesophageal mucosa 
is resistant to reflux of acid alone unless it is in high concentrations, but the 
combination of even a small amount of pepsin with the acid causes macroscopic 
oesophageal injury (Vaezi 1997a). 
Duodenogastro-oesophageal reflux is also suggested as a cause of Barrett's 
oesophagus. The duodenal contents suspected of causing oesophageal damage 
include bile acids, lysolecithin secreted in bile and the pancreatic enzyme trypsin. 
Conjugated bile acids are an important constituent of duodenal refluxate and can 
cause oesophageal damage at an acidic pH. Also unconjugated bile and trypsin 
may cause oesophageal mucosal damage in neutral pH values (Vaezi 1997a). 
Experimental work using animal models has implicated a role for bile salts in the 
pathogenesis of Barrett's oesophagus and adenocarcinoma of the oesophagus. 
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Duodenogastric reflux has been shown to occur in normal individuals, especially 
at night. Duodenogastro-oesophageal reflux probably occurs infrequently in 
normal individuals, but evidence is strong that it plays a role in Barrett's 
oesophagus and adenocarcinoma (Marshall 1997). Mucosal damage by bile salts 
depends on the conjugation state of the bile acids as well as the pH of the 
solution. Conjugated bile acids cause damage at an acidic pH, whereas 
unconjugated bile acids as well as the pancreatic enzyme trypsin cause damage 
at a pH higher than 7 (Buttar 2001). 
Cigarette smoking and alcohol have been established as risk factors for the 
development of squamous cell carcinoma of the oesophagus, but their role in 
oesophageal adenocarcinoma is less clear (Kim 1997b). Smoking and alcohol are 
both known to decrease the lower oesophageal spincter pressure a known cause 
of reflux and obesity will predispose to reflux by increasing intra-abdominal 
pressure. Dietary factors, particularly high fat content, can influence reflux 
disease and has been shown to promote the carcinogenic process in a rat model 
(Clarke 1994). An inverse association between fruit and vegetable consumption 
and oesophageal adenocarcinoma has been shown suggesting that the risk of 
adenocarcinoma maybe reduced through dietary interventions (Pera 2000). 
1.7 Gastro-oesophageal reflux disease 
Barrett's oesophagus is associated with gastro-oesophageal reflux disease; 
therefore many patients suffer with heartburn and sour regurgitation. Reflux 
disease has been defined as the response to the injurious effects of duodenal 
contents on the oesophageal mucosa. It is basically an inflammatory and 
reparative phenomenon. The reflux may consist of acid, pepsin, duodenal or 
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intestinal contents, bile, particularly being extremely dangerous (Thompson 
1989, Vaezi 1997a). 
Gastro-oesophageal reflux is a normal physiological event, but can develop into 
Barrett's oesophagus in patients with abnormal reflux. Obesity, cigarette 
smoking, hiatus hernia, alcohol abuse and some drugs amongst other things can 
cause this abnormal reflux (Thompson 1989). Reflux disease results from three 
possible abnormalities: 
9 incompetent lower oesophageal spincter, 
" inefficient oesophageal clearance of refluxed gastric juice, 
" delayed gastric emptying (Coiffi 1998). 
Patients with gastro-oesophageal reflux disease can present a variety of 
symptoms, which can be intermittent or continuous and progressive. These 
symptoms include heartburn and sour regurgitation, retrosternal and epigastric 
pain, cervical discomfort, dysphagia, belching and hiccups, bleeding, coughing 
and asthma. These can lead to complications such as oesophagitis, stricture, 
major bleeding, Barrett's oesophagus and pharyngeal complications (Coiffi 1998). 
Oesophagitis (inflammation of the oesophagus) develops when harmful 
substances in the refluxate come in contact with the oesophageal epithelium for a 
sufficient amount of time to overcome the intrinsic structural and functional 
defences. These defences can be categorised into three groups: 
" the anti-reflux barrier, for example the high pressure zone at the gastro- 
oesophageal junction, 
" efficient clearing of the refluxate, for example gravity, peristalsis and 
swallowed salivary secretions, 
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" epithelial defences, for example scattered submucosal glands that secrete 
bicarbonate (Ter 1997). 
Stricture (narrowing) of the oesophagus is caused by repeated and prolonged 
exposure to acid reflux. This causes severe inflammatory changes, which extend 
through the full thickness of the wall of the oesophagus and are even found in the 
surrounding connective tissue of the mediastinum, causing narrowing of the 
oesophageal lumen (Cioffi 1998). 
1.8 Histology of Barrett's oesophagus 
The endoscopic appearance of the oesophageal mucosa in Barrett's oesophagus is 
typically a pink-red velvety type made up of three distinct types of columnar 
epithelium: (1) specialised columnar epithelium, (2) gastric fundic-type 
epithelium, and (3) junctional/cardia-type epithelium (Paull 1976, Rothery 1986, 
and Phillips 1991). Any one or combination of these epithelia constitutes the 
mucosa of Barrett's oesophagus. These epithelia are examples of metaplasia i. e. 
the histologic change where one adult cell is replaced by another. 
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Specialised columnar epithelium is the most common from of mucosa in Barrett's 
metaplasia (Paull 1976, Offner 1996). It has a villiform surface and crypts that 
resemble the intestinal mucosa, with intestinal-like goblet cells (which secrete 
mucus) and columnar cells (Spechler 1986). Columnar epithelium represents 
incomplete intestinal metaplasia, because it lacks the intestinal absorptive cells 
and is functionally immature (Phillips 1991). 
Fundic-type epithelium resembles the mucosa of the stomach. The surface is 
pitted without villi and is lined by secreting cells and glands containing mucus- 
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secreting cells, parietal cells (which secrete hydrochloric acid) and chief cells. 
There are no goblet cells present (Spechler 1986, Phillips 1991). 
Junctional/cardia-type epithelium resembles the mucosa of the gastric cardia. 
The surface is pitted and the glands are lined almost exclusively by mucus 
secreting cells (Spechler 1986, Phillips 1991). 
These types of epithelium seem to exist as zones within Barrett's metaplasia. 
Specialised columnar epithelium usually appears adjacent to the normal 
squamous mucosa in the proximal segment of the Barrett's oesophagus, whereas 
junctional epithelium occurs more distally, with the fundic-type mucosa blending 
in with the normal gastric mucosa of the cardia (Phillips 1991). The type of 
epithelium and dysplasia cannot currently be identified by its endoscopic 
appearance. 
1.9 Dysplasia 
Dysplasia is defined as the abnormal development of tissue. Histologically, 
dysplasia is a benign neoplastic change characterised by architectural and 
cytological abnormalities (Antonioli 1997). Architectural changes include 
glandular crowding, papillary infoldings and the mucosal surface may have an 
exaggerated villiform conformation. Cytological changes include nuclear 
enlargement, large and abnormally shaped nucleoli, abnormal mitosis and 
cellular dedifferentiation (Antonioli 1997). Dysplasia in Barrett's oesophagus can 
be classified as low or high grade depending on the degree of abnormality. Many 
observers believe that virtually all oesophageal adenocarcinomas arise from these 
dysplasias. 
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1.9.1 Low grade 
When viewed histologically under the light microscope low grade dysplasia 
contains nuclei which are slightly enlarged, elongated, crowded, and stratified. 
Mucous secretions are markedly decreased and the abnormalities extent to the 
mucosal surface (Haggitt 1994). Architectural changes in low grade dysplasia are 
minimal. 
1.9.2 High grade 
When viewed histologically under the light microscope high grade dysplasia 
contains nuclei which are more enlarged, and contain prominent nucleoli. They 
also show a loss of nuclear polarity i. e. the long axis of the nucleus is not oriented 
perpendicular to the basement membrane (Haggitt 1994). The abnormalities 
extend to the mucosal surface. There are extensive architectural changes in high 
grade dysplasia. 
Adenocarcinoma in Barrett's oesophagus develops through stages of increasing 
severity of dysplasia (van Sandick 1998). Dysplasia is found more commonly in 
specialised columnar epithelium associated with adenocarcinoma compared with 
benign Barrett's oesophagus (Menke-Pluymers 1994). 
1.10 Short-segment Barrett's oesophagus 
Traditionally, Barrett's oesophagus is defined as "the replacement of the distal 
oesophageal lining by three or more centimetres of columnar epithelium in 
continuity with the gastric mucosa" (Skinner 1983). This definition however does 
not cover tongues or patches of columnar epithelium, which are often seen at the 
gastro-oesophageal junction (Stein 1993). In patients that fail to fulfil the 
26 
traditional definition, the presence of specialised intestinal epithelium at the 
gastro-oesophageal junction has been defined as short-segment Barrett's 
oesophagus (Haggitt 1994 and Nandurkar 1997). 
It has been shown that dysplastic gastro-oesophageal junction nodules can be a 
precursor to junctional adenocarcinoma. Gastro-oesophageal junctional 
adenocarcinoma may occur through increasing stages of dysplasia in small foci of 
intestinal metaplasia or in the mucus glands of the distal oesophagus without the 
presence of Barrett's oesophagus (Gangarosa 1999). 
1.11 Barrett's oesophagus in childhood 
Barrett's oesophagus is a rare disorder in children. This could be due to the fact 
that Barrett's oesophagus is an acquired disorder, that results from prolonged 
exposure to severe gastro-oesophageal reflux. Gastro-oesophageal reflux is a 
common disorder and the incidence has been estimated to be 18% in the infant 
population (Faubion 1998). In those relatively few children with Barrett's 
oesophagus there appears to be a high prevalence of serious coexisting disorders 
such as neurologic impairment, chronic lung disease, oesophageal atresia and 
malignancies treated with chemotherapy (Hassall 1997). The presence of a 
columnar lined oesophagus in childhood is often regarded as a congenital 
anomaly rather than as a consequence of gastro-oesophageal reflux (Dahms 
1984). 
Adenocarcinoma of the oesophagus is largely a disease of white males of average 
age 60 years, with ongoing reflux as a risk factor (Skinner 1983 and Cameron 
1997). However, adenocarcinoma of the oesophagus in Barrett's oesophagus does 
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occur in children and young adults (Hassall 1993). In 1993 Hassall et al 
documented 10 patients aged between 11 to 25 years who had adenocarcinoma of 
the oesophagus (Hassall 1993). 
The clinical expression of Barrett's oesophagus in children is similar to that of 
adults except that strictures appear to be more common in children and the 
endoscopic appearance of the mucosa is not the typical pink-red velvety type seen 
in adults (Hassall 1985). Also there is still an unexplainable dominance of males 
in childhood cases of Barrett's oesophagus similar to that found in adult cases 
(Hassall 1985). 
1.12 Oesophageal adenocarcinoma 
It is estimated that 10-40% of all oesophageal cancers are associated with 
Barrett's oesophagus (Skinner 1983). Barrett's oesophagus is a strong risk factor 
for the progression to adenocarcinoma of the oesophagus (Pera 1993, Cameron 
1995,1997). Barrett's oesophagus is associated with a 30- to 125-fold increased 
risk of developing oesophageal adenocarcinoma (Stein 1993). This risk seems to 
be related to the presence of specialised intestinal type epithelium, and not to the 
junctional or cardia types (Skinner 1983, Hamilton 1987 and Pera 1993). In 
particular patients with specialised columnar metaplasia (Peters 1998), dysplasia 
(van Sandick 1998) or long stretch (>8cm) Barrett's oesophagus (Iftikhar 1992) 
are at a higher risk of developing adenocarcinoma of the oesophagus. A study 
carried out by van Sandick et al supports the theory that adenocarcinoma 
develops through stages of increasing severity of dysplasia (van Sandick 1998). 
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1.13 Barrett's oesophagus and extra-oesophageal malignancies 
An increased risk of extra-oesophageal cancers in patients with Barrett's 
oesophagus, specifically of the head, neck, respiratory system and colon have 
been observed associated with smoking and alcohol abuse (Altorki 1997). A study 
carried out in 1985 reported an association between Barrett's oesophagus and 
colorectal cancer (Sontag 1985). Since this time conflicting evidence has caused 
controversy over this proposed link. Howden and Hornung carried out a 
systematic review of all the published data surrounding the association of 
Barrett's oesophagus and colon cancer in 1995 and concluded that patients with 
Barrett's oesophagus have an increased risk of colon cancer. This may be 
particularly true in those patients with specialised columnar epithelium (Howden 
and Hornung 1995). 
Morgan and Vainio hypothesised that the association between colon cancer and 
Barrett's oesophagus could be due to the disorders sharing several environmental 
risk factors such as increasing age, alcohol, smoking and obesity (Morgan and 
Vainio 1998). Both colon cancer and Barrett's oesophagus are associated with 
mutations to the APC tumour suppresser gene (Zhuang 1997) and the activation 
of the oncogene Src (Kumble 1997). 
1.14 Treatment 
Therapies for Barrett's oesophagus can be classified into those that are intended 
to cure malignancies arising in Barrett's or those to treat the premalignant 
Barrett's epithelium in order to slow, stop or reverse the progression to 
adenocarcinoma. Therapy for Barrett's oesophagus may be divided into medical 
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(proton pump inhibitor therapy), surgical (oesophagogastrectomy) and endoscopic 
(ablation of Barrett's metaplasia by potassium-titanyl-phosphate laser) (Sharma 
1998). 
The impact of high-dose proton pump inhibitor therapy on reducing the length of 
Barrett's oesophagus has been minimal (Morales 1997). Lansoprazole the proton 
pump inhibitor has been found to relieve reflux symptoms and heal erosive reflux 
oesophagitis in Barrett's oesophagus patients (Sontag 1997). Long term 
treatment of Barrett's oesophagus with omeprazole has been shown to cause the 
reappearance of squamous epithelium within the oesophagus, but has no 
significant effect on the length of the columnar lined segment has been seen 
(Neumann 1995). 
Endoscopic surgical ablation can be performed by thermal (electrosurgery or 
laser coagulation), chemical (photodynamic therapy) or mechanical (endoscopic 
mucosal resection) methods. All endoscopic surgical techniques used in 
combination with anti-reflux therapy result in reversal of both high grade 
dysplasia and Barrett's oesophagus to some extent, but some Barrett's 
metaplasia may remain with the risk of progressing to cancer (van der Boogert 
1999). 
Severe dysplasia and thin mucosal cancer of Barrett's oesophagus can be 
completely ablated by photodynamic therapy. This may therefore offer an 
alternative to oesophagectomy (Gossner 1998). A study by Berenson et al found 
that after ablation of Barrett's epithelium and suppression of acid reflux the 
growth of normal squamous epithelium occurs. This shows that a progenitor cell 
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within the metaplastic tissue has the potential to differentiate normally 
(Berenson 1993). 
1.15 Molecular markers for cancer progression 
As mentioned previously Barrett's oesophagus predisposes to malignancy, 
because it is associated with a risk of oesophageal adenocarcinoma up to 125-fold 
greater than that in the general population. Due to this risk, better cancer 
prevention, and early diagnosis are required. There are also ongoing discussions 
as to whether surveillance and screening are useful in patients with Barrett's 
oesophagus. Dysplasia in Barrett's oesophagus can be distinguished from 
adenocarcinoma using a thorough endoscopic biopsy protocol. The detection of 
dysplasia alone is however difficult, because it often has no distinguishing 
endoscopic characteristics. Detecting dysplasia in short-segment Barrett's 
oesophagus and adenocarcinoma is even more challenging (Souza 1997). A 
greater understanding of Barrett's oesophagus and associated adenocarcinoma at 
the molecular level could generate more sensitive and accurate molecular 
markers of early malignant change. For this reason, efforts to characterise the 
molecular events involved in cancer progression have intensified recently. 
A suitable molecular marker for the progression of Barrett's oesophagus to 
adenocarcinoma needs to: 
" have an established correlation with the carcinogenesis process, 
" be measurable in all patients with Barrett's oesophagus, 
" be related with other characteristics of Barrett's oesophagus, 
" be effected by intervention. 
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Over recent years a wide range of molecular markers have been studied during 
the progression of Barrett's oesophagus to adenocarcinoma. Summarised below is 
a small selection of some of the possible molecular markers studied during the 
progression of Barrett's oesophagus. 
1.15.1 Genetic alterations 
In Barrett's epithelium a sequence of changes in DNA content have been found 
during the metaplasia-dysplasia-adenocarcinoma sequence beginning with an 
increased tetraploid (4N) fraction and followed by aneuploidy in high grade 
dysplasia and cancer. Since most Barrett's associated tumours have been found 
to be aneuploid and it is relatively easy to detect with an automated flow 
cytometric system its detection has been proposed as a method of screening for 
patients with a high risk for developing adenocarcinoma (Mueller 2000). 
The genetic abnormalities studied during the progression of Barrett's oesophagus 
to adenocarcinoma could arise due to the increased rate of proliferation seen in 
Barrett's metaplasia (Krishnadath 1995). 
Microsatellite analysis of Barrett's metaplasia can be used to identify 
chromosomal loci involved in the malignant transformation of Barrett's 
metaplasia to oesophageal adenocarcinoma. Allelic imbalance has been found in 
>45% of oesophageal adenocarcinoma on chromosome arms 3q, 4q, 5q (the APC 
tumour suppresser gene), 6q, 9p (p16 gene), 9q, 12p, 12q, 17p (p53 tumour 
suppresser gene) and 18q (DCC, DPC4 and JV18-1 genes). Allelic imbalance was 
also found in several cases of premalignant Barrett's oesophagus, namely, 4q, 5q, 
9q, 9p, 12q, 17p and 18q. The shared novel microsatellite alleles in premalignant 
and malignant Barrett's epithelium are consistent with the clonal expansion 
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involved in the progression from Barrett's oesophagus to adenocarcinoma 
(Gleeson 1998). Losses of 18q and 17p occur earlier than 5q and allelic loss of 
both 17p and 18q in oesophageal adenocarcinoma identifies patients with poor 
prognosis (Wu 1998). Microsatellite analysis and familial studies of Barrett's 
oesophagus could uncover a genetic predisposition to adenocarcinoma (Keller 
1995). 
Inter-SSR PCR (Inter-Simple Sequence Repeat Polymerase Chain Reaction) is an 
established method for studying polymorphism between species and can be used 
for the detection of genetic abnormalities during cancer progression. The 
technique is based on the amplification of regions located between microsatellite 
DNA. This method has been used to study the progression of Barrett's metaplasia 
to adenocarcinoma by Licchesi et al. It is a promising technique, which will be 
used to enhance our knowledge of the genetics of the progression of Barrett's 
oesophagus (Licchesi 2002). 
Y chromosome deletion is strongly and selectively associated with carcinomas, 
particularly adenocarcinomas of the oesophagus (Hunter 1993). This could 
account for the strong dominance of this disorder in males. No X chromosome 
abnormalities have been found in Barrett's oesophagus (Krishnadath 1995). 
1.15.2 Tumour suppressor genes 
Tumour suppressor genes code for proteins that inhibit cell -division and are 
involved in apoptosis (programmed cell death). Mutations in these genes can 
cause the proteins to become inactivated and may therefore deprive cells of the 
needed restraints on proliferation (Weinberg 1996). Tumour suppresser genes 
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can be called recessive oncogenes, as both copies of the gene must be inactivated 
for their tumour suppressive affect to be lost (Souza 1997). 
A wide variety of tumour suppresser genes have been implicated in the formation 
of tumours and many have been studied as possible molecular markers for 
Barrett's associated adenocarcinoma. Below is a brief summary of some of the 
studies carried out to analyse tumour suppresser genes in Barrett's oesophagus. 
The tumour suppresser gene p53 was originally thought to play an important role 
in the progression of Barrett's metaplasia to adenocarcinoma and it could be an 
objective marker of neoplasic progression (Younes 1993). Over expression of p53 
has been found to occur early in the transformation of Barrett's oesophagus to 
adenocarcinoma and increases with histologic progression (Kim 1997a). Recent 
knowledge suggests that p53 protein over expression does not predict the future 
development of cancer or determine disease outcome (Kubba 1999). Some 
patients with Barrett's oesophagus and oesophageal adenocarcinoma can develop 
p53 antibodies that may predate the clinical diagnosis of cancer (Cawley 1998). 
This is not predictive as cancer does not always develop from this situation. 
Another tumour suppresser gene implicated in Barrett's oesophagus associated 
adenocarcinoma is retinoblastoma. Altered retinoblastoma mRNA was 
demonstrated in dysplastic and adenocarcinoma Barrett's biopsies (Huang 1992). 
It has also been shown that the accumulation of abnormal retinoblastoma protein 
during the progression of Barrett's metaplasia to adenocarcinoma leads to 
unsuppressed tumour growth (Coppola 1999). The p16 protein inhibits cell 
proliferation by preventing inactivation of the retinoblastoma gene. Inactivation 
34 
of p16 has been found to be a late event in the progression to Barrett's 
adenocarcinoma (Meuller 2000). 
The adenomatous polyposis coli (APC) gene is found on chromosome 5q and is a 
key tumour suppresser gene in the early stages of carcinogenesis of colorectal 
cancer. In Barrett's oesophagus the situation is different most studies show APC 
changes as a latter event during progression to adenocarcinoma (Mueller 2000). 
1.15.3 Cell proliferation 
Uncoordinated cell proliferation is a hallmark of neoplasic diseases including 
adenocarcinoma of the oesophagus. Useful markers of cell proliferation in 
Barrett's metaplasia and dysplasia are proliferating cell nuclear antigen (PCNA) 
and Ki-67 (also referred to as MIB-1), that can be detected 
immunohistochemically with nuclear staining. PCNA is an indicator of cell cycle 
progression at the Gi/S transition and Ki-67 can detect changes in the Gi/S and 
the G2/M cell cycle transitions (Rustgi 1997). Quantitative measuring of the 
proliferation zone as marked by Ki-67 staining has been advocated as a useful 
marker for the differentiation between low and high grade dysplasia (Hong 
1995). 
PCNA is an auxiliary protein in DNA synthase found in cells in the S phase of 
the cell cycle and is used as a marker of cell proliferation. PCNA (Jankowski 
1991) and Yd-67 (Koya 1996) have shown a positive correlation between cell 
proliferation and increasing degrees of dysplasia in Barrett's oesophagus. 
There is a significant increase in apoptotic activity in intestinal-type Barrett's 
metaplasia when compared with gastric-type. There is also a significant increase 
35 
in the glandular proliferation to apoptosis ratio in the progression of metaplasia 
to dysplasia to adenocarcinoma. Therefore the shift could be a useful and 
sensitive marker of neoplastic change in Barrett's oesophagus (Whittles 1999). 
The Fas receptor is an apoptosis-signaling surface receptor that is able to trigger 
programmed cell death. Fas over-expression may represent a cellular attempt to 
balance the uncontrolled tumour proliferation by promoting apoptosis (Coppola 
1999). An abnormality in Fas expression was observed in Barrett's metaplasia in 
which immunohistochemical staining of Fas at the cell surface was reduced or 
absent despite a high level of Fas mRNA (Hughes 1998). 
1.15.4 Oncogenes 
Genes known as proto-oncogenes code for proteins that stimulate cell division; 
mutated forms called oncogenes can cause the stimulatory proteins to be over- 
expressed and result in cells proliferating excessively (Weinberg 1996). 
Oncogenes are genes whose product may be involved in the processes leading to 
the transformation of a normal cell into a malignant state. Oncogene products 
maybe growth factors, growth factor receptors or molecules that transmit the 
receptor signals within the cell. They are usually activated during embryogenesis 
and are suppressed in mature cells, if this suppression is damaged reactivation of 
the genes can occur stimulating increased proliferation. 
Relatively few studies of oncogene abnormalities have been carried out in 
Barrett's metaplasia. Cyclin-D1 has oncogenic properties i. e. once it is over 
expressed it results in excessive cell proliferation. There is regular over 
expression of cyclin-D1 in oesophageal squamous cell carcinomas, and this has 
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also been shown in Barrett's oesophagus and oesophageal adenocarcinoma 
(Rustgi 1997). 
The oncogene Src is activated in Barrett's oesophagus before the development of 
dysplasia or adenocarcinoma (Kumble 1997). Mutations of the oncogene c-Ki-ras 
have not been found in Barrett's oesophagus, therefore the c-Ki-ras gene is not 
thought to be involved in the progression of Barrett's oesophagus to 
adenocarcinoma (Lagorce-Pages 1995). 
1.15.5 Growth factors 
Generally chronic inflammation is assumed to predispose to cancer development. 
Oesophageal adenocarcinoma is no exception due to the strong links with chronic 
gastro-oesophageal reflux disease. When this inflammation occurs there is 
increased production of growth stimuli (Souza 1997). There are various different 
families of growth factors, each of which has many members. An important 
family of growth factors is the one that binds to the epidermal growth factor 
receptor (EGFR). This includes epidermal growth factor (EGF), transforming 
growth factor-a (TGF-a), amphiregulin, heregulin and cripto. The binding of 
these substances to EGFR induces a signal transduction pathway within the cell. 
Expression of EGFR has been shown to increase in some patients with Barrett's 
oesophagus and oesophageal adenocarcinoma (Rustgi 1997). In addition both 
TGF-a and EGF are over expressed when measured by immunohistochemistry in 
Barrett's metaplasia (Souza 1997). 
37 
1.15.6 Regulatory proteins 
Telomerase is a ribonuclear protein reverse transcriptase that uses its own RNA 
component as a template for the addition of telomeric sequences to the end of 
chromosomes, therefore maintaining telomere length. Telomerase activity is 
present in most primary human cancers, but not in normal somatic tissue except 
for proliferative cells of renewal tissue (e. g. crypts of the intestine) (Shay 1997b). 
Relatively few studies have assessed telomerase activity in Barrett's oesophagus. 
In situ hybridisation has been used to look at telomerase RNA expression in 
Barrett's oesophagus. This showed low levels in basal cells of squamous mucosa 
and low to moderate levels in the basal crypts of intestinal type Barrett's 
metaplasia. This concluded expression of telomerase increased with the 
progression of Barrett's oesophagus to adenocarcinoma in most cases (Morales 
1998). This study was limited as very few samples were assesed. Telomerase and 
cancer will be covered in detail in section 1.16. 
The specialised columnar cells found in Barrett's oesophagus have been found to 
express the intestinal disaccharide sucrase-isomaltase and are therefore 
phenotypically similar to intestinal epithelium (Wu 1993). The brush border- 
associated hydrolyase, aminopeptidase-N has been detected by 
immunohistochemistry in 84% of Barrett's biopsy specimens (Moore 1994). 
The extracellular matrix and basement membrane of cells are physical barriers 
to migration and invasion. Cancer cells must overcome these barriers in order to 
invade and metastasis. Localised proteolysis is an important mechanism 
regulating cellular interactions. Plasminogen activation is a significant inducible 
extracellular proteolytic system involved in the regulation of cellular 
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interactions. So far no systematic study of plasminogen activation in metaplastic 
or dysplastic Barrett's epithelium has been carried out. A study into oesophageal 
adenocarcinomas that have been completely resected has shown that a high level 
of urokinase-type Plasminogen Activator was found to be an independent 
prognostic indicator of subsequent poor survival (Nekarda 1998). The 
Plasminogen Activator system and cancer are covered fully in section 1.18. 
1.15.7 Adhesion molecules 
Adhesion molecules are known to be involved in the attachment of epithelial cells 
to each other and to the extracellular matrix. The processes of invasion and 
metastasis are central to the development of cancer and are closely associated 
with the reduction or loss of cell adhesion molecules. 
The expression of cell surface glycoproteins encoded by the CD44 variant exons 
have been shown to be associated with poor prognosis in malignancies. CD44 and 
v6 are frequently expressed in Barrett's oesophagus. It has been shown by the 
pattern of expression that CD44 and CD44v6 may be involved in the 
carcinogenesis of Barrett's. Expression of CD44v6 in Barrett's oesophagus 
associated adenocarcinoma is correlated to the aggressive pathological features of 
the disorder (Lagorce-Pages 1998). A study by Bottger et al found CD44v4 was an 
independent prognostic parameter for adenocarcinoma of the oesophagus that 
can be determined preoperatively by biopsy (Bottger 1998). The draw back of this 
study was that only a small number of patient samples were analysed. 
Epithelial cadherin (E-cad) is the primary regulator of cell adhesion in epithelial 
tissues. Cadherin function is regulated in part by interactions with cytoplasmic 
proteins called catenins. There is a reduction in the expression of the E- 
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cadherin/catenin complexes in Barrett's oesophagus biopsy specimens during the 
progression to adenocarcinoma, therefore loss or reduced E-cadherin expression 
may play a role in the progression of Barrett's oesophagus to adenocarcinoma 
(Swami 1995, Washington 1998). A significant reduction in the expression of E- 
cadherin was shown by Bailey et al to occur during the metaplasia-dysplasia- 
adenocarcinoma sequence. P-cadherin expression was absent in Barrett's 
oesophagus, but was present in some adenocarcinomas. There was also reduced 
expression of catenins (Bailey 1998). 
Carcinoembyonic antigen (CEA) is another adhesion molecule. It is a complex 
glycoprotein comprising of 60% carbohydrate. It is found in adenocarcinomas of 
endodermally derived epithelia of the digestive system and in foetal colon. CEA 
immunoassay is useful in the diagnosis and monitoring of cancer patients for 
recurrent disease or response to therapy, particularly in colonic cancer (Oikawa 
1987). The presence of CEA has been established by histochemistry by Ferrando 
et al and was found in 7 of 9 Barrett's cases and 100% of dysplasia and 
adenocarcinoma samples tested (Ferrando 1998). 
The preliminary results of a study by Bottger et al did not show that the 
expression of the adhesion molecule 01 integrin was of prognostic value in 
patients with adenocarcinoma of Barrett's oesophagus, although further work 
needs to be carried out (Bottger 1999). 
1.15.8 Mucins and peptides 
Mucin is a glycoprotein and the main constituent of mucus. The expression of 
three types of mucins (MUC1, MUC2, and MUC5AC) have been analysed in 
Barrett's metaplasia and oesophageal adenocarcinoma along with two trefoil 
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peptides (TFF1 and TFF2). Trefoil peptides are a group of small secretory 
peptides bearing one or more trefoil structural motifs. Barrett's metaplasia was 
found to be negative for MUC2 and TFF2. TFF1 and MUC5AC were found in all 
the Barrett's samples and MUC1 in 90% of the Barrett's samples (Labouvie 
1999). 
Villin is an actin binding cytoskeletal protein found only in the small intestine 
and renal cell lineages. Recent studies have shown villin to be highly expressed 
in 100% of intestinal type Barrett's metaplasia (MacLennan 1999). 
Cytokeratins (CK) are a group of cytoskeletal structural proteins present in all 
epithelial tissue. In human epithelial cells 20 cytokeratins have been identified to 
date (Salo 1996). Various studies have been carried out to analyse the 
cytokeratins present in Barrett's metaplasia (Salo 1996, Boch 1997, and Ormsby 
1999). CK13 is characteristic of squamous epithelium including oesophagus. 
Simple columnar epithelium, such as Barrett's epithelium, express mainly CK8, 
18 and 19. The presence of CK 13 in Barrett's metaplasia indicates its origin is 
from squamous epithelium and is not caused by the migration of columnar cells 
of the gastric cardia (Salo 1996). CK7 is a marker of ductal differentiation and is 
not expressed in the normal epithelium of the oesophagus. CK20 is a marker of 
intestinal differentiation and is expressed in the surface and crypt epithelium of 
the colon and small intestine. Ormsby et al found that cytokeratin 7 and 20 could 
reliably identify intestinal metaplasia in the oesophagus and stomach (Ormsby 
1999). Barrett's adenocarcinoma has been found to express CK8,18 and 19 in 
high amounts (Moll 1982). 
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The human erythrocyte glucose transporter (GLUT1) is expressed in 
adenocarcinoma of Barrett's oesophagus, but not in dysplasia or metaplasia. 
GLUT1 is expressed as a late event in the neoplastic change (Younes 1997). 
A wide variety of molecular changes have been studied increasing our 
understanding of the molecular biology during the metaplasia-dysplasia- 
adenocarcinoma sequence of Barrett's Oesophagus. Although a few of these 
changes appear quite early along the pathway the majority are late events and 
are only found when high grade dysplasia or adenocarcinoma are evident (See 
figure 1.1). This means the systematic endoscopic biopsy program for the 
detection of dysplasia remains the "gold standard" to identify patients at high 
risk for development of adenocarcinoma. In the future identification of early 
molecular changes will lead to a more accurate risk assessment for the patient 
and may also provide targets for intervention to prevent development of 
dysplasia and adenocarcinoma. 
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1.16 Telomerase 
1.16.1 Telomeres 
Telomeres are specialised structures found at the ends of chromosomes. They 
appear to function in chromosome protection, positioning and replication. In 
vertebrates telomeres consist of hundreds to thousands of tandem repeats of the 
sequence TTAGGG (Feng 1995). In humans telomeres are made up of an average 
of 5000-15,000 base pairs of telomeric repeats and telomere binding proteins. The 
exact number and combination of telomere repeats varies slightly from species to 
species, but their function is the same, 
" they form specific complexes with telomere-binding proteins, 
" they protect chromosome ends from exonuclease digestion, 
9 they prevent aberrant recombination, and 
" they prevent chromosome ends from activating checkpoint controls that sense 
DNA damage (McKenzie 1999). 
Chromosomes lacking telomeres can suffer fusion, degradation and extremely 
high loss rates (Blackburn 1997). Despite the importance of telomeres there is 
little information of the mechanism by which these tandem repeated DNA base 
pairs ensure short-term chromosome stability or even at what stage in the cell 
cycle their job is performed (Blackburn 1997). 
1.16.2 The chromosome end-replication problem 
DNA replication can be defined as the process by which one parent DNA strand 
is copied to produce two identical daughter strands. The so-called end-replication 
problem arises from the inability of standard chromosome replication 
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mechanisms to do a complete job. When DNA polymerase copies the original 
DNA strands in a chromosome they leave each of the new daughter strands with 
a shortened tip at the 5' end. The replication process causes the loss of 50-100 
base pairs (see figure 1.2. ). If cells did not compensate for this problem in the 
replicative mechanism chromosomes would shrink and there would be loss of 
important pieces of coding DNA (Greider 1996 and Cech 1997). Cells have 
evolved a number of systems to overcome this loss including complex 
recombination and retrotransposition schemes. The problem is overcome initially 
by the presence of tandem repeats, telomeres, at the end of chromosomes. Part of 
the telomere will be missed during the DNA replication mechanism and lost in 
the daughter strands without being detrimental to the cell. Therefore the cell can 
divide a certain predisposed number of times before the telomeres are completely 
lost and the cell reaches crisis (Lange 1995 and Cech 1997). In higher eukaryotes 
this end-replication problem is overcome by a specialised reverse-transcriptase 
enzyme, telomerase (see figure 1.3. ). 
The existence of telomerase was proposed in the early 1980's as a possible 
solution to this end-replication problem (Greider 1996). One scheme for how 
telomerase solves the end-replication problem proposes that the enzyme adds 
DNA to chromosomes before replication begins. The added DNA consists of one or 
more telomeric subunits. This addition ensures the daughter strand will be at 
least as long as its parent strand (Greider 1996). The telomerase process 
maintains a dynamic equilibrium and prevents chromosomes from shortening to 
a critical length and prevents cells from receiving the signal to stop dividing. 
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Figure 1.2. The end replication problem. 
During DNA replication the 5' section of DNA under the RNA primer is not 
copied and this short section of DNA is lost. This is over come by the telomeres at 
the end of chromosomes (Grieder 1996). 
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1.16.3 Telomerase 
Telomerase is a ribonuclear protein complex with a reverse transcriptase activity 
that uses its own RNA component as a template for the addition of the tandem 
telomeric sequences to the end of chromosomes, therefore maintaining telomere 
length. The telomerase protein complex contains several protein subunits 
including, the human RNA component (hTR) which contains a domain that is 
complementary to the one hexameric unit of the DNA telomeric repeat sequence, 
TTAGGG, and the catalytic subunit of human telomerase (hTERT) is homologous 
to reverse trancriptases. Therefore the enzyme complex contains both template 
and polymerase activity (McKenzie 1999). Telomerase binds to the 3' ends of 
DNA strands and extends them by copying it's own RNA template in multiples of 
the hexamer repeat sequence (see figure 1.3). 
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Figure 1.3. How telomerase overcomes the end replication problem by 
transcribing telomeres at the end of chromosomes. 
Initially telomerase binds to the telomere and elongates the DNA adding 
telomeric repeats. Next the telomerase translocates, binds again to the newly 
transcribed telomeric repeat and elongates again (Greider 1996). 
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Telomerase is synthesised in nearly all organisms with nucleated cells. The 
precise makeup of the enzyme can differ from species to species, but each version 
possesses a species-specific RNA template for building telomeric repeats (Greider 
1996). The essential RNA component of telomerase contains a 9-30 nucleotide 
template that dictates the synthesis of telomeric repeats onto DNA in vivo and in 
vitro (Autexier 1996). The RNA component of human telomerase has been cloned 
and the expression studied in germline tissues and tumour cell lines. This 
showed human telomerase is a critical enzyme for the long-term proliferation of 
immortal tumour cells (Feng 1995). 
Telomerase in single cell organisms is vital because the organisms are immortal 
and barring accidents and genetic upsets they can divide indefinitely and the 
species can survive (Greider 1996). 
From experiments analysing telomere length and telomerase activity in 
immortalised and cancer cells in culture, a simple model has emerged to describe 
the role of telomerase in mammalian cells: 
1) Telomerase is present in germline tissues where telomere length is 
maintained, 
2) Telomerase is not present in normal somatic cells where telomere shortening 
occurs, 
3) During the extended lifespan, telomeres continue to shorten and the cells 
enter crisis, 
4) After crisis, cells with activated telomerase are selected and telomere length 
is stabilised in the resulting culture (Autexier 1996). 
See figure 1.4 for a graphical representation. 
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Successive telomere shortening with each cell division Immortalisation 
Figure 1.4. Activation of Telomerase Stabilises Telomere Length and 
leads to immortality in cells. 
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If telomerase regulation in human tumours is similar to this cell culture model, 
telomerase could be an important new target for anti-cancer therapy. 
1.16.4 Telomerase and Ageing 
Telomerase expression is repressed early in development in all somatic tissues 
(Harley 1997). Telomerase is active in germline cells, maintaining long stable 
telomeres, but is repressed in most somatic cells resulting in telomere loss during 
division. 
The shortening and loss of telomeres may explain the limited reproductive 
lifespan of normal diploid cells in culture. The hypothesis is that one or more of 
the shortened telomeres will generate a specific signal or evoke a DNA damage 
checkpoint, in either case causing the cell to leave the cell cycle irreversibly 
(Shall 1997). Somatic cells from human new-borns will usually divide 80-90 times 
in culture, whereas cells from a 70-year old are only likely to divide 20-30 times 
(Autexier 1996). 
1.16.5 Telomerase Detection 
Telomerase can be detected in various ways. Northern blot and reverse 
transcripase PCR (RT-PCR) allow the expression of mRNA to be studied but 
require the degradation of the tissues. In Situ Hybridisation has the advantage of 
detecting mRNA within the cells. The protein can be detected using specific 
antibodies either by immunoblotting or immunohistochemistry. The most 
popular method developed to date to assay for telomerase activity in small 
samples of human tissues is a sensitive PCR-based assay (Kim 1994). This assay 
is called the Telomeric Repeat Amplification Protocol (TRAP). TRAP relies on the 
fact that telomerase will elongate a G-rich primer non-telomeric sequence. The 
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method comprises of two steps initially a G-rich oligonucleotide is added to cell 
lysates as a substrate primer and if telomerase is present it adds TTAGGG 
repeats to the primer. After the initial telomerase reaction the telomerase 
products are specifically amplified using a PCR step with non-telomeric sequence 
and (CCCTTA)e primers (Kim 1994, Greider 1995 and McKenzie 1999). This 
method allows for the detection of telomerase activity and can be measured in as 
little as 12 cells. The simplicity and increased sensitivity of this assay has 
resulted in an increase in the study of telomerase expression and activity in 
many cancers and normal tissues as long as they are fresh or freshly frozen 
samples. Using the TRAP method telomerase activity can be measured in various 
clinical specimens such as: frozen sections and fine needle aspirates, normal 
secretions, pathological fluids, aspirates and brushes/washes. Fixing tissues 
inactivates the enzyme making many banked cancer and tissue samples 
unavailable for TRAP analysis. 
The TRAP method has been further developed and combined with an ELISA 
detection system instead of a gel for a rapid, easy and reliable telomerase 
detection. Two kits are currently available commercially, the TRAPEZEW ELISA 
Telomerase Detection Kit (Intergen Company, Oxford, UK) and the Telomerase 
PCR ELISA (Roche Molecular Biochemicals, Lewes, W. The principles of the 
TRAPEZE TM kit are described below, as that is the method used for the telomerase 
detection in this study. 
The method combines a one-step TRAP assay with direct non-isotopic, 
chromogenic detection of the TRAP product through ELISA. In the first step 
telomerase adds a varied number of telomeric repeats onto the 3' end of a 
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biotinylated oligonucleotide substrate (See figure 1.5). In step two these 
extension products are amplified using PCR with a deoxynucleotide mix 
containing dCTP labelled with dinitrophenyl (DNP). The ELISA step involves the 
immobilisation of the biotinylated; DNP-labelled TRAP products to a streptavidin 
coated microtitre plate followed by detection using anti-DNP-peroxidase antibody 
and tetramethylbenzidine (TMB) substrate. 
More recently the cloning of the RNA component and the catalytic subunit of 
telomerase have opened up new avenues in the analysis and the detection of 
telomerase-RNA and telomerase-protein components. This will allow for the 
analysis of fixed tissues for the hTERT protein immunohistochemically, but the 
results may not mirror those for detectable telomerase activity (McKenzie 1999). 
The protein may be present in the cells, but not in the active form. hTERT has 
also been detected using RT-PCR in a variety of tissues. Analysis of hTERT by in 
situ hybridisation has been applied to both normal and tumour tissues and 
correlates well with telomerase activity detected with the TRAP assay. 
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Figure 1.5. Principles of the TRAPEZETM' ELISA Telomerase Detection 
Kit. 
Abbreviations: B- Biotinylated label, TS - oligonucleotide substrate, RP - 
Reverse PCR primer, HRP - anti-DNP-peroxidase antibody and TMB - 
tetramethylbenzidine substrate (colour). 
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The main disadvantage of using the TRAP method for analysing telomerase 
activity in clinical tissue samples is there is no way of telling exactly which cells 
within the sample are expressing telomerase. This problem can be overcome with 
the use of in situ hybridisation techniques. The application of in situ 
hybridisation techniques for detecting telomerase RNA expression in archival 
paraffin-embedded and fresh frozen material can easily distinguish cancer from 
normal cells (Shay 1997a). The use of in situ hybridisation for the detection of the 
RNA template within the enzyme complex should allow the localisation of 
specific cells with telomerase activity. 
The RNA component of telomerase can be detected with a variety of different 
methods. Initially studies using northern blotting of mRNA were disappointing 
as these indicated that expression levels did not correlate with telomerase 
activity. When RT-PCR was used the molecule was detected in tumour tissues as 
well as normal tissues although higher levels were found in tumour tissues. RT- 
PCR detects telomerase mRNA and so does not give information on whether the 
active molecule is in the tissues. It only gives information about gene expression. 
In some circumstances analysis of the RNA component of telomerase in paraffin 
embedded sections correlates with telomerase activity (Matthews 2001). 
1.16.6 Telomeres, Telomerase and Cancer 
During the progression from normal tissue to cancer telomeres pass through four 
distinct phases: 
1) Telomeres are in decline, but still sufficiently long to protect chromosome 
ends 
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2) Loss of telomere function occurs on one or a few chromosome ends. The 
resulting ends arrest cell proliferation and/or induce apoptosis. 
3) Cells continue to lose telomeric DNA and enter a period of increased genome 
instability with high rates of loss of heterozygosity and gene amplification. 
4) The harmful effects of generalised telomere loss may eventually provide a 
selective advantage to cells that have restored telomere function through the 
increased expression of telomerase. In the resulting growth phase tumour 
telomeres are functionally restored, although not necessarily long. 
Most tumours may not be clinically detectable until they reach phase 4 (Kipling 
1995). 
Telomerase activity is present in most (approximately 85%) of primary human 
cancers, but not in normal somatic tissue, except for the proliferative cells of 
renewal tissue (e. g. crypts of the intestine) (Shay 1997b and McKenzie 1999). 
Telomerase activity and expression has been studied in various human cancers 
including bladder, prostate, breast, neck, lung, colon, pancreas, stomach, liver 
and ovary. The time of activation of telomerase during the progression of cancer 
varies from cancer to cancer; for example, telomerase is activated at an early 
stage in the pathogenesis of breast, neck, lung and skin cancers and late in the 
pathogenesis of colon, pancreas and thyroid cancers. There is insufficient or 
conflicting data for the time of activation of telomerase in renal, ovary, prostate, 
stomach and oesophagus cancers (Shay 1997a). In patients with oesophageal 
carcinoma the measurement of telomerase in normal epithelium has been found 
to be highly sensitive method of detecting the microinvasion of cancer cells 
(Koyanagi 1999). 
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Although tumours have different expression compared to normal tissues of the 
same type the results can be confused by the presence of telomerase activity in 
certain benign lesions. Usually measuring the presence or absence of telomerase 
is enough, but in some cancers, such as lymphomas a more quantitative analysis 
is needed. 
A number of studies have compared the length of telomeres in human tumours to 
those in non-tumour tissue from the same organ. It has been shown that some 
tumours such as colorectal and renal cell carcinoma have significantly shortened 
telomeres compared to normal colon and renal tissue and the shortened length is 
maintained during further divisions (Kipling 1995). 
Telomerase activity may prove to have another advantage over other histological 
techniques in the diagnosis of cancer. Telomerase activity can be assayed in cells 
that are extracted by less invasive methods than surgery. For example oral 
rinses in head and neck cancer, urine in bladder cancer, pap smear in cervical 
cancer and pancreatic juice in pancreas cancer (McKenzie 1999). The 
disadvantage could be that the tumours are made up of many cell types and only 
a small proportion of them may be expressing telomerase. 
The analysis of telomerase may provide insights into two general stages of cancer 
progression. Firstly telomerase might be useful in identifying pre-cancerous 
lesions that might progress to cancer, and secondly telomerase analysis may be 
useful for predicting the clinical course of the patient once cancer has been 
diagnosed. Both these areas are under intense investigation at the moment in 
breast and prostate cancer (McKenzie 1999). 
57 
Once the mechanism and requirements of telomerase activation and activity are 
understood fully telomerase should be a viable tool in the diagnosis and 
treatment of cancer. 
1.16.7 Telomerase and Barrett's oesophagus 
As mentioned previously in section 1.15.6 telomerase activity has been measured 
in Barrett's oesophagus using the TRAP assay and it was suggested that 
Barrett's metaplasia has an immortal potential similar to that found in cancer 
cells (Ozawa 1997). In situ hybridisation has been used to study the expression of 
the RNA component of telomerase in Barrett's oesophagus. It was found that 
100% of oesophageal adenocarcinomas and high-grade dysplasia were strongly 
positive for telomerase RNA. Basal cells of Barrett's metaplasia demonstrated 
weak to moderate telomerase RNA in 70% of cases and 90% of low-grade 
dysplasia had moderate levels of telomerase RNA. The study suggested that the 
expression of telomerase increased with the progression of Barrett's oesophagus 
to adenocarcinoma (Morales 1998). 
Telomerase activity has been detected in both oesophageal squamous cell 
carcinoma and adenocarcinoma, squamous carcinoma in situ, squamous and 
glandular dysplasia and Barrett's metaplasia. Telomerase activity has been 
measured in Barrett's oesophagus using the telomeric repeat amplification 
protocol (TRAP) and found 50% of Barrett's oesophagus samples had telomerase 
activity, suggesting that Barrett's epithelia has an immortal potential similar to 
that of cancer cells (Ozawa 1997). 
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Quantitative RT-PCR for the detection of the RNA component of telomerase 
shows an increase from normal through intestinal metaplasia and dysplasia to 
adenocarcinoma in Barrett's oesophagus (Lord 2000). 
1.17 Proteases in Cancer 
Tumour progression is a step-wise process beginning with multiple alterations in 
a normal cell, which lead to a localised tumour. This finally progresses to a 
tumour that has the ability to invade and metastasise. Tumour cell invasion 
involves the attachment of tumour cells to the underlying basement membrane, 
local proteolysis and migration of tumour cells through the degraded region. 
Proteases are involved throughout the metastatic process. In order for a cell to 
metastasise it must be able to move into blood vessels (intravasate), survive in 
circulation, arrest, move out of the blood vessels (extravasate), invade 
surrounding tissues and grow. All these steps involve interactions between 
tumour cells, stromal cells, invading lymphocytic cells, endothelial cells and the 
extracellular matrix. Proteases which are expressed in these cells (including 
Cathepsin B and D, Urokinase-type Plasminogen Activator and receptor, and 
interstitial collagenase), are believed to participate in many of these steps 
(Figure 1.6) (Kobinski 2000). 
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Figure 1.6. The role of proteases in the metastatic process. 
Multiple changes occur in the normal epithelial cells (NEC) leading to tumour 
formation and growth (1). The tumour cells (TC) also undergo epithelial- 
mesenchymal transformation (2) during this time. Angiogenesis is stimulated 
where endothelial cells (EC) proliferate and invade towards the tumour site (3). 
TC also invades the connective tissue (4) and then the blood vessels (5). The TC 
must survive in circulation (6), arrest (7), leave the blood vessels (8), invade the 
local environment (4), and grow (1) to set up distant metastases (MTC: 
metastatic tumour cell). These metastatic steps occur through the interaction of 
TC, EC, fibroblasts (F), Invading inflammatory cells (IC), such as macrophages, 
and the extracellular matrix. Steps where proteases are thought to be involved 
are shown in bold (Kobinski 2000). 
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The extracellular matrix and basement membrane of cells are physical barriers 
to migration and invasion. They need to be disrupted and reassembled by 
migrating cells such as those involved in embryonic developmental processes, 
inflammatory responses and cancer metastasis. Trophoblast (placental) invasion 
is analogous to tumour invasion and the same proteolytic mechanisms are 
involved (Strickland 1976 and Lala 1990). Migration and invasion are properties 
of many cells, but need to be controlled. Cells which need to overcome barriers 
need to be equipped with a inducible system that allows them to overcome the 
extracellular barriers (Blasi 1993b). Tumour cells must overcome extracellular 
matrix barriers consisting of the basement membrane and interstitial stroma in 
order to penetrate lymphatic and blood systems (Liotta 1984). In order for 
tumour invasion and metastasis to occur cancer cells need to co-ordinate the 
mechanisms involved in the formation and degradation of structural matrix 
proteins (Reuning 1998). Several processes cause cancer metastasis. These 
include: 
" detachment of cancer cells from their original location 
" cancer cell migration 
" invasion of cancer cells into the surrounding tissue, requiring adhesion to and 
subsequent degradation of the extracellular matrix components 
" access of cancer cells to blood and lymphatic vessels 
" adhesion to and invasion through the endothelium, allowing colonisation at 
distant sites (Andreasen 1997). 
Localised proteolysis is an important mechanism regulating cellular interactions. 
Fibrinogen, fibronectin, vitronectin, alpha-2-antiplasmin, plasminogen activators 
and plasminogen activator inhibitors are components of the extracellular matrix 
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or the basement membrane and have a role in cell adhesion and migration. They 
are themselves components of the extracellular proteolytic processes (Blasi 
1993b). 
1.18 Plasminogen 
Plasminogen expression has also been linked as a late event in the progression of 
Barrett's oesophagus to adenocarcinoma. It is a sign of the cells becoming 
invasive and invading the extracellular matrix of surrounding cells. The study of 
plasminogen and telomerase as late events in Barrett's cancer progression should 
help build up a clearer picture of the late events in cancer progression within this 
disease. 
1.18.1 The Plasminogen System 
Plasminogen activation is a significant inducible extracellular proteolytic system 
involved in the regulation of cellular interactions. Plasminogen activators convert 
inactive plasminogen into the trypsin-like serine protease plasmin. Plasmin can 
degrade circulating and tissue proteins as well as activate zymogen or growth 
factor precursors (Plow 1986, Blasi 1993b, and Plesner 1997). There are two 
types of plasminogen activator urokinase plasminogen activator (uPA) and 
tissue-type plasminogen activator (tPA) (Blasi 1993b). uPA is a 55kD protein 
produced by a variety of cell types including fibroblasts, various epithelia, 
monocytes and neutrophils. uPA is produced as a single chain inactive precursor 
(pro-uPA) which is activated when it binds to the receptor, uPAR (Plesner 1997 
and Herszenyi 2000). 
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uPAR was first detected on monocytes and monocyte-like cells and has since been 
observed on a variety of cultured cells derived from both cancerous and normal 
cells. It is a single chain highly glycosylated protein of Mr 55-60,000, which is 
attached to the plasma membrane by a glycosyl-phophatidyl-inositol lipid anchor 
(Ronne 1991 and Blasi 1993b). Most cells bearing uPAR have also been found to 
secrete uPA. The attachment of uPA to its receptor increases the ability of the 
cell to convert plasminogen to plasmin and degrade the basement membrane and 
extracellular matrix proteins (Herszenyi 2000). uPAR is often expressed together 
with uPA at the foci of cancer invasion. 
The activity of uPA and uPAR is regulated by plasminogen activator inhibitors 
known as PAI-1 and PAI-2 (Bacharach 1992 and Andersen 1997, Blasi 1993b). 
The plasminogen inhibitors are members of the serpin family of proteins. 
Plasminogen activator inhibitor-type 1 is produced by vascular endothelial cells 
and inhibits both uPA and tPA, whereas plasminogen activator inhibitor-type 2 
inhibits only uPA (Herszenyi 2000). They are present in general in the 
extracellular matrix and are capable of forming a covalent complex that 
inactivates the protease. The formation of a receptor bound uPA: PAI-1 complex is 
an essential component of the regulation of the extracellular proteolytic pathway. 
It triggers the internalisation and degradation of the complex (Blasi 1993b). The 
inhibitors are less active against uPA bound to receptor than soluble uPA. 
The gene map locations of the components of the Plasminogen Activator system 
are: 
" uPA 10g24 (Tripputi 1985), 
" uPAR 19g13 (Borglum 1991), 
63 
9 PAI-1 7g21.3-q22 (Ginsburg 1986), 
" PAI-2 18g21.3 (Antalis 1988). 
1.18.2 Plasminogen and cancer 
The role of the plasminogen activator system in cancer invasion and metastasis 
has been covered in many reviews including Blasi 1993a, Mignatti 1993, 
Andereasen 1997 and Reuning 1998. 
In breast cancer uPA has been found to be a possible new and independent 
prognostic marker. It was found that patients with high levels of uPA had 
increased risk of recurrence and a shorter survival rate than patients with low 
levels (Duffy 1991). Carcinogenesis of the human colon is associated with an 
increase in the tissue content of uPA (Sier 1991). uPA levels have been found to 
be higher in human lung tumours than the adjacent non-involved tissue (Markus 
1980). 
The role of the plasminogen activator system in invasive gastro-oesophageal 
carcinoma has been studied. Hewin et al has shown that there is increased 
expression of uPA and decreased expression of PAI-2 in oesophageal carcinoma 
compared to normal mucosa (Hewin 1994) and uPA and uPAR are at elevated 
levels in gastric carcinoma (Hewin 1995b and Hewin 1996). Plasminogen was 
also shown to significantly increase basement membrane degradation in 
oesophageal and gastric cell lines (Hewin 1995a). Immunohistological staining 
has shown the presence of uPA in gastric tumours (Takai 1991), but no studies 
have been done to look at the distribution of these proteins at the invasion front 
in gastric or oesophageal tumours. 
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Nekarda et al carried out a study in 1998 to assess the level of expression and 
significance of uPA and PAI-1 in resected adenocarcinoma of the oesophagus 
using ELISA techniques. Tumour samples were compared to matched normal 
gastric mucosa samples. It was found that uPA and PAI-1 levels were 
significantly elevated when compared with the normal mucosa. Overall it was 
concluded that tumour uPA content appears to be a powerful independent 
prognostic factor for survival in adenocarcinoma of the oesophagus (Nekarda 
1998). No studies were made of the PA system in the early stages of the 
progression of Barrett's oesophagus to adenocarcinoma. 
1.19 Molecular Biological Techniques 
In order to unravel the molecular changes within tissues during the progression 
of Barrett's oesophagus to adenocarcinoma various molecular biological 
techniques have been utilised in numerous studies, some of which are described 
below. 
1.19.1 Immunochemical Techniques 
All immunochemical techniques rely on the ability of antibodies to recognise and 
bind to specific antigens. The effectiveness of antibodies is dependent on the 
quality of the antibody employed. It is possible to make antibodies to proteins, 
peptides, carbohydrates and nucleic acids, but in general immunochemical 
methods are devised for use with antibodies that recognise proteins or peptides. 
Antibodies can be either monoclonal (derived from a single B cell clone and show 
identical amino acid sequence) or polyclonal (recognises several different epitopes 
and shows heterogeneity in the amino acid sequences). Monoclonal antibodies 
can be advantageous for immunochemical purposes. 
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In most immunochemical assays binding of antibody to antigen can only be 
visualised by labelling the antibody either with a radioactive isotope, an enzyme 
or a fluorochrome. Antibodies labelled with a fluorochrome or enzyme are 
commonly referred to as conjugates. 
Immunobinding assays such as ELISA (enzyme-linked immunosorbent assay) 
utilise either imobilised antigen or antibody to assess the concentration of a 
molecule in solution. They are very quick, easy, cheap and simple to carry out. 
Antigen containing solution is simply incubated in the wells of a plastic 
microtitre plate allowing the imobilised antibody to bind to the antigen. The 
antigen is then detected either directly or indirectly by an enzyme conjugated 
antibody. The enzyme then reacts with an added substrate to allow visualisation 
of the antigen. 
In order to understand cell structure and organisation in disease it is often 
necessary to be able to determine the distribution of a protein in situ. 
Immunohisto/cytochemical (IHC/ICC) techniques exploit the specific interaction 
of an antibody with its antigen to locate or determine the distribution of the 
antigen in tissues or cells respectively. The principle of IHC is analagous to 
ELISA except the antibody is incubated with thin tissue sections mounted on 
microscope slides or cell preparations containing the antigen. The antibody must 
be conjugated with a fluorescent or enzyme label that gives a signal to allow 
visualisation under the microscope. 
All IHC procedures require stringent positive and negative controls for 
comparison to ensure the immunostaining is specific. The main advantage of 
enzyme labels (usually horse radish peroxidase [HRP] or Alkaline Phosphatase 
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[AP]) is that an ordinary white light microscope can be used for viewing the 
slides and the use of a chemical counterstain such as heamatoxylin aids the 
identification of morphology. The main disadvantage is the presence of 
endogenous tissue enzymes, which can give a high background staining. This can 
be overcome with blocking steps during the procedure. 
Immunohisto/cytochemistry techniques give information on the cellular location 
of a protein or peptide detected with an antibody. It does not give information on 
the expression or activity of the protein. You can measure the expression of 
proteins within the cell by the detection of mRNA using either reverse 
transcriptase-PCR or in situ hybridisation techniques. 
1.19.2 Reverse Transcriptase-PCR 
Polymerase Chain Reaction (PCR) is used to amplify a precise fragment of DNA. 
It requires some knowledge of the DNA sequence, which flanks the target DNA. 
From this information two oligonucleotide primers can be chemically synthesised 
each complementary to a stretch of DNA to the 3' side of the target DNA, one 
oligonucleotide for each of the two strands of DNA. The technique is analogous to 
the DNA replication process within the cell in that it results in the generation of 
new complimentary DNA strands based upon existing ones. 
The process of PCR consists of three defined sets of time and temperatures: i) 
denaturation, ii) annealing and iii) extension. Each of these steps is repeated for 
30 or 40 cycles. In the first step the double stranded DNA fragment is denatured 
by heating to above 90°C. Next the temperature is cooled to allow the 
oligonucleotide primers to anneal to their complimentary sites either side of the 
target DNA strand to be replicated. The final step, extension is carried out by a 
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thermostable DNA polymerase (in most cases Taq DNA polymerase). The time 
and temperatures of these steps are critical, but vary and have to be optimised 
and defined for each reaction. 
The method of PCR has been utilised to analyse mRNA through the development 
of a technique called Reverse Transcriptase-PCR (RT-PCR). Here the RNA is 
isolated and a first strand cDNA synthesis is carried out using reverse 
transcriptase. The resulting cDNA is then used as target DNA in conventional 
PCR. One of the main benefits of RT-PCR is the ability to identify rare or low 
levels of mRNA transcripts with great sensitivity. RT-PCR also gives information 
on the gene expression of possible protein molecular markers. 
The method of PCR has also been modified to detected active telomerase within 
protein tissue extracts. TRAP (Telomerase Repeat Amplification Protocol) is 
covered in section 1.16.5. 
1.19.3 In Situ Hybridisation 
In Situ Hybridisation (ISH) makes it possible to determine the chromosomal 
location of a particular gene fragment or mutation, or the cellular location of 
mRNA within a tissue section. ISH is carried out by preparing either a 
radiolabelled or non-isotopic labelled RNA or DNA probe and applying it to a 
tissue or chromosomal preparation fixed to a microscope slide. Any probe that 
does not completely hybridise to complementary sequences is washed off and an 
image of the distribution or location of the bound probe is viewed by 
autoradiography or under the light microscope after the reaction of an enzyme 
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similar to IHC. In situ hybrdisation is covered in detail in sections 1.16.5 and 4.3. 
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2 Aims and Objectives 
2.1 Aim 
The aim of this thesis is the study of molecular markers for the 
progression of Barrett's oesophagus to adenocarcinoma, to identify 
markers that can be used as diagnostic tools. 
Currently there are no molecular markers available to distinguish between 
patients with Barrett's metaplasia who are at high risk of developing 
adenocarcinoma and those that are not. Current screening programmes for 
Barrett's oesophagus are not cost effective and therefore a marker for dysplasia 
and adenocarcinoma has the potential to improve surveillance for patients at a 
high risk of developing adenocarcinoma. 
2.2 Objectives 
1. To investigate the timing and significance of telomerase reactivation 
during the metaplastic-dysplastic-neoplastic progression of Barrett's 
oesophagus. 
Both immortalisation and invasion are important factors in the development of 
malignant tumours and therefore could be significant markers during the 
progression of Barrett's oesophagus. So far little work has been performed to 
assess the development of an immortal phenotype, i. e. telomerase reactivation, 
during the progression of Barrett's oesophagus to adenocarcinoma. This study 
discusses the timing and significance of telomerase reactivation during the 
metaplastic-dysplastic-neoplastic progression of Barrett's oesophagus. The 
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Telomerase Repeat Amplification Protocol (TRAP Assay) and in situ 
hybridisation techniques will be utilised for this purpose. 
2. To investigate the progression of Barrett's oesophagus to 
adenocarcinoma with reference to the components of the urokinase- 
type Plasminogen Activator system. 
The invasive potential of the non-neoplastic stages of Barrett's oesophagus has 
also been largely neglected from previous investigation. This study therefore 
involves a full assessment of the levels of the components of the urokinase-type 
Plasminogen Activator system, by means of immunohistochemistry, enzyme- 
linked immunosorbant assay (ELISA) and cell culture techniques. One objective 
of this project is to investigate the progression of Barrett's oesophagus to 
adenocarcinoma with reference to the components of the Plasminogen Activator 
system. 
3. The characterisation of oesophageal cell lines as potential in vitro 
models of oesophageal tumours and the effects of exposure to bile 
salts and acidic conditions on molecular markers of disease 
progression. 
The potential role of bile salts and exposure of the oesophageal mucosa to acidic 
conditions in the development of Barrett's metaplasia and its neoplastic 
progression are discussed. Oesophageal cell-lines, which have been fully 
characterised as in vitro models of oesophageal tumours during this study, are 
utilised for this purpose along with various molecular biological techniques 
including reverse transcriptase-PCR and immunocytochemistry. 
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In this thesis Chapter 3 details the materials and methodology used during this 
study. In Chapter 4 the Telomeric Repeat Amplification Protocol has been 
utilised to assess the timing and significance of telomerase reactivation in tissue 
from patients suffering from various stages of the Barrett's oesophagus 
adenocarcinoma sequence. Also a method of non-isotopic in situ hybridisation for 
the detection of the RNA component of telomerase has been developed to assess 
the cellular localisation of telomerase within paraffin embedded sections of 
neoplastic tissues. 
Chapter 5 describes the components of the urokinase-type Plasminogen Activator 
system during the metaplastic: neoplastic progression of Barrett's oesophagus. 
Urokinase-type Plasminogen Activator, its receptor and two inhibitors have been 
examined by immunohistochemistry on paraffin embedded sections of tissue and 
on the same protein lysates from the telomerase study using ELISA techniques. 
In Chapter 6 cell-culture methods are utilised to assess two oesophageal cell-lines 
as in vitro models of Barrett's associated adenocarcinoma and oesophageal 
squamous cell carcinoma. Molecular markers are assessed using Reverse 
Transcripase-PCR, immunocytochemistry, and ELISA techniques. Chapter 7 
discusses the use of these cell-lines to determine the effects of bile salts and 
acidity on cellular adhesion, invasiveness and immortality during Barrett's 
oesophagus, as refluxate is thought to be a causal factor in the formation of 
oesophageal neoplasia. 
Chapter 8 discusses the data obtained in the previous chapters and suggests 
areas of further study. Finally Chapter 9 draws together the conclusions of this 
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study into molecular markers for the progression of Barrett's oesophagus to 
adenocarcinoma. 
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3 Materials and Methods 
3.1 Chemicals, Reagents and Other Materials 
A full list of suppliers and equipment are listed in Appendix 2. 
3.2 Cell culture 
Human oesophageal cell-lines OE21 and OE33 (also known as JROECL21 and 
JROECL33) (Rockett 1997) were cultured in RPM1-1640 modified medium 
supplemented with 10% foetal bovine serum, 5m1 stabilised penicillin- 
streptomycin solution and lml amphotericin B solution per 500m1 (all regents 
from Sigma cell culture, Poole, Dorset, England). OE21 is a human oesophageal 
squamous cell carcinoma cell-line established in 1993 from a mid oesophageal 
carcinoma of a 74 year-old male patient. OE33 is a human oesophageal 
adenocarcinoma cell-line also established in 1993 from an adenocarcinoma of the 
lower oesophagus (with Barrett's metaplasia) of a 73 year-old female patient 
(Rockett 1997). 
Cells were grown in various sized culture flasks ranging from T25cm2 to 
T100cm2. Once established the cells were checked daily for possible infections 
and to assess growth. The media was replaced every 2 days. Once the cells were 
75-80% confluent they were detached from the culture flask surface using lx 
trypsin-EDTA solution (Sigma cell culture, Dorset, England) and split into 
further flasks, frozen down or treated for protein extraction. The growth medium 
was removed and the cells washed once in sterile phosphate-buffer saline (PBS), 
then 5m1 of trypsin solution was added and the flask left to stand for 1 minute. 
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Gentile tapping on the side of the flask helped to detach the cells. Trypsin was 
inhibited using 5m1 of growth medium and the cells were pelleted by 
centrifugation at 100 xg for 5 minutes at 4°C. The pellet of cells could then be 
split into further flasks, frozen down in 5% Dimethyl sulfoxide (DMSO) in foetal 
bovine serum, used for Tri Reagent extraction or TRAP Assay/IMUBIND ELISA 
(see sections 4.2 and 5.3). 
Cell-lines were also grown in 0.1mM concentrations of different conjugated bile 
acids or acidified growth media (pH5) to analyse if this altered telomerase 
activity or the of components of the Plasminogen Activator system (see section 
7.2). 
3.3 Clinical Samples 
All the clinical samples, both fresh frozen and paraffin embedded were obtained 
from the histopathology department of Gloucestershire Royal Hospital. Ethical 
approval for this work was arranged on 11th June 1999 and copies of all the 
relevant letters and forms can be found in Appendix 1 at the back of this report. 
All fresh frozen samples were collected with patient written consent during 
routine surveillance endoscopy and from resected tissue during routine 
pathological analysis. The samples were placed on card and into cryovials before 
they were snap frozen in liquid nitrogen. 
Tissues were fixed in 10% neutral buffer formalin for a minimum of 24 hours and 
then embedded in Polywax (Difco Laboratories, Surrey, UK). Sections 
approximately 4µm thick were taken and placed on vectabond coated slides 
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(Vector Laboratories, Burlingame, USA) and dried for 24 hours. Full details of 
the protocol for sample donation can be found in Appendix 1 as mentioned above. 
3.4 Haematoxylin and Eosin staining 
Haematoxylin and Eosin staining is the most commonly used staining method. 
This stain differentiates tissues by colouring the nuclei and basic parts of cells 
blue/black with haematoxylin and connective tissues and acidic parts of cells 
shades of red and pink with eosin. 
The fresh frozen sections of tissue were initially fixed in formal acetic alcohol for 
1 minute. They were then washed in tap water and placed in Mayers 
haematoxylin for 1 minute and rinsed in tap water. The slides were then placed 
in saturated lithium carbonate to increase the blue colouration and rinsed in tap 
water. Next the slides were placed in 1% eosin for 15 seconds and rinsed once 
more in tap water. The slides were then dehydrated in ethanol, cleared in xylene 
and finally mounted in pertex and cover slipped. 
3.5 Tri ReagentTM' RNA, DNA and protein extraction 
Tri ReagentTM (Sigma-Aldrich Company Ltd. Poole, Dorset, England) is a quick 
and convenient reagent for the simultaneous isolation of RNA, DNA and protein. 
Isolation was carried out according to the manufacture's protocol and is detailed 
below. 
3.5.1 Sample preparation 
A monolayer of cells approximately 75-80% confluent which had been grown for 5 
to 6 days was lysed directly on the surface of the culture dish. (For a T25 culture 
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flask 200µl of Tri-reagent [Sigma-Aldrich Company Ltd. Poole, Dorset, England] 
was used. This increased proportionally for the larger flasks. ) This was left to 
stand for 5 minutes to allow complete dissociation of nucleoprotein complexes. 
The resulting solution was transferred to a 2m1 sterile eppendorf tube and 200µ1 
of chloroform was added. The tube was shaken vigorously for 15 seconds and left 
to stand for 10 minutes at room temperature. The tube was then centrifuged for 
15 minutes at 12,000 xg at 4°C. This resulted in the separation of the mixture 
into three phases: a red organic phase (containing protein), an interphase 
(containing DNA) and a colourless upper aqueous phase (containing RNA). 
3.5.2 RNA Isolation 
The upper aqueous phase containing RNA was completely removed and 
transferred to a new tube and 500µ1 of isopropanol was added and the sample 
was left to stand at room temperature for 10 minutes. This was then centrifuged 
for at 4°C for 10 minutes at 12,000 x g. The RNA precipitate formed a pellet on 
the side and bottom of the tube. The supernatant was removed and the pellet 
washed in lml of 75% ethanol. This was centrifuged at 7,500 xg for 5 minutes at 
4°C to re-pellet the RNA. The pellet was briefly dried in the air for 10 minutes 
and redissolved in 300gl of nuclease free water. 
3.5.3 DNA Isolation 
All the remaining aqueous phase was removed and 3O0gl of 100% ethanol was 
added. This was mixed by inversion and left to stand for 3 minutes at room 
temperature. It was then centrifuged at 2,000 xg for 5 minutes at 4°C and the 
pink supernatant removed and saved for protein extraction. The pellet was 
washed twice in O. 1M sodium citrate, 10% ethanol solution for 30 minutes and 
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centrifuged at 2,000 xg for 5 minutes at 4°C each time. The resulting pellet was 
resuspended in 75% ethanol and left to stand for 20 minutes at room 
temperature, before it was dried and dissolved in 3O0µ1 8mM NaOH. This was 
then centrifuged at 12,000 xg for 10 minutes to remove any insoluble material 
and the supernatant was transferred to a fresh tube. 
3.5.4 Protein Isolation 
To the pink supernatant saved from the DNA isolation step for protein isolation 
1.5m1 of isopropanol was added and incubated at room temperature for 10 
minutes. This was centrifuged at 12,000 xg for 10 minutes at 4°C and the 
supernatant was discarded. The resulting pellet was washed 3 times for 20 
minutes in 2m1 of 0.3M guanidine hydrochloride/95% ethanol solution and 
centrifuged at 7,500 xg for 5 minutes at 4°C each time. The supernatant was 
removed and 2 ml of 100% ethanol was added and left to stand at room 
temperature for 20 minutes. This was centrifuged for 7,500 xg for 5 minutes at 
4°C. The pellet was dried and redissolved in 300µl 1% SDS. Any insoluble 
material was removed by centrifugation at 10,000 xg for 10 minutes at 4°C and 
the supernatant transferred to a fresh tube. 
3.6 Quantification of RNA and DNA 
To estimate the concentration of DNA and RNA UV spectrophotometery was 
utilised with the M350 double beam UV-visible spectrophotometer (Camspec, 
Cambridge UK). By measuring the absorbance at 260 and 280 nm the purity and 
the concentration of the sample could be assessed. Each sample was diluted in 
water and readings made at each wavelength, blanked against water alone. The 
resulting readings were used in the following calculations: 
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Purity = Also / A28o (where a value of 1.8 means pure DNA and 2.0 means pure 
RNA) 
Yield (ug/ml) = A26o x dilution factor x 50 (for genomic DNA) or x 40 (for RNA) 
3.7 Measurement of Total Protein Concentration 
The protein lysates were diluted 1: 5 in distilled water and mixed with 1.5m1 of 
BioRad Protein Assay dye. This was mixed and incubated for at least 5 minutes 
at room temperature. The A595 was measured for each sample and the 
concentration estimated from a standard curve of six IgG standards at 
concentrations between 0 and 1000µg/ml. 
3.8 Gel Electrophoresis for the analysis of DNA and RNA 
To assess the quality and quantity of extracted DNA and RNA, agarose gel 
electrophoresis was utilised using the Embitech RunOne system. Agarose gel 
electrophoresis was also carried out to visualise PCR and in vitro transcription 
products. The percentage of agarose in the gels varied according to the size of 
product as shown in table 3.1. 
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Table 3.1 Agarose gel selection chart. 
Gel (%) Optimum Separation Range (Kb) 
0.3 5-60 
0.6 1-20 
0.7 0.8-10 
0.9 0.5-7 
1.2 0.4-6 
1.5 0.2-3 
2.0 0.1-2 
Gels were stained using ethidium bromide solution (0.5µg/ml) for 15 minutes and 
then destained in dH2O for 10 minutes. The DNA was visualised using a 
shortwave (254nm) UV transilluminator within the Syngene Gene Genius Bio- 
imaging System (Synoptics Ltd. ) and images archived on the computer. 
3.9 Immunohistochemistry 
Immunohistochemistry was used on both cell-lines cultured in slide flasks and 
paraffin embedded sections of tissue. The overall method was the same although 
there were differences in the preparation and mounting of the slides. 
Non-specific reactions were blocked using the appropriate serum (1: 5) (v/v) in 
PBS. The serum used was from the same species as the secondary antibody was 
raised in, usually rabbit, goat or sheep. The diluted serum was added to the 
slides completely covering the tissue section and incubated at room temperature 
in a humid chamber for 1 hour. The blocking serum was removed without 
washing and the primary antibody added diluted with PBS containing 1% serum 
(as used for blocking) again completely covering the tissue section and left in a 
humid atmosphere at 4°C overnight. 
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The next day the slides were removed from the fridge and allowed to reach room 
temperature. The primary antibody was removed and the slides washed three 
times for 5 minutes each in tris-buffered saline (TBS). Next endogenous hydrogen 
peroxidase activity was blocked by incubation with 3% hydrogen peroxide in 
100% methanol for 10 minutes and the slides washed 3 times for 5 minutes each 
in TBS. The secondary antibody was then added diluted in PBS and 1% serum 
and left to incubate for 1-2 hours in a humid chamber. The secondary antibody 
again varied depending on the animal in which the primary antibody was raised 
in. The avidin-biotinylated horseradish peroxidase conjugate (ABComplex) (Dako 
Ltd. Cambridge UK was prepared according to the manufacturers instructions 
20 minutes before it was needed and stored in the dark. The secondary antibody 
was removed and the slides washed as previously described and the ABComplex 
added. This was left to incubate for approximately 1 hour and then washed. The 
slides were then incubated with 3,3'-Diaminobenzine (DAB) (Sigma-Aldrich 
Company Ltd. Poole, Dorset, England) (50mg DAB in 100ml TBS and 100µ1 
Hydrogen peroxide) and the reaction monitored until staining was seen. The 
slides were then washed in tap water and counter stained with haematoxylin and 
mounted. Slides were then viewed under the microscope and archived using 
AxioVision Version 3 (Imaging Associates, Thame, UK). 
3.10 Western Blot Analysis 
Immunodetection of proteins extracted from both cell-lines and fresh frozen 
tissue samples was carried out using the ECL chemiluminecent detection system 
(Amersham Pharmacia Biotech). Glass plates, plastic spacers and combs from the 
BioRad Mini Protein II were cleaned and assembled according to the 
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manufacturers instructions. A 6% main gel and a 4% stacking gel were made 
according to the recipes shown in table 3.2. 
Table 3.2 Acrylamide Gel Composition 
Gel 30% Bis/ Tris Buffer 10% TEMED Ammonium RO Total 
Acylamide SDS Persul hate Water 
6% 2m1 2.5m1 (1.5M 10Oµ1 10µl 5Oµ1 5.35m1 lOml 
pH8.8) 
4% 650µ1 1.25m1 (0.5M 500 100 25µ1 3.05 5m1 
pH7.5 
Once the gels were poured into the frame (main gel first then stacking gel) and 
had dried a1 in 3 dilution of the samples were prepared with 4x loading dye. The 
samples were boiled at 95°C for five minutes and placed on ice before a volume 
was loaded into a well of the gel. One well was loaded with 10µ1 of pre-stained 
molecular weight marker (SeeBlueTMPre-stained Standard, Novel Experimental 
Technology). The gel was then run at 75V for 15 minutes to allow the samples to 
move through the stacking gel and then at 100V for about 1 hour (or until the 
sample buffer reached the bottom of the gel). 
The gel was then removed from the glass plates and blotted onto an Immobilon-P 
Transfer Membrane, (Millipore) using an electroblotter (Hoefer SemiPhorrM 
Amersham Pharmacia Biotech) run for 55 minutes at 40-44mA. The pre-stained 
marker could be seen on the membrane once transfer was completed. 
The membrane was blocked in 5% Marvel/TSB for 1 hour. The primary antibody 
was diluted 1 in 1000 in 5% Marvel/TBS and the membrane incubated with the 
antibody overnight at 4°C. 
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The following day the membrane was removed from the fridge and left for 30 
minutes to reach room temperature. Next it was washed 5 times for 5 minutes in 
0.1% Tween 20/TBS. The membrane was then placed in the peroxidase 
conjugated secondary antibody again diluted 1 in 1000 in 5% MarvellTBS and 
incubated for 1 hour at room temperature. It was then washed 5 times for 5 
minutes in 0.1% Tween 20/TBS. The proteins were detected using the ECL 
detection system (Amersham Pharmacia Biotech) according to the 
manufacturer's instructions. Once the reagents were added the membranes were 
incubated for 1 minute wrapped in cling film and placed in a film cassette on a 
sheet of autoradiography film (Kodak X-OMAT). Exposure was carried out for at 
least two hours before developing and fixing of the film with solutions from 
Sigma. 
3.11 Production of cDNA (RT-PCR) 
ß-Actin primers were used to check the mRNA content of the total RNA samples 
extracted from the cell-lines using Tri-reagent. The primers (as desribed in 
appendix 4) amplified a product of approximately 500 base pairs from the ß-actin 
gene in cDNA produced from the RNA samples using reverse transcription from 
both the cell-lines. This proved the RNA samples were viable and therefore were 
suitable for further RT-PCR analysis. 
Using total RNA samples produced by Tri-reagent extraction (section 3.5) a 
reverse transcription reaction (RT-PCR) was made. The Promega RT System 
(Promega Corporation, Southampton, UK) was utilised using AMV Reverse 
Transcriptase to synthesise single-stranded cDNA. Each RT reaction was carried 
out in a 2Oµ1 reaction containing 5mM MgC12, lx Reverse Transcription Buffer 
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(10mM Tris-HC1 [pH 9.0 at 25°C], 50mM KC1,0.1% Triton(b X-100), 1mM each 
dNTP, 1U/µ1 Recombinant RNasin® Ribonuclease Inhibitor, 15U/µl Oligo (dT)n 
Primer, 1µg substrate total RNA and nuclease-free water to volume. The reverse 
transcription reaction was then incubated at 42°C for 15 minutes followed by 
99°C for 5 minutes to denature the AMV Reverse Transcriptase. The samples 
were then placed on ice for 5 minutes. 
The RT reaction was then diluted to 100µl with nuclease-free water and 20µl 
used in the PCR mix with 2mM MgC12, lx Reverse Transcription Buffer (10mM 
Tris-HC1 [pH9.0 at 25°C], 50mM KC1,0.1% Triton® X-100), 50pmol of the 
upstream and down stream primers and 2.5U Red Hot DNA polymerase 
(Advanced Biotechnologies Ltd. Epsom Surrey, UK) was added after a "Hot 
start". No extra dNTP needed to be added as enough was left in the RT mix. The 
cycling was carried out using the Hybaid Touchdown machine (Hybaid Ltd. 
Basingstoke, UK). Cycling conditions were one cycle of 94°C for 5 minutes when 
the DNA polymerase was added. This was followed by 30 cycles of 94°C for 1 
minute, 1 minute at the appropriate annealing temperature calculated by the TM 
of each primer and a 72°C extension step varying between 30 seconds and 2 
minutes. The annealing temperature was 55°C for 1 minute and extension of 2 
minutes for the ß-actin primers R and F (see appendix 4). 
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4 Telomerase During the Metaplastic: Neoplastic 
Progression of Barrett's Oesophagus 
4.1 Introduction 
As mentioned in section 1.16 telomerase is a ribonuclear protein complex with 
reverse transcriptase activity that uses its own RNA component as a template for 
the addition of telomeric repeat sequences to the end of chromosomes, therefore 
maintaining telomere length. Telomerase activity is present in approximately 
85% of primary human cancers, but not in most normal somatic tissues. 
Telomerase activity has been studied in a wide range of cancers using various 
methods of detection. To assay for telomerase activity in small samples of human 
tissues, a sensitive PCR-based assay has been developed (Kim 1994), called the 
telomeric repeat amplification protocol (TRAP). The TRAP method has been 
further developed and combined with an ELISA detection system instead of a gel 
for a rapid, easy and reliable telomerase detection in human tissue samples. The 
TRAPEZETM ELISA Telomerase Detection Kit (Intergen) is the method utilised 
here to study telomerase activity in the progression of Barrett's Oesophagus to 
adenocarcinoma in fresh frozen clinical samples. 
The main disadvantage of using the TRAP method for analysing telomerase 
activity in clinical tissue samples is there is no way of telling exactly which cells 
within the samples are expressing telomerase. This problem can be overcome 
with the use of in situ hybridisation techniques. The application of in situ 
hybridisation techniques for detecting telomerase RNA expression in archival 
paraffin-embedded and fresh frozen material can easily distinguish cancer from 
85 
normal cells (Shay 1997a). The use of in situ hybridisation for the detection of the 
RNA template within the enzyme complex should allow the localisation of 
specific cells with telomerase activity. Previously a method of in, situ 
hybridisation for the detection of the RNA component of telomerase in tissue 
samples from the metaplastic: neoplastic progression of Barrett's Oesophagus 
using radiolabeled RNA probes has been developed (Morales 1998). The main 
problem with this study was the small number of samples analysed. Therefore 
this chapter describes the development of a method of in situ hybridisation for 
the detection of telomerase using a non-isotopic method. 
4.2 The TRAPEZEN ELISA Telomerase Detection Kit 
For non-quantitative detection of telomerase activity in cells and tissues the 
Oncor TRAPEZETM ELISA telomerase detection kit (Intergen Company, Oxford, 
UK) was utilised. The kit contains all the reagents necessary to perform the 
Telomeric Repeat Amplification Protocol (TRAP) and Enzyme-Linked 
Immunosorbent Assay (ELISA). The assay was carried out according to the 
manufacture's protocol and is detailed below. The overall protocol is shown in the 
form of a flow diagram in figure 4.1. 
4.2.1 Extract Preparation 
Sections of fresh frozen oesophageal tissue, which had been stored in liquid 
nitrogen (-146°C) for up to 4 years (mainly resected samples) were removed from 
cryovials and frozen onto metal chucks. The top of the sample was flattened and 
then using a cryostat a section 10nm thick was cut and placed on a vectabond- 
coated slide. The next 10 sections were placed in a cold 1.5ml nuclease-free 
micro-centrifuge tube. The next section was placed on the slide and the following 
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10 sections placed in the cold tube. A final section was cut and placed on the slide 
ready for heamatoxylin and eosin staining, section 3.4. The three sections on the 
slides were used to check the tissue remained the same through the whole block 
and all the sections in the tube had the same diagnosis. The sections were lysed 
in 2O0µ1 of CHAPS lysis buffer containing 120U/ml RNasin® Ribonuclease 
inhibitors (Promega Corporation, Southampton, UK). 
The sample suspensions were incubated on ice for 30 minutes and then spun at 
12,000 xg for 20 minutes at 4°C. The supernatant (160µ1) was transferred to a 
fresh tube and 6 t1 set aside for determination of protein concentration (see 
section 3.7). The kit recommended diluting the sample extracts with CHAPS lysis 
buffer prior to use tissue extracts (0.01µg/111 - 0.50µg/µl) using less than 1.0µg per 
assay. Titre experiments were also carried out to find the optimum concentration 
of protein required for the assay. 
4.2.2 Controls 
Telomerase is a heat-sensitive enzyme and therefore as a negative control a heat- 
inactivated sample was produced for each protein extract. Telomerase was 
inactivated by heat-treating 100 of each tissue extract at 85°C for 10 minutes 
prior to the TRAP assay. 
For each set of TRAP assays two positive telomerase extract controls, two 
PCR/ELISA positive controls and two primer-dimer/PCR contamination controls 
were included. A telomerase containing cell extract was included in the kit as a 
positive control. This was prepared in the same way as the cell samples and 
diluted 1/10 with CHAPS lysis buffer. TSR8 was used as a PCR/ELISA positive 
control. TSR8 is a synthetic oligonucleotide with 8 telomeric repeats and 
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therefore acted as a template for the PCR reaction. The TRAP assay was also 
performed with CHAPS lysis buffer instead of the tissue extract. This acted as a 
PCR contamination control. 
4.2.3 TRAP Assay 
The TRAP assay was set up for each sample containing l0gl 5x TRAP reaction 
mix (containing Tris buffer; primers: Biotinylated Telomerase Substrate primer 
[AATCCGTCGAGCAGAGTT] and Reverse primers [For the PCR step]; dNTPs: 
dCTP labelled with dinitrophenyl), dGTP, dATP, and dTTP), 2U Taq polymerase 
and dH2O up to 48µl. 21l of the test extracts, heat activated extracts or controls 
were then added to each mix. 
Firstly the samples were incubated for 30 minutes at 30°C to allow extension of 
the telomeric repeats on the biotinylated telomerase substrate oligonucleotide. In 
the second step the extended products were amplified by PCR. The cycling 
conditions were 33 cycles of 94°C for 30 seconds followed by 55°C for 30 seconds 
with no extension step. 
A streptavidin-coated microtiter plate was pre-treated with Blocking/Dilution 
Buffer. Each well was filled with 25Oµ1 Blocking/Dilution Buffer, covered in 
parafilmTM and incubated at 37°C for 30 minutes. This was then removed and 
each well washed once with 4O0µ1 lx Wash Solution. Into each well 100µl of 
Blocking/Dilution Buffer was added along with 51l of the TRAP reaction product. 
This was mixed thoroughly by pipetting 10 times. The wells were covered in 
parafilmTM and incubated at 37°C for 1 hour. Table 4.1 shows the sample 
arrangement for the assay on the microtitre plate. 
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A. Sample Preparation 1. Cell pellet or tissue in a 1.6m1 micro-centrifuge tube 
2. Add CHAPS lysis buffer 200µl 
3. Incubate on ice for 30 minutes 
4. Centrifuge at 12,000 xg for 20 minutes 
5. Transfer supernatant to a fresh tube 
6. Determine protein concentration 
B. TRAP Assay Set Up 1. Prepare master mix: 
5x TRAP reaction mix 10µl 
Taq DNA polymerase 2 units 
DH2O up to 480 
2. Aliquot into PCR tube (48µ1/tube) 
3. Add sample extract (20) 
C. TRAP Reaction 1. Extension/amplification step 30°C for 30 
minutes 
2. PCR Cycling 94°C for 30 seconds 
55°C for 30 seconds 
for 33 cycles 
D. ELISA Detection 1. Pipette blocking/dilution buffer into microtitre 
plate (250pl/well) incubate 37°C for 30 minutes 
2. Wash once with Ix wash solution (400pl/well) 
3. Add l000 of blocking/dilution buffer and 50 
TRAP reaction products per well. 
4. Incubate at 37°C for 1 hour 
5. Wash 5 times with Ix wash buffer 
6. Add anti-DNP antibody (100pl/well) 
7. Incubate at room temperature for 30 minutes 
8. Wash 5 times with lx wash buffer 
9. Add TMB substrate (100pl/well) for 3-10 
minutes 
10. Add Stop solution (1000well) 
11. Measure absorbance at 450nm and 650nm 
Figure 4.1 TRAPEZETM ELISA protocol flow chart. 
Table 4.1. Sample arrangement for the TRAPEZETM ELISA on the 
microtitre plate. 
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1 2 3 
A Positive Control Sample 1 Sample 1 
B Positive Control Heat-treated sample 1 Heat-treated sample 1 
C TSR8 Sample 2 Sample 2 
D TSR8 Heat-treated sample 2 Heat treated sample 2 
E Buffer Sample 3 Sample 3 
F Buffer Heat-treated sample 3 Heat-treated sample 3 
G Sample 4 Sample 4 
H Heat-treated sample 4 Heat-treated sample 4 
The solution was removed and each well was rinsed 5 times with lx Wash 
Solution. Anti-dinitrophenyl antibody conjugated to horseradish peroxidase was 
diluted 1: 250 with Blocking/Dilution Buffer and l00µ1 added to each well. This 
was incubated at room temperature for 30 minutes and then each well rinsed 5 
times with lx Wash Solution. Next 100µl of the horseradish peroxidase substrate 
tetramethylbenzidine (TMB) was added to each well and incubated for between 3 
and 10 minutes at room temperature. To achieve uniform mixing of reagent the 
microtitre plate was tapped every 1-2 minutes. To change the peroxidase product 
from blue to yellow 100111 of Stop Solution was added to each well. The plate was 
then read on a MRX Microplate reader (Dynex Technologies (UK) Ltd. 
Billingshurst, West Sussex, UK) and the absorbance of the samples at 450nm 
and 690nm calculated. 
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The value for each sample was calculated as: 
Absorbance (units) = A450 - A69o 
For the assay to give valid results the controls must have had values of: 
" Primer dimer/PCR contamination control: Absorbance units must be below 
0.200. 
9 TSR8 PCR/ELISA control: Absorbance units must be greater than 0.800. 
" Heat-treated sample extract: Absorbance units must be less than 0.250. 
" If the extract was telomerase positive: AA> 0.150. 
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4.3 'In Situ Hybridisation for the Detection Telomerase 
In situ hybridisation for the detection of telomerase was carried out using an 
RNA anti-sense probe to the RNA component of telomerase. During this study 
three main methods of in situ hybridisation were tested. The DNA template used 
for producing RNA labelled probes was the same for all methods tested. The first 
method was carried out using biotin labelled RNA probes and commercially 
available kits from Ambion (Ambion International, Texas, USA) according to the 
manufacturer's instructions. The second method was carried out using DIG 
labelled RNA probes and anti DIG-POD conjugated antibodies with DAB 
detection (Chang 1999). The final method was a further development of the 
Chang et al method using anti DIG-AP antibodies and BCIP/NBT Alkaline 
Phosphatase substrate for detection. 
4.3.1 Production of the RNA probe 
The plasmid pGRN83 was acquired from Geron corp. This construct was made by 
the PCR of the exact 5' end and approximate 3' end of the RNA component of 
human telomerase from the genomic clone of hTR. The PCR product was blunted 
and cloned into the ECL3611 site of pGEM5Zf+ (Geron corp. details). The total 
size of the plasmid pGRN83 was 3558bp. 
The plasmid was transformed into both "home-made" and commercially available 
competent E. coli cells. 
`7n House" competent cells 
JM83 bacterial cells were grown in solution of LB broth overnight and the 
following day 100ml of LB broth was inoculated with 1ml of this stock. This was 
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incubated with shaking at 37°C until the A55o was between 0.4 and 0.5. The 
culture was then placed on ice for 10 minutes. Cells were harvested from 40m1 of 
culture by centrifugation and resuspended in 10ml of cold 0.1M MgC12. The cells 
were then pelleted and resuspended in lml of cold 0.1M CaC12 and left on ice for 
2 hours. 
To 200µ1 of competent cells 25ng of plasmid was added and incubated on ice for 
30 minutes. The cells were then heat-shocked for 2 minutes at 42°C and then 
placed immediately on ice. The cells were diluted 1: 10,1: 100,1: 1000 and 1: 10,000 
and 1000 was plated out on LB agar containing 1mg/ml amphicillin and 
incubated overnight at 37°C. 
Commercial competent cells 
The commercially available competent cells were JM109 (Promega, UK). The 
frozen competent cells were placed on ice to defrost. Once defrosted 100µ1 of the 
cells were aliquoted into pre-chilled thin-walled PCR tubes. To these 25ng of 
plasmid DNA was added and the tubes placed in ice for 10 minutes. The cells 
were then heat-shocked for 2 minutes at 42°C and 9O011 of cold LB broth was 
added. This was then incubated at 37°C for 30 minutes with shaking. Dilutions 
were made of 1: 10 and 1: 100 and 1001l plated onto antibiotic plates as above and 
incubated overnight. 
4.3.2 Plasmid DNA isolation 
The plasmid DNA was extracted from the transformed cells using the SNAP 
MidiPrep Kit available from Invitrogen (Invitrogen Corporation, USA). The 
procedure required the following steps: 
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" Lyse cells with Lysis buffer 
" Precipitate protein and genomic DNA 
" Filter the Lysate/precipitate through Column A 
" Add Binding buffer to the flow through and apply to column B 
" Wash the bound plasmid and dry the resin by centrifugation 
9 Elute the Plasmid DNA with sterile water. 
A single colony of transformed bacteria cells was grown for 12 hours at 37°C in 
100m1 of LB containing amphicillin. The cells were then pelleted by 
centrifugation at 400 x g. The cells were resuspended in 4m1 of Cell Resuspension 
Buffer by vortexing. To this 4m1 of Lysis Solution was added, mixed by inversion 
and incubated for 3 minutes at room temperature. Next 4m1 of Precipitation Salt 
was added, mixed again by inversion and incubated for 5 minutes in ice. Two 
50m1 centrifuge tubes were labelled A and B. The Filtering column A was placed 
in tube A and the Binding column B was placed in the tube labelled B. The 
precipitated solution was added to column A and centrifuged for 5 minutes at 
3,000 x g. 
The filtrate was saved, 12m1 of Binding buffer added and mixed by inversion. The 
solution was transferred to column B and centrifuged for 2 minutes at 1,000 x g. 
The bound plasmid was washed in 5m1 of Washing Buffer and centrifuged for 1 
minute at 2,000 x g, then washed in 5m1 Final Wash Buffer and centrifuged for 2 
minutes at 2,000 x g. A final wash of 10m1 Final Wash Buffer was added and 
centrifuged for 2 minutes at 2,000 x g. The column was spun for 5 minutes at 
4,000 xg to dry the resin. Column B was then transferred to a clean tube and 
7500 of sterile water was added and left to incubate in the column for 3 minutes 
at room temperature. The column was then centrifuged for 5 minutes at 4,000 xg 
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to elute the plasmid DNA. To analyse the quality, quanity and size of the 
resulting plasmid DNA gel elctrophoresis was carried out as described in section 
3.8. 
4.3.3 Restriction digest of plasmid DNA 
In order to produce an RNA probe the template DNA sequence had to be removed 
from the plasmid DNA including the 19-23 base promoter regions for the phage 
RNA polymerases, T7 and SP6. From the plasmid map it was decided that the 
restriction enzyme Bal 1 (Promega, UK) would be used to obtain the DNA 
template for the T7 promoter producing a fragment of DNA approximately 200bp 
with blunt ends. Various restriction enzymes were tried to obtain the SP6 
promoter, including Nar 1 (Promega, UK), Sma I (Promega, UK) and Eco RV 
(Roche). It was decided Eco RV was the most successful restriction enzyme 
producing an approximately 200bp DNA fragment containing the template region 
with blunt ends. All restriction digests were carried out in the same way. 
In a sterile thin-walled PCR tube the following reaction mix was compiled; 20 of 
lOx Restriction Buffer (500mM Tris-HC1 [pH 8.2] and 50mM MgC12), O. 2µ1 
Acetylated BSA (10µg/µ1) and 1µg of plasmid DNA made up to 2Oµ1 with 
nuclease-free water. The resulting solution was mixed by pipetting and then 5U 
of the restriction enzyme was added and incubated at 37°C for 3 hours. The 
enzyme was inactivated by heating the reaction to 65°C for 15 minutes. To check 
the digest was successful 2µl of the resulting mixture was run on a 1% agarose 
gel and viewed under W after staining with ethidium bromide solution. See 
section 3.8 for further details of gel electrophoresis. 
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4.4 In Situ Hybridisation Techniques - Method 1 
All glassware and bench areas used during this procedure were cleaned 
thoroughly with RNA Zap (Ambion) prior to any in situ hybridisation work in 
order to protect the RNA probes from degradation. All solutions were made with 
nuclease-free water (BDH Merck) and all plastic consumables were brought 
sterile and RNase free. 
4.4.1 In Vitro Transcription 
In Vitro Transcription uses phage RNA polymerases to produce RNA from DNA. 
This was initially carried out using the MAXIscriptTM in vitro transcription kit 
(Ambion International, Texas, USA) to produce biotin labelled RNA probes. The 
polymerase T7 was used to produce sense RNA probes and SP6 was used to 
produce anti-sense RNA probes. Label was incorporated into the probes during 
the transcription process using a biotin labelled nucleotide (Biotin-126-uradine- 
5'-trophosphate) (Roche Biochemicals, East Sussex, UIQ. Both the sense and 
anti-sense probe reactions were carried out in the same way. 
Into a sterile thin-walled PCR tube the following reaction mix was compiled; 2µl 
10x Buffer (containing DTT and Spermidine), 1 i1 of 10mM ATP, CTP and GTP, 
0.6µl of unlabelled 10mM UTP and 0.41il of 10mM biotin-16-UTP, 1µg of template 
DNA and 2 t1 RNA polymerase (10U/µl polymerase and 5U/µl Ribonuclease 
inhibitor) made up to 2Oµ1 with nuclease-free water. This was mixed thoroughly 
and incubated at 37°C for 1 hour. The DNA template was removed by the 
addition of 2U of DNase 1 followed by incubation at 37°C for 15 minutes. The 
reaction was stopped by the addition of 1 t1 0.5M EDTA. The resulting probes 
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were stored at -20°C until use. Gel electrophoresis was carried out as described in 
section 3.8 to assess the quality and size of the RNA probes produced. 
4.4.2 Hybridisation 
Initially in situ hybridisation for the detection of the RNA component of 
telomerase was carried out using the commercially available kit mRNAlocatorr"'- 
Hyb in combination with mRNAlocatorTM-biotin both available from Ambion 
(Ambion International, Texas). The method was carried out according to the 
manufacturer's instructions as described below. 
Paraffin embedded sections of tissue were deparaffinised using xylene and 
rehydrated using decreasing concentrations of ethanol from 100% to 50%, before 
being placed in Tris buffer. The sections were then digested in Proteinase K 
solution (4µg/ml in Tris buffer). The proteinase K solution was added to the slide 
completely covering the tissue section and a clean coverslip placed on top. The 
slide was then placed in a humid chamber and incubated for 30 minutes at 37°C. 
The slides were then washed 3 times for 4 minutes in tris buffer. 
The probes were diluted 1 in 50 in in situ hybridisation buffer and 500 applied to 
each slide. The slides were then covered with a clean coverslip, placed in a humid 
chamber and hybridised at temperatures between 40 and 55°C for either 4 hours 
or overnight. 
Wash solutions of lx and 2x were prepared and warmed to 50°C. One wash was 
carried out for 4 minutes in 2x wash buffer. Then sections were washed twice for 
4 minutes in lx wash buffer at 50°C. 
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The Biotin labelled probe was detected using the mRNAlocatorTM-Biotin kit 
(Ambion) again according to the manufacturer's instructions. Slides were 
incubated with a 1/300 dilution of Streptavidin-Alkaline Phosphatase Conjugate 
for 30 minutes at 37°C in a humid chamber. The slides were then washed twice 
in tris buffer for 4 minutes each. Next 50µl of NBT/BCIP substrate solution was 
added to each slide and left to incubate for 60 minutes to overnight at 37°C. 
Slides were then washed in water, dehydrated in ethanol, cleared in xylene and 
mounted with pertex. 
4.5 In Situ Hybridisation Techniques - Method 2 
4.5.1 In Vitro Transcription 
DIG labelled RNA probes were produced using the DIG RNA Labelling Kit 
(SP6/T7) from Roche Diagnostics Ltd. East Sussex. RNA probes were produced 
containing DIG-11-UTP. The reactions were set up according to the 
manufacturer's instructions; the purified template DNA and nuclease-free water 
were added to a clean tube up to a volume of 13µl. Next 2µl of 10x NTP-labelling 
mix, 2µl lOx Transcription buffer, lµ1 RNase Inhibitor and 20 of either SP6 or 
T7 RNA polymerase were added to each tube. The reaction was mixed gently and 
incubated for 2 hours at 37°C. The DNA template was removed by the addition of 
2 pd of DNase I and the reaction incubated for 15 minutes at 37°C. The reaction 
was stopped by the addition of lµl 0.5M EDTA (pH8.0). The probes were stored 
at -20°C until needed. 
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4.5.2 Hybridisation 
The second in situ hybridisation method was carried out according to the method 
described by Chang et al (1999). Tissue sections were dewaxed and rehydrated in 
Histoclear and ethanol. The sections were then digested with proteinase K 
(20µg/ml) for 30 minutes at 37°C. Followed by post-fixation in 4% 
paraformaldehyde/PBS and rinsed in PBS. Acetylation was carried out in freshly 
prepared 0.1M triethanolamine/0.25% acetic anhydride twice for 5 minutes with 
rocking. The DIG labelled probes were diluted 1/50 in DIG Easy Hyb (Roche), 
applied to the sections and covered with a clean plastic coverslip. The slides were 
then incubated for 10 minutes at 65°C in a humid chamber to denature the 
probes and hybridised overnight at 45°C. 
The following day the plastic coverslips were removed by placing the slides in 4x 
SSC for 5 minutes. The slides were then washed in 4x SSC for 5 minutes, 2x 
SSC10.1% SDS twice for 5 minutes at room temperature, 0.2x SSC/0.1% SDS for 
15 minutes at 55°C, 1x Washing buffer (Roche) for 5 minutes and 1x Blocking 
buffer (Roche) for 2 hours at room temperature with rocking. Next 5Oµ1 0.5 
unit/ml anti-DIG POD conjugate (Roche) was added to each and incubated for 1 
hour in a humid chamber at room temperature. The slides were then washed 3 
times for 5 minutes in lx Wash buffer at room temperature and 0.1% Tween 
20/PBS for 5 minutes all with rocking. Colourimetric detection was then carried 
out using DAB solution and the slides incubated for 10 minutes. The slides were 
washed in water, counterstained in heamatoxylin, dehydrated and mounted 
using PDX. A DIG Easy Hyb alone control was carried out with each experiment. 
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4.6 In Situ Hybridisation Techniques - Method 3 
4.6.1 In Vitro Transcription 
In vitro transcription was carried out as previously described in section 4.5.1. The 
probes were cleaned to see if unincorporated-labelled nucleotides were effecting 
the results. Unincorporated nucleotides, salts and labels were removed from the 
RNA probes using the NucAwayTM Spin Columns (Ambion). The columns were 
prepared according to the manufacturer's instructions. The 2Oµ1 transcription 
reaction was added to the top of the column and spun at 750 xg for 2 minutes. A 
small amount of the resulting solution was analysed using gel electrophoresis 
(section 3.8) and the rest was stored at -20°C until needed. 
4.6.2 Hybridisation 
Hybridisation was carried out as previously described in section 4.5.2 with 
modifications. The probes were denatured at 95°C for 5 minutes and placed on ice 
before addition to the tissue sections. Hybridisation was carried out overnight at 
42°C. 
The following day washes included: 4x SSC for 5 minutes, 2x SSC/0.1% SDS 
twice for 5 minutes at room temperature, 0.2x SSC/0.1% SDS for 15 minutes at 
55°C, 0.1X SSC10.1% SDS for 15 minutes at room temperature, lx Washing 
buffer (Roche) for 5 minutes and 1x Blocking buffer (Roche) for 2 hours at room 
temperature with rocking. Next 5Oµ1 0.5 unit/ml anti-DIG Alkaline Phosphatase 
(AP) conjugate (Roche) was added to each and incubated for 1 hour in a humid 
chamber at room temperature. The slides were then washed 3 times in 1x Wash 
buffer for 5 minutes at room temperature and 0.1% Tween 20/PBS for 5 minutes 
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all with rocking. Colourimetric detection was then carried out using Alkaline 
Phosphatase Substrate kit IV (Vector Laboratories) made according to the 
manufacturer's instructions. The slides were washed in water, counterstained in 
Nuclear Fast Red (Vector Laboratories), dehydrated and mounted using 
VectaMountTm (Vector Laboratories). A DIG Easy Hyb alone control was carried 
out with each experiment. 
4.7 Methods for checking probes were labelled and hybridising to 
the correct target. 
4.7.1 Dot blots 
In order to check the sense and anti-sense RNA probes were labelled and the 
detection antibodies were working correctly a dot blot was carried out with each 
experiment. Probe (2 i1) was pipetted onto a small piece of Hybond N* membrane 
optimised for nucleic acid transfer (Amersham Pharmacia Biotech) and left to 
dry. Once the dots were dry the membrane was placed in lx wash buffer (Roche) 
for 5 minutes then incubated for 2 hours in Block buffer (Roche) with rocking. 
The membrane was treated in exactly the same way as the slides. All the washes 
and detection steps were exactly the same as in the hybridisation methods 
explained above. 
4.7.2 North Western Blot 
A north-western blot was carried out to see whether the probes to the RNA 
component of telomerase bound to telomerase once extracted proteins were run 
on a gel and transferred to a membrane. Protein samples from the oesophageal 
cell-lines OE21 and OE33 were used. The western blot method was carried out as 
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previously described in section 3.10, but instead of immunodetection the RNA 
probes were utilised to detect the telomerase protein band on the membrane. 
Glass plates, plastic spacers and combs from the BioRad Mini Protein II were 
cleaned and assembled according to the manufacturers instructions. A 6% main 
gel and a 4% stacking gel were made. Once the gels were poured into the frame 
and had dried a1 in 3 dilution of the samples was prepared with 4x loading dye. 
The samples were boiled at 95°C for five minutes and placed on ice before a 
volume was loaded into a well of the gel. One well was loaded with 10µ1 of pre- 
stained molecular weight marker. The gel was then run at 75V for 15 minutes to 
allow the samples to move through the stacking gel and then at 100V for about 1 
hour. 
The gel was then removed from the glass plates and blotted onto an Immobilon-P 
Transfer Membrane, (Millipore) using an electroblotter (Hoefer SemiPhorTM 
Amersham Pharmacia Biotech) run for 55 minutes at 40-44mA. The pre-stained 
marker could be seen on the membrane once transfer was completed. 
Once the protein bands had been blotted across onto the membrane hybridisation 
method 3 (section 4.6.2) was used to detect the telomerase band on the 
membrane. The probes were denatured at 95°C for 5 minutes and placed on ice 
before addition to 15m1 DIG Easy Hyb buffer in a dilution of 1/1000. 
Hybridisation was carried out overnight at 42°C. 
On the following day these washes were carried out: 4x SSC for 5 minutes, 2x 
SSC/0.1% SDS twice for 5 minutes at room temperature, 0.2x SSC/0.1% SDS for 
15 minutes at 55°C, O. lx SSC/0.1% SDS for 15 minutes at room temperature, lx 
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Washing buffer (Roche) for 5 minutes and 1x Blocking buffer (Roche) for 2 hours 
at room temperature with rocking. Next 15m10.5 unit/ml anti-DIG AP conjugate 
(Roche) was added and incubated for 1 hour at room temperature. The membrane 
was then washed 3 times in lx Wash buffer for 5 minutes at room temperature 
and 0.1% Tween 20/PBS for 5 minutes all with rocking. Colourimetric detection 
was then carried out using BM Purple AP Substrate (Roche) used according to 
the manufacturer's instructions. The membrane was washed in water and dried 
between filter paper. 
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4.8 Results 
4.8.1 Telomerase Repeat Amplification Protocol (TRAP) results from 
tissue samples. 
The TRAP assay was carried out on 156 different fresh frozen tissue types (81 
from resected tissues and 75 from biopsy tissues) from 64 patients. They can be 
broken down into the following: 
" 29 Cancer cases 
9 25 Dysplasia cases 
" 23 Barrett's Metaplasia cases 
" 33 Non-involved Oesophageal Epithelium cases. 
The details of the patients and sections are explained more in table 4.2. 
The TRAP assay was optimised using four resected cancer samples. Titre 
experiments were carried out to find the optimum protein concentration for the 
assay. It was found to be about 0.0124µg/µ1 and to have a similar sensitivity to 
the cell-line extracts. All the tissue extracts were diluted to a similar 
concentration before use in the assay. 
The results of the TRAP assay on tissue sections from individual patients are 
shown in table 4.2. A and B. The complete results from the tissue extracts are 
shown in table 4.2. C. 
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Table 4.2. TRAP tissue results 
Abbreviations: Sample Diagnosis N Oes = non involved squamous epithelium, N 
Stom = Non-involved gastric epithelium with or without Helicobactor pylori (h. P. ) 
infection, Barrett's IM = Barrett's oesophagus with intestinal metaplasia, CIF Barrett's = 
Barrett's oesophagus with cardiac or fundic metaplasia, Low Dys = Low grade Dysplasia, 
High Dys = High grade Dysplasia, and Cancer = adenocarcinoma either well diff., mod 
diff. or poorly diff. (well, moderately or poorly differenciated). 
Telomerase positive either yes no or unsure where a sample gave both a positive and 
negative result. 
A. Trap assay results from resected tissue sections from the individual patients 
tested. 
Patient Sample diagnosis Telomerase Positive 
1 N Oes No 
N Stom(h. P infection) No 
Cancer well diff. ) Yes 
2 N Oes No 
N Stom No 
Low Dys No 
3 N Oes Yes 
N Stom No 
Barrett's IM No 
Cancer (well diff. Yes 
4 N Stom No 
C Barrett's No 
Low Dys No 
Cancer (mod diff. Yes 
5 N Oes No 
N Stom No 
Cancer (Poorly diff. ) Yes 
6 N Oes No 
N Stom No 
N Oes/Cancer No 
Cancer (mod diff. With mucin) Unsure 
7 N Oes No 
N Stom (h. P infection) No 
Cancer (mod diff. Yes 
8 N Oes No 
N Stom No 
Barrett's IM Yes 
Cancer Yes 
9 N Stom No 
10 N Stom No 
N Stom (h. P infection) No 
Cancer well diff. Yes 
11 N Oes No 
N Stom No 
Cancer (poorly diff. Yes 
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12 N Oes No 
N Stom (h. P infection) No 
Cancer (mod diff. ) Yes 
13 N Oes No 
N Stom No 
Cancer (mod diff. with mucin) No 
14 N Oes No 
N Stom No 
Cancer (poorly diff. diffuse) No 
15 N Stom No 
Cancer (well diff. ) Yes 
16 N Stom (h. P infection) No 
N Oes Yes 
Cancer (mod diff. Yes 
17 N Oes/Cancer Yes 
N Stom No 
Cancer (poorly diff. ) Yes 
18 N Stom No 
19 N Stom No 
Cancer (poorly diff. with No 
mucin) 
20 N Stom (h. P infection) No 
Low Dys No 
21 N Stom No 
Cancer (poorly diff. No 
22 N Oes No 
N Stom No 
Cancer (sqamous carcinoma) Yes 
23 Cancer Yes 
24 N Oes No 
25 OF Barrett's No 
26 N Oes No 
N Stom No 
Cancer (mod. diff. ) Yes 
27 N Stom (h. P infection) No 
N Oes/Cancer No 
Cancer (poorly diff. ) No 
28 N Stom No 
Barrett's IM Yes 
Cancer (poorly diff. Yes 
29 N Stom .P infection) No 
30 N Oes No 
31 N Oes No 
32 Hi h Dys No 
33 N Stom No 
Barrett's IM No 
Cancer (mod diff. Yes 
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B. Trap assay results from biopsy tissue sections from the individual patients 
tested. 
Patient Sample Diagnosis Telomerase Positive 
34 N Oes No 
C/F Barrett's No 
35 N Oes No 
Low Dys No 
High Dys Yes 
High Dys (different surgery) Yes 
36 N Oes No 
High Dys No 
Intramucosal carcinoma No 
37 N Oes No 
C Barrett's No 
High Dys No 
38 N Oes No 
N Stom No 
HihDs Yes 
39 Low Dys No 
High Dys No 
Cancer in situ Yes 
40 Low Dys No 
HihDs No 
41 N Stom No 
HihDs Yes 
42 N Oes No 
C Barrett's No 
Barrett's IM No 
Low Dys No 
43 N Oes No 
C Barrett's No 
Barrett's IM No 
High Dys No 
Cancer (well diff. ) Yes 
44 Squamous Dys No 
High Ds No 
45 N Oes No 
N Stom No 
46 N Oes No 
OF Barrett's No 
High Dys Yes 
Cancer (well diff. ) Yes 
47 Barrett's IM No 
C Barrett's No 
48 Low Dys No 
Cancer (mod diff. ) No 
49 N Oes No 
N atom No 
Barrett's IM Yes 
Low Dys Yes 
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50 N Oes No 
Cancer (mod diff. ) Yes 
51 N Stom No 
52 N Oes No 
F Barrett's No 
53 N Oes No 
HihDs No 
54 N Oes Unsure 
Barrett's IM Yes 
Low Dys Yes 
55 N Oes No 
Low Ds Yes 
56 N Oes No 
C/F Barrett's No 
57 N Oes No 
HihDs Yes 
58 N Oes No 
59 N Oes No 
Barrett's IM Unsure 
60 High Ds No 
61 C Barrett's No 
High Dys No 
62 Barrett's IM No 
63 N Oes No 
C Barrett's No 
Low Ds Yes 
64 N Oes No 
Cancer (mod diff. ) Yes 
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C. Summary of all the tissue section results. As each sample was assayed twice 
the unsure samples are those where one test was telomerase positive and the 
other was telomerase negative. 
Diagnosis Number Number of Percentage of Unsure 
of cases cases cases telomerase 
Telomerase positive 
positive 
Non-involved 38 2 5.2% 1 
oesophagus 
Non-involved 32 0 - 0 
stomach 
Barrett's Non- 11 0 - 0 
intestinal 
Metaplasia 
Barrett's 11 4 36.4% 1 
Intestinal 
Metaplasia 
Low-grade 12 4 33.3% 0 
Ds lasia 
High-grade 15 6 46.2% 0 
Ds lasia 
Adenocarcinoma 29 22 75.9% 0 
Total 156 38 - 2 
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During this study telomerase activity was assayed in 156 fresh frozen samples 
(81 from resected tissue and 75 biopsy samples) from the 64 patients, using the 
TRAPEZETM ELISA assay. Of the 38 non-involved oesophagus cases assayed, 2 
(5.2%) were telomerase positive and one was undefinable for telomerase activity. 
All of the non-involved stomach samples showed no telomerase activity, as did all 
the non-intestinal Barrett's metaplasia cases. Of the 11 intestinal metaplasia 
cases assayed, 4 (36.4%) were positive for telomerase activity and one case was 
undefinable. Of the 12 low-grade dysplasia cases assayed, 4 (33.3%) were 
telomerase positive. Of the 15 high-grade dysplasia cases assayed, 6 (42.6%) were 
telomerase positive. Of the 29 adenocarcinoma cases assayed, 22 (75.9%) were 
telomerase positive. 
4.8.2 Results of In Situ Hybridisation Techniques for the Detection of the 
RNA Component of Telomerase 
The application of in situ hybridisation techniques for detecting telomerase RNA 
expression in archival paraffin-embedded and fresh frozen material can easily 
distinguish cancer from normal cells (Shay 1997a). The use of in situ 
hybridisation for the detection of the RNA template within the enzyme complex 
should allow the localisation of specific cells with telomerase activity. Previously 
in situ hybridisation has been used by Morales et al to study telomerase activity 
in the progression of Barrett's Oesophagus using a radioactive based method 
(Morales 1998). Here a method of in situ hybridisation for the detection of 
telomerase using a non-radioactive method has been developed. Figures 4.2,4.3 
and 4.4 contain images showing examples of the resulting staining from each of 
the in situ hybridisation methods developed. 
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In ISH method 1 the RNA probes were biotin labelled and detected using the 
enzyme alkaline phosphatase (AP). ISH Method 1 did not work, successfully to 
detect the RNA component of telomerase. From figure 4.2 you can see there was 
no positive dark grainy staining in either the sense (A) or anti-sense (B) 
experiments. The kit contained a positive control experiment which resulted in 
strong dark black/purple staining (results not shown) implying there was a 
problem with the RNA probes or labelling of the probes. The dot blots and north- 
western blots for these experiments did work successfully showing the probes 
were labelled correctly so a new method was devised (results not shown). 
In ISH method 2 the RNA probes were labelled with DIG and detected using the 
enzyme horse radish peroxidase (HRP). As the HRP substrate DAB results in 
red/brown staining a heamatoxylin counterstain was used in these experiments 
as shown in figure 4.3. Again this method was not successful as no red/brown 
staining can be seen in either the sense (A) or anti-sense (B) results. Again there 
did not seem to be a problem with the RNA probes or labels as the dot blots and 
north-western blots gave positive results (results not shown). 
ISH Method 3 was the most successful and utilised DIG labelled sense and anti- 
sense RNA probes, an anti-DIG-AP antibody and BCIP/NBT AP substrate. From 
figures 4.4 and 4.5 it can been seen that dark black purple staining was present 
in sections hybridised with the anti-sense probe (A and B figure 4.4 and B figure 
4.5). The sense probes were used as a negative control and in these experiments 
resulted in much weaker to negative staining. The staining was grainy and 
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present in the nuclei of tumour and dysplastic cells (results not shown). 
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Figure 4.2. Examples of the results obtained on sections of oesophageal 
adenocarcinoma using ISH Method 1. 
A. Sample 102 Sense ISH Method 1 (x10) B. Sample 102 Anti-sense ISH Method 
1 (x10) C. Sample 102 stained for E-Cad IHC (x10). 
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Figure 4.3. Examples of the results obtained on sections of Oesophageal 
adenocarcinoma using ISH Method 2. 
A. Sample 111 Sense ISH Method 2 B. Sample 111 Anti-sense ISH Method 2. 
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Figure 4.4. Examples of the results obtained on sections of Oesophageal 
metaplasia using ISH Method 3. 
A. Sample 105 Anti-Sense ISH Method 3 (x10) B. Sample 105 Anti-Sense ISH 
(x40) C. Sample 105 Sense ISH (x10) D. Sample 105 Sense ISH (x40). 
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Figure 4.5. Examples of the results obtained on sections of Oesophageal 
adenocarcinoma using ISH Method 3. 
A. Sample 94 Sense ISH Method 3 (x10) B. Sample 94 Anti-sense ISH (x10) C. 
Sample 94 Stained for PAI-2 IHC (x10). 
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4.9 Discussion 
Telomerase is an important enzyme found in renewal tissues and most cancer 
cells (see section 1.16 for further details). In 1994 a sensitive method for the 
detection of telomerase was described which suggested that telomerase activity 
was associated with both immortal and cancer cells (Kim 1994). Very little 
research has been carried out into the expression and activity of telomerase 
during the progression of Barrett's metaplasia to adenocarcinoma. From previous 
studies into telomerase activity in Barrett's metaplasia it has been shown using 
the original TRAP method on fresh frozen samples that 50% of Barrett's 
oesophagus samples were positive for telomerase activity (Ozawa 1997). The 
disadvantage of this small study was that only 8 Barrett's metaplasia samples 
were tested. 
Another study into telomerase expression in the progression of Barrett's 
oesophagus to adenocarcinoma used in situ hybridisation to detect the RNA 
component of telomerase in paraffin embedded samples. It was found that 100% 
of high grade dysplasia and adenocarcinomas were telomerase positive, 90% of 
low grade dysplasia showed moderate telomerase activity and 70% of Barrett's 
metaplasia showed weak to moderate telomerase activity (Morales 1998). The 
results of this study are misleading, as the case numbers were very low (10 
Barrett's metaplasia samples were tested and no details were given as to what 
type of metaplasia they were). 
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4.9.1 Detection of Telomerase Activity Utilising the TRAP Method 
Overall 64 patients have been studied using the TRAP assay, 33 patients 
provided samples from resected tissues and 31 patients provided biopsy tissue 
samples. The resected tissues were considerably larger than biopsy samples. 
Resected tissues come from patients who have undergone surgery to remove 
large oesophageal adenocarcinomas from their oesophagus, whereas the biopsy 
samples come from patients who had been diagnosed with Barrett's oesophagus 
and were undergoing surveillance at the hospital on a regular basis. 
There was a large difference in the amount of protein extracted from biopsy 
samples and resected samples. The biopsy sections were approximately 3-5mm 
across, whereas the resected samples were between 1.2cm across, therefore from 
the twenty sections cut from each block there was a larger amount of tissue in 
the tube of resected sample than biopsy sample. This was overcome by the 
dilution of the samples before the assay was carried out, but there were more 
likely to be other types of cells and inhibitors in the resected samples than the 
smaller biopsy samples. 
A study by Bachor et al looking at telomerase activity in normal gastrointestinal 
mucosa and pre-cancerous lesions using the conventional TRAP assay found that 
all normal gastrointestinal mucosa contained active telomerase and it was not up 
regulated in pre-cancerous lesions (Bachor 1999). In Bachor's study only 
superficial biopsy samples were assayed. Here both biopsy and resected tissue 
samples have been assayed. It has been suggested that the main difference in the 
two types of tissues is in the amount of connective tissue. This is minimal in 
superficial biopsy samples, but substantial in resected samples. Connective 
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tissues are known to be telomerase negative (Harle-Bachor 1996) and may 
therefore dilute the activity of the telomerase expressing cells. Also proteins 
maybe present in the connective tissues that inhibit Taq polymerase, which is 
used in the PCR step of the TRAP assay reducing the amplification of the 
telomerase products. 
Confirmatory histological diagnosis was carried out independently using three 
heamatoxylin and eosin (H and E) stained sections for each sample. These were 
accessed to check the sample diagnosis remained the same throughout the 
sections cut and placed in the tube. The tissue type was found to remain the 
same throughout all the cases used during this study. Although some of the 
resected samples contained a varied selection of cell types the diagnosis was 
given for the majority of cell type in the sample. 
Of the 38 non-involved oesophagus cases 21 were from patients undergoing 
biopsy surveillance and 17 were from patients who had undergone oesophageal 
resection. The two non-involved oesophagus samples, which were telomerase 
positive, were resected tissue from patients #3 and #16. Both these patients have 
undergone oesophageal resection to remove oesophageal adenocarcinomas. The H 
and E sections for both these patients have been thoroughly examined and no 
cancer cells can be seen. Both patients had strongly positive cancer samples 
although each was of a different type (patient #6 had a well-differentiated cancer 
and patient #16 had a moderately differentiated cancer). It could be that the 
cancer cells in the tumour had influenced the surrounding cells in the non- 
involved oesophageal epithelium to express telomerase. The undefinable non- 
involved oesophageal sample came from patient #54. This is a biopsy sample. The 
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other samples from this patient an intestinal metaplasia sample and a low grade 
dysplasia sample were both telomerase positive. Each sample in this study was 
assayed twice and was defined as telomerase positive if both samples had an 
absorbance >0.150. This sample gave one positive and one negative result and 
was therefore undefinable. 
In skin, telomerase activity has been detected in the basal level of the epidermis, 
i. e. the proliferative compartment and is switched off during differentiation 
(Harle-Bachor 1996). All normal telomerase positive tissues are permanently 
renewing epithelia or tissues that proliferate in regular cycles. Therefore it would 
be expected that oesophageal epithelium would contain a population of 
telomerase positive cells. For gastrointestinal tissues it has been found that 
telomerase activity is detectable in all epithelia of the gastrointestinal tract using 
the conventional TRAP assay on biopsy samples (Bachor 1999). This could 
explain the telomerase positive non-involved oesophagus samples. 
Of the 32 non-involved stomach samples 5 were biopsy samples coming from 
patients undergoing surveillance for Barrett's oesophagus and 27 came from 
patients who had undergone oesophageal resection to remove a large oesophageal 
adenocarcinoma. All of the samples assayed were telomerase negative. 
The non-intestinal Barrett's metaplasia samples include both cardiac and fundic 
type metaplastic tissues. Of the 11 samples 9 are biopsy samples from patients 
undergoing surveillance for Barrett's oesophagus and 4 are samples from 
patients who had undergone oesophageal resection. All of these samples were 
telomerase negative. 
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Of the 13 intestinal metaplasia samples 7 were biopsy samples from patients 
undergoing surveillance for Barrett's oesophagus and 4 were from patients who 
had undergone oesophageal resection. The telomerase positive samples come 
from 4 different patients, 2 were biopsy samples (patient #49 and #54) and 2 
were from resected tissue (patients #8 and #28). The undefinable sample came 
from patient #59 and was a biopsy sample. 
It has been suggested that the amount of telomerase activity in Barrett's 
metaplasia samples maybe difficult to detect (Bachor 1999). In Barrett's 
oesophagus the stratified epithelium is replaced by a single-layered epithelium 
(resembling stomach and intestine). This will result in a larger amount of 
connective tissues in the samples tested, as only the thin surface layer of the 
tissue will contain the metaplastic cells. This problem could be over come with 
the use of laser capture micro-dissection apparatus where only the metaplastic 
cells could be selected and lysed for use in the TRAP assay. This was not 
available for this study. 
Of the 12 low-grade dysplasia samples 9 were biopsy samples from patients 
undergoing surveillance for Barrett's oesophagus and 3 were from resected 
tissues. All 4 telomerase positive samples were biopsy samples (patients #49, 
#54, #55, and #63). 
Of the 15 high grade dysplasia samples 14 were biopsy samples from patients 
undergoing surveillance for Barrett's oesophagus and one sample was from 
resected tissue. All 6 of the telomerase positive samples were biopsy samples 
(patients #35 [twice on two different surgeries], #38, #41, #46, and #57). 
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There were significantly more dysplastic samples from patients undergoing 
surveillance for Barrett's metaplasia than oesophageal resection. This is because 
it is virtually impossible to differentiate between dysplasia and Barrett's 
metaplasia with the naked eye. Therefore it is impossible to select a dysplastic 
area within a piece of resected tissue. It is much easier to collect a biopsy sample 
from a patient with known dysplasia who is undergoing surveillance. Also there 
were more fresh frozen biopsy samples than resected tissues available for 
analysis. 
Of the 29 adenocarcinoma samples 6 were biopsy samples from patients 
undergoing surveillance for Barrett's oesophagus, these can also be defined as 
cancer in situ samples and 23 were from patients undergoing oesophageal 
resection. One cancer in situ sample was telomerase negative (patient #48) and 5 
resected samples were telomerase negative (patients #13, #14, #19, #21, and 
#27). The telomerase negative cancer samples were mainly from poorly 
differentiated adenocarcinoma samples (patients # 14, #19, #21, and #27). The 
samples also contained a large amount of mucin, which would act to dilute the 
amount of telomerase containing cells in the sample (patient #13 and #19). The 
biopsy sample and one of the resected samples were moderately differentiated 
adenocarcinomas (patients #48 and #13). These samples also only contained just 
over 50% of the diagnosed tissue type (adenocarcinoma) the rest of the section 
was connective tissue. This could act to dilute the amount of telomerase 
expressing cells present. 
The TRAPEZE TM ELISA kit used here is not as sensitive for telomerase activity as 
the conventional TRAP assay. It only gives a positive/negative answer there is no 
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way of quantifying the telomerase activity and no information about which cells 
in the samples have telomerase activity. This problem can only be overcome by 
using a method for detecting telomerase within a section of tissue on a slide. In 
situ hybridisation can be used to detect the RNA component of telomerase in 
specific cells (Morales 1998). The in situ hybridisation technique should be more 
specific than the TRAPEZETM kit and therefore should locate small amounts of 
telomerase in individual cells within the tissue sections. 
The main disadvantage of using the TRAP method for analysing telomerase 
activity in clinical tissue samples is there is no way of telling exactly which cells 
within the samples are expressing telomerase. As mentioned some of the resected 
tissue samples studied contained a range of tissue types. In order to get a 
complete picture of telomerase activity within the progression of Barrett's 
metaplasia to adenocarcinoma a method of in situ hybridisation for the detection 
of the RNA component of telomerase has been developed. 
4.9.2 Detection of Telomerase Utilising in situ Hybridisation 
As the active telomerase molecule contains an integral RNA template telomerase 
can be detected by northern blot, RT-PCR or in situ hybridisation. Initial studies 
into Northern blotting for the detection of the RNA component of telomerase 
were disappointing. The RNA component appeared to be ubiquitously present in 
both normal and tumour tissues and expression levels did not correlate with 
telomerase activity. When RT-PCR was used for detection the molecule was 
found in tumour as well as normal tissues, although quantitatively higher levels 
were seen in tumour tissues. Interestingly, in some circumstances analysis of the 
RNA component of telomerase in paraffin embedded tissues using in situ 
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hybridisation correlates with telomerase activity (Matthews 2001). In situ 
hybridisation for the detection of the RNA component of telomerase has become 
the most widely used alternative marker for telomerase detection, which allows 
preservation of tissue morphology. 
Two studies have looked at telomerase in oesophageal tumours using in situ 
hybridisation, Morales et al detected the RNA component of telomerase during 
the progression of Barrett's oesophagus to adenocarcinoma (Morales 1998) and 
Hiyama et al detected telomerase mRNA in squamous cell carcinoma and 
dysplasia (Hiyama 1999). Hiyama found low levels of telomerase the in basal 
cells of oesophageal squamous mucosa and high levels in cases of oesophageal 
carcinoma and dysplasia. This is in keeping with other epithelial tissues such as 
the cervix (Yashima 1998). In the study by Morales et al there was a marked 
increase in expression between low and high grade dysplasia of the oesophagus 
as well as in other areas of the intestinal tract (Morales 1998). 
In Morales study, in situ hybridisation for the detection of the RNA component of 
telomerase has been carried out on tissue samples during the progression of 
Barrett's Oesophagus using radiolabelled RNA probes (Morales 1998). It was 
found that 100% of high grade dysplasia and adenocarcinomas were telomerase 
positive, 90% of low grade dysplasia showed moderate telomerase activity and 
70% of Barrett's metaplasia showed weak to moderate telomerase activity. The 
main problem with Morale's study was that only a small number of samples were 
analysed. As radioactive labelling was unavailable here a method of non-isotopic 
in situ hybridisation, for the detection of the RNA component of telomerase, 
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during the progression of Barrett's oesophagus to adenocarcinoma has been 
developed. 
In situ hybridisation for the detection of telomerase was carried out using an 
RNA anti-sense probe to the RNA component of telomerase. Three main methods 
of in situ hybridisation were tested. The first method was carried out using biotin 
labelled RNA probes and commercially available kits from Ambion International, 
Texas, USA according to the manufacturer's instructions. The second method 
was carried out using DIG labelled RNA probes and anti DIG-POD conjugated 
antibodies with DAB Detection (Chang 1999). The final method was a further 
development of Chang's method using anti DIG-AP antibodies and BCIP/NBT 
Alkaline Phosphatase substrate for detection. 
Dot blots were used throughout the development of the in situ hybridisation 
methods to check the labelling of the probes and that the detection steps worked 
successfully in each experiment. The north-western blot described here also 
worked well as a method of checking that the RNA probes used were specific and 
did in fact hybridise to the RNA component of the telomerase protein (results not 
shown). 
In ISH method 1 the RNA probes were biotin labelled and detected using AP. 
This method did not work successfully there was no positive dark grainy staining 
in either the sense or anti-sense experiments. This commercially available kit 
was developed to detected mRNA in tissues. A positive control experiment was 
included in the kit which detected c-myb mRNA in sections of mouse brain. When 
tested the positive control experiments resulted in strong dark black/purple 
staining, implying there was a problem with the RNA probes or labelling of the 
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probes. The dot blots and north-western blots for these experiments did work 
successfully showing the probes were labelled correctly. The problem with this 
method could be that the kit was unsuitable for the detected of the small RNA 
component of telomerase. 
In ISH method 2 the RNA probes were labelled with DIG and detected using 
HRP. As the HRP substrate DAB resulted in red/brown staining a heamatoxylin 
counterstain was used in these experiments. Again this method was not 
successful as no red/brown staining was seen in either the sense or anti-sense 
experiments. Again there did not seem to be a problem with the RNA probes or 
labels as the dot blots and north-western blots gave positive results. 
This method was altered, as an AP based detection system resulting in dark 
black/purple staining with a red counterstain would give clearer visualisation of 
weak staining. In method 2 the heamatoxylin counterstain was too strong for 
clear visualisation of possible weak red/brown staining in the nucleus of cancer 
cells. 
The most successful of the in situ hybridisation methods tested here was the final 
method developed. This method was loosely based on that described by Chang et 
al 1999 and utilised DIG labelled RNA sense and anti-sense probes detected by 
the reaction of the enzyme alkaline phosphatase with BCIP/NBT. Dark black 
purple staining was present in the sections hybridised with the anti-sense probe. 
The sense probe was used as a negative control and in these experiments 
resulted in much weaker to negative staining. The staining was grainy and 
present in the nuclei of cancer and dysplasia cells in the cases analysed. 
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The results of the few tumour samples analysed with this method looked 
promising. Unfortunately only eight cases were fully analysed with this method. 
All eight cases contained telomerase positive cells within dysplasia, 
adenocarcinoma and lymph node metastasis tissue sections. In the future method 
3 could very easily be utilised to carry out a full assessment of the RNA 
component of telomerase in the metaplastic: neoplastic progression of Barrett's 
oesophagus and its correlation with telomerase activity detected with the TRAP 
assay. 
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5 The Components of the urokinase-type Plasminogen 
Activator System During the Metaplastic: Neoplastic 
Progression of Barrett's Oesophagus 
5.1 Introduction 
Tumour cell invasion involves the attachment of tumour cells to the underlying 
basement membrane, local proteolysis and migration of tumour cells through this 
degraded region. Proteases are involved throughout the metastatic process. In 
order for a cell to metastasise it must be able to move into blood vessels, survive 
in circulation, arrest, move out of the blood vessels, invade surrounding tissues 
and grow. All these steps involve interactions between tumour cells, stromal 
cells, invading lymphocytic cells, endothelial cells and the extracellular matrix. 
Proteases, which are expressed in these cells (including Cathepsin B and D, 
urokinase-type Plasminogen Activator and receptor, and interstitial collagenase), 
are believed to participate in many of these steps. 
The progression of Barrett's oesophagus through increasing degrees of dysplasia 
to adenocarcinoma is characterised by the ability of epithelial cells to invade the 
basement membrane. Changes in the expression of components of the 
plasminogen activation system, which allows increased production of plasmin, 
are thought to have an important role in malignant cell invasion, but little is 
known about the expression of these components in the premalignant stages of 
Barrett's oesophagus. Here the components of the plasminogen activation system 
have been studied during the metaplastic: neoplastic progression of Barrett's 
Oesophagus using both immunohistochemistry and ELISA techniques. 
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5.2 Immunohistochemistry on paraffin embedded sections using 
antibodies to the components of the urokinase-type 
Plasminogen Activator System 
Immunohistochemistry was carried out as described in section 3.9 with the 
following modifications. Paraffin embedded sections of tissue were dewaxed using 
Histoclear® (Fisher Scientific) and rehydrated using decreasing concentrations of 
ethanol from 100% to 50% before being placed in PBS to equilibrate the slides. 
Non-specific reactions were then blocked using rabbit serum (1: 5 [v/v] in PBS). 
The blocking serum was removed without washing and the primary antibody 
added diluted with PBS containing 1% rabbit serum and left in a humid 
atmosphere at 4°C overnight. Details of primary antibodies and working 
concentration are given in table b. 1. 
Each case was analysed using five antibodies to the components of the 
plasminogen system (polyclonal uPA, monoclonal uPA, uPAR, PAM and PAI-2). 
The same cases were analysed using E-Cad antibodies (see table 5.1). This was to 
ensure the results of the plasminogen components could be comparable to other 
well-documented molecular markers for disease progression in Barrett's 
oesophagus. Western blot analysis, as described in section 3.10, was carried out 
using protein samples from the oesophageal cell-lines OE21 and OE33 to assess 
the specificity of the primary antibodies. 
Once counterstained with heamatoxylin the slides were viewed under a light 
microscope and archived using AxioVision Version 3 (Imaging Associates, Thame, 
UK)" 
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Table 5.1 Antibodies used for immunohistochemistry on slide flasks. 
Antibody Type Working Company 
Concentration 
uPA Polyclonal goat 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
uPA Monoclonal mouse 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
uPAR Monoclonal mouse 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
PAI-1 Monoclonal mouse 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
PAI-2 Polyclonal goat 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
E-Cadherin Monoclonal mouse 2µg/ml Alexis Biochemicals, 
anti-human Nottingham, UK 
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5.3 Detection of the components of the urokinase Plasminogen 
Activator System using ELISA techniques 
The quantitative analysis of the components of the urokinase Plasminogen 
Activator system was carried out on the same cell extracts as were analysed 
using the TRAPEZETM ELISA using commercially available kits. These kits were 
the IMUBIND® uPA ELISA kit, the IMUBIND® Total uPAR ELISA kit, the 
IMUBIND®Tissue PAI-1 ELISA kit and the IMUBIND® PAI-2 ELISA kit 
(American Diagnostica Inc. Greenwich, USA). These kits contained all the 
reagents necessary to perform enzyme-linked quantitative analysis of protein 
extracts from fresh-frozen tissue samples. Analysis was carried out according to 
the manufacturer's protocol and is detailed below. The principles of ELISA 
detection are shown in Figure 5.1. 
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5.3.1 uPA, uPAR and PAI-1 
Each kit contained lyophilised standards of varying concentrations which were 
rehydrated at the start (uPA 0.00,0.10,0.25,0.50,0.75,1. Ong/ml, uPAR 0.00, 
0.25,0.75,1.5,2.0,3. Ong/ml and PAI-1 0.00,1.0,2.5,5.0,7.5,10. Ong/ml). Protein 
extracts were selected from those used in the TRAP assay that had a 
concentration >0.5gg/ml. These were then diluted 1/20 with Sample buffer (1% 
BSA in Wash buffer [PBS with 0.025% Triton-X 100]). To the microtitre plate 
100µ1 of the standard or diluted protein extract was added to each well as shown 
in figure 5.2. The plate was then covered and incubated overnight at 4°C in a 
humid chamber. 
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1. Antibody 2. Protein 
bound to the binds to the 3. Biotinylated 
plastic plate antibody antibody recognises the 
bound protein 
molecules. 
4. 
Streptavin/HRP 
completes the 
enzyme 
detection 
complex. 
5. 
Addition 6. Addition of 
of TMB sulphuric 
changes acid solution 
the HRP makes a 
to 
Figure 5.1. The Principles of ELISA detection of the components of the 
urokinase-type Plasminogen Activator system. 
Abbreviations: B= biotin label, HRP = Horseradish Peroxidase and TMB 3,3', 5,5' 
Tetramethylbenzidine. 
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Table 5.2. Sample arrangement for the IMUBIND® ELISA on the 
microtitre plate. 
1 2 3 4 5 6 7 8 9 10 11 12 
A Si Si T3 T3 T11 T11 T19 T19 T27 T27 T35 T35 
B S2 S2 T4 T4 T12 T12 T20 T20 T28 T28 T36 T36 
C S3 S3 T5 T5 T13 T13 T21 T21 T29 Y29 T37 T37 
D S4 S4 T6 T6 T14 T14 T22 T22 T30 T30 T38 T38 
E S5 S5 T7 T7 T15 T15 T23 T23 T31 T31 T39 T39 
F S6 S6 T8 T8 T16 T16 T24 T24 T32 T32 T40 T40 
G Ti Ti T9 T9 T17 T17 T25 T25 T33 T33 T41 T41 
H T2 T2 T10 T10 T18 T18 T26 T26 T34 T34 T42 T42 
The following day the plate was washed four times with 200µ1 of wash buffer in 
each well. Next 100µ1 of detection antibody (biotinylated antibody that recognises 
the bound molecule; either uPA, uPAR or PAI-1) was added to each well. Each 
standard and sample was tested in duplicate. The plate was covered and 
incubated for 1 hour at room temperature. The plate was again washed four 
times with wash buffer before the enzyme conjugate (streptavidin conjugated to 
the enzyme horseradish peroxidase) was added (diluted 1/1000). The plate was 
covered once more and incubated for 1 hour at room temperature. Next the plate 
was washed four times using wash buffer and 1000 of enzyme substrate was 
added (perborate/3.3', 3,5'-tetramethylbenzidine [TMB]). This complex was 
incubated at room temperature for 20 minutes while the enzymatic reaction took 
place producing a blue colour. The reaction was stopped with the addition of 
100µl 0.5N H2SO4 that caused the solution to turn yellow. The absorbance was 
then measured at a wavelength of 450nm within 30 minutes. The background 
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blank value for O. Ong. ml standard was deducted from all the standard and 
sample readings. 
5.3.2 PAI-2 
The PAI-2 ELISA was carried out in the same way as those for uPA, uPAR and 
PAI-1, with the exception of the overnight incubation of the sample at 4°C in a 
humid chamber. For the detection of PAI-2 the sample or standard (0.0,0.5,1.0, 
2.5,5.0,10. Ong/ml) was added to the wells and left to incubate for 2 hours at 
room temperature. Then the plate was washed 4 times in wash buffer and the 
detection antibody added as for the detection of the other components. The rest of 
the method was completed as described above. 
5.3.3 Calculation of Results 
A standard curve was constructed for each experiment by plotting the mean 
absorbance value for each standard versus the corresponding concentration. A 
new standard curve was generated every time the assay was performed. The 
mean absorbance value for each of the diluted samples was then used to 
determine the concentration in ng/ml from the standard curve. The sample value 
was then multiplied by 20 and divided by the protein concentration of the tissue 
extract (mg/ml) to convert ng/ml sample to ng/mg protein. 
5.3.4 Statistical Analysis 
Statistical analysis of the data was carried out using the computer programme 
GenStat for Windows. The results of this are detailed in appendix 7. 
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5.4 Results 
In order to assess the usefulness of the components of the urokinase-type 
Plasminogen Activator system as molecular markers for the progression of 
Barrett's oesophagus to adenocarcinoma, immunohistochemistry and enzyme 
linked immuno-sorbent assays (ELISA) techniques were utilised. 
5.4.1 Results of Immunohistochemistry on paraffin embedded sections 
using antibodies to the components of the urokinase Plasminogen 
Activator System 
Overall 847 archived paraffin-embedded sections from 121 clinical cases have 
been analysed using immunohistochemistry for the detection of the components 
of the plasminogen activator system, and E-Cadherin. These cases ranged from 
non-dysplastic Barrett's (40 cases), through low and high grade dysplasia (8 and 
18 cases respectively) to adenocarcinoma (41 cases) and lymph node metastasis 
(14 cases). The results are summarised in table 5.3. Examples of the 
immunoreactivity for each of the components of the plasminogen activator 
system are shown in figures 5.2,5.3,5.4, and 5.5. 
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Figure 5.2 uPA immunoreactivity in: A. Fundic-type metaplasia (x10). B. Non- 
involved oesophageal mucosa on left and cardiac-type metaplasia on right (x10). C. 
Cardiac type metaplasia (x10). D. Fundic-type metaplasia (x10). E. Cardiac metaplasia 
on left and intestinal metaplasia on the right (x10). 
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Figure 5.3 uPAR immunoreactivity in: A. Poorly Differentiated Adenocarcinoma 
(x10). B. Cardiac-type metaplasia (x10). C. Non-involved oesophageal mucosa (x10). D. 
Adenocarcinoma (x10). E. Adenocarcinoma with a small amount of squamous mucosa at 
surface (x10). 
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Figure 5.4 PAI-1 immunoreactivity in: A. Fundic-type metaplasia with positive 
staining for parietal cells (x40). B. Non-involved oesophageal mucosa (x 10). C. 
Adenocarcinoma (x 10). D. Intestinal and cardiac type Barrett's metaplasia with minimal 
staining of glandular areas and staining in stromal cells (x10). E. Intestinal metaplasia 
with nuclear staining (x10). 
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Figure 5.5 PAI-2 immunoreactivity in: A. Gastric/fundic-type metaplasia (x40). B. 
Intestinal metaplasia with strong nuclear staining (x10). C. Non-involved oesophageal 
mucosa (x10). D. Adenocarcinoma (x10). E. High grade dysplasia (x10). F. Intestinal-type 
metaplasia (x10). G. Fundic-type metaplasia (x10). 
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Examples of uPA immunoreactivity during the progression of Barrett's 
oesophagus to adenocarcinoma are shown in figure 5.2. The level of staining for 
uPA increased during the metaplastic: neoplastic progression of Barrett's 
oesophagus. The strongest staining for uPA was seen in both adenocarcinoma 
and lymph node metastasis samples. Barrett's metaplasia and low grade 
dysplasia samples showed moderate staining for uPA. 
Examples of uPAR immunoreactivity during the progression of Barrett's 
oesophagus to adenocarcinoma are shown in figure 5.3. The level of staining for 
uPAR increased during the neoplastic progression of Barrett's oesophagus. The 
strongest levels of staining were again seen in the cancer and lymph node 
metastasis samples. Barrett's metaplasia and dysplastic tissues showed weak to 
moderate staining for uPAR. 
Examples of PAI-1 immunoreactivity during the progression of Barrett's 
oesophagus to adenocarcinoma are shown in figure 5.4. There was moderate 
staining for the inhibitor PAI-1 in non-dysplastic Barrett's metaplasia, low and 
high grade dysplasia samples. The level of staining for PAI-1 was again strongest 
in the cancer and lymph node metastasis samples. 
Examples of PAI-2 immunoreactivity during the progression of Barrett's 
oesophagus to adenocarcinoma are shown in figure 5.5. There was also moderate 
to weak staining for the inhibitor PAI-2 in the non-dysplastic Barrett's 
metaplasia, low and high grade dysplasia samples. The level of staining was very 
strong in the cancer and lymph node metastasis samples. 
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The components of the plasminogen activator system were detectable by IHC at 
all stages of the progression in Barrett's oesophagus. The levels appear to stay 
relatively low in non-dysplastic Barrett's metaplasia, low grade and high grade 
dysplasia, but are increased in Barrett's associated adenocarcinoma. 
Surprisingly, levels are lower in lymph node metastasis than adenocarcinoma 
samples, as the components of the plasminogen activator system are associated 
with cancer invasiveness. 
In order to assess if the components of the plasminogen activator system are 
involved in metastasis during the progression of Barrett's oesophagus to 
adenocarcinoma the cancer cases were divided into those with lymph node 
metastasis and those without and the staining levels compared. A pattern of 
staining was seen as shown in figure 5.7. 
Levels of staining for uPA in metastatic cancer samples appeared stronger than 
those from non-metastatic cancers, but levels were weaker in lymph node 
metastasis. The levels of staining for uPAR were strongest in non-metastatic 
cancer samples when compared to lymph node metastasis and cancer samples. 
Interestingly the levels of staining for the inhibitor PAI-1 are weaker in 
metastatic and lymph node metastasis than the non-metastatic cancer samples. 
A similar pattern was also seen in samples stained for the inhibitor PAI-2, but to 
a lesser extent. 
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5.4.2 Results of the Detection of the components of the urokinase 
Plasminogen Activator System using ELISA techniques 
The protein concentrations of the components of the plasminogen system were 
measured using ELISA techniques in the samples that had previously been 
analysed using the TRAP assay for the detection of telomerase (Chapter 4). The 
samples analysed were as follows; non-involved oesophageal mucosa (n=23), non- 
involved gastric mucosa (n=31), non-dysplastic Barrett's metaplasia (n=14), 
Barrett's oesophagus with low grade dysplasia (n=10), Barrett's oesophagus with 
high grade dysplasia (n=10) and oesophageal adenocarcinoma (n=30) the results 
of which are shown in table 5.4. 
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Table 5.4. Results of samples analysed using ELISA techniques to detect 
both telomerase and the components of the Plasminogen Activator 
system. 
A= Resected Patients and B= Biopsy patients (* Same patient, but different surgery) C. 
Median antigen levels in ng/mg protein. 
Abbreviations: N= no, Y= Yes, uPA = urokinase-type Plasminogen Activator, uPAR = 
urokinase-type Plasminogen Receptor, PAI-1= Plasminogen Inhibitor type-1 and PAI-2 = 
Plasminogen Inhibitor type-2. 
Antigen levels given in ng/mg protein. 
A. Resected Patients 
Patient Diagnosis Telomerase 
Result 
Protein concentration ng/mg protein 
uPA uPAR PAI-i PAI-2 
1R N Stom N 0.066 <0.025 1.967 22.295 
N Oes N 0.240 1.867 1.333 3.467 
2R N Stom N 0.105 <0.025 3.158 <0.5 
LGD N 1.364 <0.025 3.030 <0.5 
LGD N 0.231 <0.025 1.538 <0.5 
3R N Stom N 0.101 0.633 1.519 <0.5 
N Oes y 0.074 0.741 0.741 >200 
IM Barr N 0.101 0.336 1.681 <0.5 
Cancer y 0.280 0.9 0.296 3.4 
4R N Stom N 0.164 0.164 3.217 0.656 
C Barr N 0.167 <0.025 1.667 <0.5 
LGD N 0.170 0.532 1.277 0.851 
Cancer y 1.548 4.783 13.217 3.652 
5R N Stom N 0.087 0.611 2.795 <0.5 
N Oes N 0.054 1.119 0.805 >200 
Cancer y 1.212 3.232 12.929 5.253 
6R N Stom N 0.071 0.118 2.353 0.471 
N Oes N 0.054 0.268 0.805 >200 
Cancer N 1.187 5.167 4.785 >200 
Cancer N 0.6 3.0 7.0 130.0 
7R N Stom N 0.049 0.366 0.894 0.650 
N Oes N 0.070 <0.025 1.033 39.649 
Cancer y 2.369 5.049 380447 33.010 
8R N Stom N 0.111 0.062 4.198 0.864 
N Oes N 0.103 1.379 1.7724 62.069 
IM Barr y 0.207 <0.025 3.448 1.379 
Cancer y 0.963 0.012 3.951 2.469 
9R N Stom N 0.151 <0.025 2.642 3.774 
1OR N Stom N 0.315 2.526 1.789 3.371 
Cancer y 0.868 6.509 6.792 2.830 
Cancer y 0.580 2.839 6.562 6.183 
11R N Stom N 0.101 0.404 1.818 <0.5 
N Oes N 0.036 0.264 0.714 >200 
Cancer y 0.590 5.082 2.295 1.639 
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12R N Stom N 0.174 1.375 2.899 10.725 
N Oes N 0.317 4.024 5.366 >200 
Cancer y 0.560 2.0 3.6 8.8 
Cancer y 1.028 5.587 89.39 4.693 
13R N Stom N 0.082 0.619 0.928 2.165 
N Oes N 0.107 0.982 1.429 >200 
Cancer N 2.202 10.674 12.135 >200 
14R N Stom N 0.051 0.380 2.278 >200 
N Oes N 0.163 9.0 10.0 34.0 
15R N Stom N 0.165 0.722 2.268 0.412 
Cancer y 0.264 1.069 2.421 3.176 
16R N Stom N 0.189 0.863 1.890 3.780 
N Oes N 0.108 0.753 10.968 >200 
Cancer y 0.8 3.2 17.6 13.6 
17R N Stom N 0.133 0.623 2.0 <0.5 
Cancer y 0.258 0.748 4.731 68.387 
Cancer y 1.277 3.987 11.277 >200 
18R N Stom N 0.184 2.212 2.212 1.475 
19R N Stom N 0.079 0.984 3.684 0.789 
Cancer N 1.965 12.281 11.930 14.035 
20R N Stom N 0.249 1.891 2.189 3.582 
LGD N 0.216 1.802 1.712 0.631 
21R N Stom N 0.134 1.033 0.486 1.216 
Cancer N 0.933 4.513 5.128 10.769 
22R N Stom N 0.149 2.299 0.805 1.839 
N Oes N 0.206 1.031 2.887 >200 
Cancer y 2.346 4.935 44.557 3.207 
23R Cancer y 1.030 7.345 6.667 8.485 
24R N Oes N 0.275 1.875 1.5 >200 
25R N Stom N 0.212 0.909 1.667 2.424 
F Barr N 0.690 2.414 4.138 50.345 
26R N Stom N 0.304 1.772 1.688 4.895 
N Oes N 0.217 1.356 0.814 >200 
Cancer y 0.786 5.556 21.709 4.615 
27R N Stom N 0.135 1.422 2.751 2.284 
C Barr N 0.271 1.711 1.416 1.652 
Cancer N 0.936 8.511 20.426 1.702 
28R N Stom N 0.154 0.988 2.037 1.790 
IM Barr N 0.385 2.404 1.154 2.308 
Cancer y 0.545 4.848 3.636 6.061 
30R N Oes N 0.078 0.340 1.165 >200 
31R N Oes N 0.308 1.385 1.538 75.692 
32R* HGD N 0.462 1.536 3.077 4.615 
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B. Bionsv patients 
Patient Diagnosis Telomerase 
Result 
Protein concentration ng/mg protein 
uPA uPAR PAI-1 PAI-2 
35B HGD Y 0.509 2.182 2.909 >200 
HGD N 0.714 2.857 7.143 >200 
36B* Cancer N 1.00 3.750 6.667 10.833 
38B N Stom N 0.093 0.577 1.860 0.930 
41B N Stom N 0.571 18.095 16.190 22.857 
HGD Y 0.276 0.345 2.759 2.069 
42B C Barr N 0.2 <0.025 3.0 4.0 
IM Barr N 0.6 <0.025 3.0 2.0 
LGD N 0.167 <0.025 2.5 <0.5 
43B HGD N 0.766 1.702 2.979 5.957 
HGD N 0.480 <0.025 2.4 9.6 
Cancer y 1.538 <0.025 6.154 7.692 
44B HGD N 0.4 <0.025 8.0 112.0 
45B N Stom N 0.125 6.875 2.5 2.5 
N Oes N 0.054 0.941 1.622 >200 
46B N Oes N 0.111 <0.025 3.333 >200 
HGD Y 0.385 0.385 3.077 9.231 
Cancer y 0.638 2.029 5.797 5.797 
47B F Barr N 0.162 1.351 1.081 1.622 
C Barr N 0.833 5.0 6.667 1.667 
48B LGD N 0.267 0.333 0.667 14.0 
Cancer N 0.571 1.42 3.265 17.143 
Cancer N 1.391 2.383 6.957 17.391 
49B N Stom N 0.078 0.649 2.338 0.779 
N Oes N 0.118 <0.025 1.176 >200 
LGD Y 0.25 1.667 3.333 5.833 
50B N Oes N 0.174 0.643 1.739 >200 
Cancer y 0.171 1.429 4.0 12.571 
52B F Barr N 0.048 1.190 0.959 <0.5 
54B N Oes N 0.457 1.566 2.289 >200 
N Oes y 0.464 <0.025 2.319 >200 
IM Barr y 0.593 5.185 5.926 <0.5 
LGD Y 0.303 4.545 3.636 <0.5 
55B N Stom N 0.197 0.984 1.311 >200 
IM Barr N 0.615 3.077 6.154 35.385 
LGD Y 0.818 0.909 3.636 6.364 
57B HGD Y 0.857 2.571 5.143 >200 
61B HGD N 0.748 0.514 2.286 67.429 
63B N Oes N 0.465 2.326 1.860 4.651 
C Barr N 1.125 3.750 157.5 95.00 
LGD Y 0.632 2.102 4.211 >200 
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C. Median antigen levels in ng/mg protein. 
Diagnosis uPA uPAR PAM PAI-2 
Non-involved 0.14 0.86 2.19 1.79 
Stomach 
Non-involved 0.11 0.94 1.54 200.0 
Oesophagus 
Non-Dysplastic 0.33 1.53 3.00 1.66 
Barrett's 
Low Grade 0.26 0.72 2.77 0.74 
Dysplasia 
High Grade 0.49 1.03 3.03 38.51 
Dysplasia 
Adenocarcinoma 0.93 3.87 6.67 8.09 
153 
Levels of urokinase-type Plasminogen Activator increased with the progression 
from non-involved mucosa (median 0.13ng/mg protein) through non-dysplastic 
Barrett's metaplasia (0.33ng/mg protein), Barrett's with low grade dysplasia 
(0.26ng/mg protein), and high grade dysplasia (0.49ng/mg protein) to high levels 
in adenocarcinoma (0.93ng/mg protein). There were similar changes in the levels 
of Plasminogen Activator Receptor (non-involved 0.89 ng/mg protein; Barrett's 
metaplasia 1.53ng/mg protein; low grade dysplasia 0.72ng/mg protein; high grade 
dysplasia 1.03ng/mg protein, adenocarcinoma 3.87ng/mg protein). Plasminogen 
Activator Inhibitor type-1 levels were higher in non-dysplastic Barrett's (median 
3. Ong/mg protein) and dysplastic Barrett's (low grade 2.77ng/mg protein, and 
high grade dysplasia 3.03ng/mg protein) than in non-involved oesophagus 
(1.88ng/mg protein), but less than in adenocarcinoma of the oesophagus 
(6.67ng/mg protein). Plasminogen Activator Inhibitor type-2 levels were very 
high in high grade dysplasia (38.51ng/mg protein) when compared to non- 
involved epithelium (4.77ng/mg protein), Barrett's metaplasia (1.66ng/mg 
protein), low grade dysplasia (0.74ng/mg protein) and adenocarcinoma 
(8.09ng/mg protein). 
Statistical analysis of the data was carried out using GenStat for windows. The 
results are shown in Figure 5.8 and appendix 7. 
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Figure 5.8. Statistical representation of the plasminogen ELSIA results. 
Box Plots of the results where the rectangles represent the upper and lower 
quartiles with the median marked in the middle and the tails represent the 
range of the results. 
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From the Box Plots (figure 5.8) it can be seen the detectable concentration of uPA 
increased during the progression of Barrett's oesophagus. Most of the boxes are 
small showing the majority of values were similar within the upper and lower 
quartiles. The ranges of values for the detection of uPA were reasonably small, 
with the exception of the adenocarcinoma samples, which had both high and low 
extremes. These results are reliable as all the values were within the range of the 
standards within the kit. 
The ranges of values for uPAR were not as good as those for uPA. Samples of 
non-involved stomach, non-involved oesophagus, low grade dysplasia and 
adenocarcinoma had values below the standards within the kit (<0.025ng/ml 
protein). There were large ranges of values for non-involved oesophagus and 
adenocarcinoma with very high extremes. The boxes for non-involved stomach 
and oesophagus, and low and high grade dysplasia were reasonably small 
showing the majority of values were similar. 
The results for the detection of PM-1 were reliable, again all the values were 
within the range of standards within the kit and the boxes were small showing 
the majority of values between the upper and lower quartiles were similar. The 
overall ranges of values are quite small except for the adenocarcinoma samples 
where high extreme values were detected. The levels of PM-i remain quite 
constant during the progression of Barrett's oesophagus, but were increased in 
adenocarcinoma. 
The least reliable results were from the detection of PAI-2. This kit used a 
polyclonal antibody to detect PAI-2, whereas all the other kits utilised 
monoclonal antibodies. A large proportion of samples gave values above 
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(>200ng/mg protein) and below (<0.5ng/mg protein) the standards within the kit. 
Nearly all the non-involved oesophagus samples gave values > 200ng/mg protein 
hence the small box at the extreme of the chart. High grade dysplasia gave a 
wide range of values and therefore had a very large box. 
5.5 Discussion 
As mentioned previously tumour cell invasion involves the attachment of tumour 
cells to the underlying basement membrane, local proteolysis and migration of 
tumour cells through this degraded region. Proteases are involved throughout the 
metastatic process. In order for a cell to metastasise it must be able to move into 
blood vessels, survive in circulation, arrest, move out of the blood vessels, invade 
surrounding tissues and grow. All these steps involve interactions between 
tumour cells, stromal cells, invading lymphocytic cells, endothelial cells and the 
extracellular matrix. Proteases, which are expressed in these cells (including 
Cathepsin B and D, Urokinase-type plasminogen activator and receptor, and 
interstitial collagenase), are believed to participate in many of these steps. 
Urokinase-type Plasminogen activator (uPA) is a protein that has a molecular 
weight of about 54,000 daltons and is composed of 2 disulphide-linked chains, A 
and B of molecular weights 18,000 and 33,000 respectively. uPA may occur as a 
single-chain form or as a 2-chain derivative, which is gained by cleavage of the 
peptide bond between Lys(158) and Ile(159). It has been found the amino acid in 
position 158 is the main determinate of the functional properties of the single- 
chain form, but not the 2-chain form. uPA is a prognostic marker in many 
malignancies including cancers of the lung, breast, stomach and colorectal 
cancers. 
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The urokinase-type Plasminogen Activator Receptor (uPAR) is a key molecule in 
the regulation of cell-surface plasminogen activation and therefore plays an 
important role in many normal and pathological processes. Plasminogen 
activator receptor is also known as CD87. uPAR expression in vivo is associated 
predominately with macrophages at inflammatory sites. It is a highly glcosylated 
protein of about 5OkD in monocytes where it is anchored to the plasma 
membrane by a glycosyl-phosphatidylinositol linkage. 
There are two naturally occuring inhibitors for uPA, Plasminogen activator 
inhibitor type-1 (PAI-1) and Plasminogen activator inhibitor type-2 (PAI-2). PAI- 
1 is a protein containing 402 amino acids with a predicted non-glycosylated 
molecular mass of 45kD. It is thought to be a member of the serine protease 
inhibitor (serpin) superfamily of proteins. PM. 1 comes from endothelial cells 
whereas PAI-2 comes from placenta, monocytes and macrophages. PAI-2 is a 
protein containing 450 amino acids with a predicted non-glycosylated molecular 
weight of 46kD. PAI-2 is also a member of the superfamily of serine proteases in 
which the target specificity of each is determined by the amino acid residue 
located at its reactive centre. 
Although a large body of information has accumulated on the biology, 
biochemical and clinical aspects of PAI-2, suggesting it is involved in many 
physiological processes, its precise role in placenta and inflammatory conditions 
as well as diagnostic and therapeutic possibilities of PAI-2 remain to be 
established (Kruithof 1995). PAI-2 is thought to serve as a primary regulator of 
plasminogen activation in the extravascular compartment. High levels of PAI-2 
are found in keratinocytes, monocytes and the human trophoblast, the latter 
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suggesting a role in placental maintenance or in embryo development. The 
primarily intracellular distribution of PAI-2 may also indicate a unique 
regulatory role in a protease-dependent cellular process such as apoptosis 
(Dickinson 1995). 
The progression of Barrett's oesophagus through increasing degrees of dysplasia 
to adenocarcinoma is characterised by the ability of epithelial cells to invade the 
basement membrane. Changes in the expression of components of the 
plasminogen activation system which allows increased production of plasmin are 
thought to have an important role in malignant cell invasion, but little is known 
about the expression of these components in the premalignant stages of Barrett's 
oesophagus. Both uPA and uPAR are implemented in the invasion of oesophageal 
cells. It has been shown utilising oesophageal cells derived from both squamous 
cell carcinoma and Barrett's associated adenocarcinoma that when uPA and 
uPAR are co-expressed the cells display stronger invasiveness. Anti-sense 
oligonucleotide inhibition of both uPA and uPAR resulted in a marked reduction 
in invasiveness (Morrissey 1999). Co-expression of uPA and uPAR is therefore 
required for functional involvement of the plasminogen activator system in the 
invasion of neoplastic oesophageal cells. Here the components of the plasminogen 
activation system have been studied during the metaplastic: neoplastic 
progression of Barrett's Oesophagus using both immunohistochemistry and 
ELISA techniques. 
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5.5.1 Tissue distribution of the components of the Plasminogen Activator 
system 
The localisation of the protein and mRNA of uPA, uPAR and the PA inhibitors 
varies from tumour type to tumour type. It has been shown that in colon 
carcinoma uPA is expressed in cancer cells, uPAR is found in cancer cells and 
macrophages surrounding cancer cells and PAI-1 and PAI-2 are found in 
endothelial cells (Pyke 1994 and Naitoh 1995). In Breast cancer uPA, uPAR and 
PAI-2 are expressed in cancer cells and the surrounding stromal cells (Pyke 1993 
and Umeda 1997). A study by Shiomi et al used immunohistochemistry and in 
situ hybridisation to investigate the expression of uPA, uPAR and PAI-2 in 
oesophageal squamous cell carcinoma found uPA and PAI-2 were expressed in 
cancer cells as well as in adjacent fibroblasts. In contrast uPAR was only 
expressed in cancer cells at the periphery of the tumours (Shiomi 2000). These 
data suggest that the differential expression of uPA, uPAR and PAIs may 
contribute to the organ and cellular specificity of various malignant 
characteristics. 
Here the IHC results appear to show that staining levels of all the components of 
the plasminogen system are increased in Barrett's associated adenocarcinoma. 
The levels appear to stay relatively low in non-dysplastic Barrett's metaplasia, 
low grade and high grade dysplasia. This implies the expression of these 
molecules is a late event in the progression of Barrett's associated cancer. 
Surprisingly levels are lower in lymph node metastasis than adenocarcinoma 
samples, as the components of the plasminogen activator system are associated 
with cancer invasiveness and metastasis. 
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Examples of uPA immunoreactivity during the progression of Barrett's 
oesophagus to adenocarcinoma are shown in figure 5.2. The 
immunohistochemical staining of uPA in non-dysplastic Barrett's metaplasia was 
strongest towards the basement membrane of the cells. There was also strong 
sub-nuclear staining and staining in the stroma between the metaplastic cells. 
There was moderate peri-nuclear/nuclear staining for uPA in high grade 
dysplasia. In adenocarcinoma there were increased levels of staining for uPA 
through the tissue towards the inner oesophagus. This pattern of staining was 
also seen in the sections stained for uPAR implying co-localisation of uPA and 
uPAR. Examples of uPAR immunoreactivity during the progression of Barrett's 
oesophagus to adenocarcinoma are shown in figure 5.3. 
In vitro uPAR-bound to pro-uPA is activated much more quickly than is the fluid 
based uPAR protein. uPAR is considered to enhance the ability of uPA to mediate 
invasiveness by localising uPA to the surface of the tumour cell (Shiomi 2000). A 
resent study by Morrissey et al shows that co-expression of uPA and uPAR is 
required for maximum invasiveness of oesophageal carcinoma cell-lines in vitro 
(Morrissey 1999). 
Blood vessel spread stained weak to negative for uPA, but strongly for uPAR. 
Staining for uPA becomes stronger as the cancer becomes less differentiated. 
There was no staining for uPA in signet ring cancer cells. These mucin containing 
cells may express uPA, but not strongly, the high levels of mucin may have 
diluted it. There is strong staining for uPA in nerve cells, muscle and 
oesophageal glands. Where there is staining for uPAR in the nucleus of cells 
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there is also weak staining in the cytoplasm. There was also strong staining for 
uPAR in mast cells. 
uPA is present in circulation in minute quantities. When uPA binds to the 
receptor or inhibitor it is incorporated into the cellular cytoplasm (Naitoh 2000). 
Therefore even if uPA antigen is detected it does not mean it was produced there. 
This could be true for all the other components of the plasminogen system. For 
this reason identification of the mRNA of the components of the plasminogen 
activation system is needed. This could be investigated utilising an in situ 
hybridisation method. 
Examples of PAI-1 and PAI-2 immunoreactivity during the progression of 
Barrett's oesophagus to adenocarcinoma are shown in figures 5.4 and 5.5 
respectively. Staining for PAM and PAI-2 was strongest in the nucleus of cells. 
Blood vessel spread was very strongly stained for both the inhibitors. There was 
very strong staining for PAM in the stroma between cells. Again signet ring cells 
appeared as negative holes in the staining for PAI-1. The staining for PAI-1 was 
diffuse in cancer cells. In cardiac and fundic Barrett's metaplasia there was 
moderate staining towards the basement membrane for PAI-1. Peri-nuclear 
staining was seen in non-dysplastic metaplasia cells. Diffuse staining for PAI-1 
was seen in dysplastic and intestinal metaplasia. The muscle in blood vessel 
walls and nerve cells also stained positively for PAI-1. There was strong staining 
for PAI-2 in the stroma between the cells as seen in sections stained for PAI-1. In 
high grade dysplasia there was focal peri-nuclear staining for PAI-2. Non- 
involved oesophagus was strongly stained for all components of the plasminogen 
system. 
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There are few reports on the levels of PAI-1 in tumour tissues. Reilly et at 
observed PAT-1 expression in cancer cells in breast tumours and suggested that 
either PAI-1 is necessary in the process of cancer invasion and metastasis 
mediated by uPA or PAI-1 represents a defence mechanism against cancer 
invasion and metastasis (R. eily 1992). The incidence of Lymph node metastasis 
has been reported to become lower with in increasing amount of PAI-2 in the 
cancer tissues of the stomach and breast (Naitoh 2000), but these results have 
been contradicted by Gleeson et al in endometrial cancer (Gleeson 1993). 
A study by Naitoh et al looking at uPA, PAI-1 and PAI-2 in colon cancer found 
that uPA expression in cancer cells was significantly more frequently detected in 
cases with lymph node metastasis than in cases without metastasis (Naitoh 
2000). Here when metastatic Barrett's adenocarcinoma and non-metastatic cases 
were compared (figure 5.7) staining for uPA was increased in cases with lymph 
node metastasis. This was also seen in the staining for uPAR, but to a lesser 
extent. Interestingly, staining levels for the inhibitors PAI-1 and PAI-2 was 
decreased in cases with lymph node metastasis. This implies all the components 
of the plasminogen activator system are involved in the metastatic progression of 
Barrett's associated adenocarcinoma. 
The increased levels of uPA and uPAR in metastatic tumours will increase the 
production of plasmin the protease involved in the degradation of the basement 
membrane during cellular invasion. The decreased levels of the inhibitors PAI-1 
and PAI-2, which inhibit the production of plasmin by binding to uPA, show a 
decline in the cellular control of invasion in metastatic tumours. 
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In contrast to other current methods for the detection of the components of the 
plasminogen activator system in tumour tissues, (e. g., Western blots and ELISA) 
immunohistochemistry provides the opportunity to directly analyse exactly which 
cells (e. g., tumour or stroma cells) are positive or negative for protein expression 
in the tissue sample. Furthermore, immunohistochemistry staining of paraffin- 
embedded tissues facilitates prognostic studies of a large archival series of one 
tumour type. The validity of immunohistochemistry has been shown by direct 
comparison with quantitative methods (ELISA) of uPA measurement (Kobayashi 
1994). Here the ELISA and immunohistochemistry results cannot be compared 
as different cases and samples were assessed in each study. Fresh frozen samples 
were utilised in the ELISA experiments and paraffin embedded tissues were used 
for immunohistochemistry. 
A possible mechanism for the over expression of uPA in tumour samples could be 
the modulation of the plasminogen activation by inflammatory mediators. It has 
been shown that the amount of stromal inflammatory cell reaction has a 
significant influence on the prognosis of patients with breast and oesophageal 
cancers (Torzewski 1997). Alternatively, strong cytoplasmic staining for uPA in 
tumour cells could be caused by increased and rapid internalisation of inactive 
uPA: PAI-1 and uPA: PAI-2 complexes. Both these mechanisms alone or combined 
could result in the increased availability of uPA on the cell surface and determine 
the capacity for the cell to invade and metastasise. 
Previous studies have shown that in some tumour types intense staining for uPA 
is found in the stromal cells surrounding tumour cells as well as the tumour cells 
themselves (Torzewski 1997). In line with previous studies here intense staining 
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for uPA has been observed in non-cancerous elements of the tumour tissues. The 
staining was of equal intensity between the cell types. 
Epithelial cadherin (E-cad) is the primary regulator of cell adhesion in epithelial 
tissues. Cadherin function is regulated in part by interactions with cytoplasmic 
proteins called catenins. Levels of E-Cad were assessed during this study as a 
positive control for the immunohistochemistry technique. The levels of staining 
for E-cad follow the patterns of previous studies. In the past it has been shown 
there is a reduction in the expression of the E-cadherin/catenin complexes in 
Barrett's oesophagus biopsy specimens during the progression to 
adenocarcinoma, (Swami 1995, Washington 1998). A significant reduction in the 
expression of E-cadherin was also shown by Bailey et al to occur during the 
progression of Barrett's oesophagus to adenocarcinoma (Bailey 1998). 
The cellular localisation of E-cadherin would be expected to be on the surface of 
the cells in the membrane as it is an adhesion molecule. This was seen in non- 
involved oesophageal sections, but in metaplastic, dysplastic and adenocarcinoma 
tissues the antigen was cytoplasmic. The reason for this is unclear, although it 
could result from a change in the mechanism required to insert the protein in the 
membrane. The result is that E-cadherin loses the ability to perform as an 
adhesion molecule during disease progression. The reduced levels of E-cadherin 
during disease progression could be due to mutation or down regulation of the 
gene. The epitope recognised by the antibody could be altered resulting in loss of 
antibody specificity. 
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5.5.2 Analysis of the levels of the components of the Plasminogen Activator 
System 
The ELISA results show levels of uPA increased with the progression from non- 
involved mucosa through non-dysplastic Barrett's metaplasia, dysplasia, to high 
levels in adenocarcinoma. There were similar changes in the levels of 
plasminogen activator receptor. Plasminogen Activator Inhibitor type-1 levels 
were higher in both non-dysplastic and dysplastic Barrett's than in non-involved 
oesophagus, but less than in adenocarcinoma of the oesophagus. Plasminogen 
Activator Inhibitor type-2 levels were very high in high grade dysplasia when 
compared to non-involved oesophagus, Barrett's metaplasia, low grade dysplasia 
and adenocarcinoma. 
Various studies into the levels of the components of the plasminogen activator 
system have been carried out using ELSIA techniques by Hewin et al on tumours 
of the gastrointestinal tract (Hewin 1994 a and b). These studies are summarised 
in table 5.5. The median levels of the components were very different to those 
found here, but the patterns of expression are similar. Levels of plasminogen 
activator and its receptor were elevated in the tumours when compared to 
matched normal and non-involved samples. Levels of plasminogen activator 
inhibitor type-1 were undetectable in previous studies, but detected here and 
were increased in tumour samples. A large increase in levels of PAI-1 is seen 
between gastric and oesophageal mucosa. Levels of inhibitor type 2 were reduced 
in tumour samples when compared to matched normal and non-involved cases. 
The differences in median values could be explained by the small number of 
samples assessed in the previous studies. 
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In ELISA experiments carried out in this study protein samples were extracted 
from tissue sections using CHAPS lysis buffer. CHAPS is an ionic detergent. 
Ionic detergents are strongly amphiphilic and therefore tend to denature 
proteins. Amphiphilic substances are both hydrophobic and hydrophilic and 
breakdown these interactions in the tertiary structure of proteins. This could 
effect the ELISA detection methods for the components of the plasminogen 
system. The protein samples were originally extracted from fresh frozen tissue to 
detect active telomerase not the components of the plasminogen activator system. 
Extraction with CHAPS could denature the proteins and alter the antibody 
epitopes. A neutral detergent such as Triton X-100 could be used instead to 
confirm this. 
No previous studies have assessed the cellular levels of the components of the 
plasminogen activator system during the metaplastic: neoplastic progression of 
Barrett's, but here patterns in the levels of the components of the plasminogen 
activator system have been shown. Levels of plasminogen activator, its receptor 
and inhibitor type-1 increase during disease progression, whereas levels of 
inhibitor type 2 decrease. These changes appear as a late event during the 
progression of the disease showing the invasive phenotype of Barrett's 
oesophagus allowing cells to invade the basement membrane does not appear 
until severe dysplasia or neoplasia is present in the oesophagus. 
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Table 5.5. Summary of previous studies into the components of the 
plasminogen activator system in the gastrointestinal tract using ELISA 
techniques. 
Antigen levels in ng/mg protein. 
Previous studies uPA uPAR PAI-1 PAI-2 
Hewin et al Oesophageal 6.2 Not in Not 2.4 
1994a adenocarcinoma study detected 
Normal mucosa 1.5 Not in Not 30.8 
study detected 
Oesophageal 20.7 Not in Not 8.2 
carcinoma study detected 
Normal mucosa 0.8 Not in Not 105.2 
study detected 
Hewin et al Gastric 1.93 1.72 0.04 2.52 
1994b carcinoma 
Normal mucosa 0.28 1.03 0.75 2.78 
Hewin et al Oesophageal 2.16 2.01 Not 6.0 
1996 adenocarcinoma detected 
Normal mucosa 0.61 0.49 Not 64.77 
detected 
Oesophageal 4.05 1.95 Not 10.68 
carcinoma detected 
Normal mucosa 0.66 0.50 Not 46.91 
detected 
Results of Oesophageal 0.93 3.87 6.67 8.09 
this study adenocarcinoma 
Non-involved 0.11 0.94 1.54 200.00 
mucosa 
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The ELISA and immunohistochemistry results follow similar patterns of 
expression for the components of the plasminogen activator system during the 
progression of Barrett's oesophagus to adenocarcinoma, but both methods have 
their shortcomings when assessing the validity of molecular markers. 
Immunohistochemistry allows the analysis of the proteins in situ elucidating the 
cellular location of the molecules within tissue, but gives no information on the 
levels of expression or activity of the proteins. ELISA techniques allow the 
quantification of the components of the plasminogen activator system, but as 
extracted protein samples were utilised localisation and expression of the 
proteins cannot be assessed. Immunohistochemistry relies upon surgical 
procedures for the collection of tissues for analysis either biopsy or resection. 
Smaller amounts of tissue can be assessed using ELISA techniques, either 
brushed cytological samples from the oesophagus or laser capture micro-dissected 
samples where a specific cell or cell type can be analysed. For a complete analysis 
of the plasminogen activator system during the progression of Barrett's 
associated adenocarcinoma expression of the proteins could be assessed using in 
situ hybridisation techniques to detected mRNA. 
The gene map locations of the components of the Plasminogen Activator system 
are: uPA 10g24 (Tripputi 1985), uPAR 19g13 (Borglum 1991), PAI-1 7g21.3-q22 
(Ginsburg 1986), PAI-2 18g21.3 (Antalis 1988). As yet no mutations in these 
regions of the chromosomes have been discovered during the progression of 
Barrett's oesophagus to adenocarcinoma. If a mutation in any of these gene 
locations was found it could explain the changes in the expression of the 
components of the plasminogen activator system and be utilised as a diagnostic 
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tool. As yet no investigation into the expression control of the components of the 
Plasminogen Activator system has been carried out. 
5.5.3 The Effect of Telomerase Reactivation on the Levels of the 
Components of the Plasminogen Activator System 
Levels of the plasminogen activator system and telomerase reactivation were 
assessed here as the same protein samples were utilised during both studies. 
Levels of plasminogen activator were higher in telomerase negative samples 
except in cases of low grade dysplasia during disease progression. Levels of 
plasminogen activator receptor were higher in telomerase positive samples in the 
early stages of progression, but this relationship was reversed in later stages. 
Levels of Plasminogen activator inhibitor type-1 were high in telomerase 
negative samples of non-dysplastic Barrett's metaplasia and in telomerase 
positive samples of adenocarcinoma. Levels of plasminogen activator inhibitor 
type-2 exhibited a very different pattern with low levels in all telomerase positive 
samples. High levels of inhibitor type-2 were seen in telomerase negative samples 
in the later stages of progression. 
The levels of the components of the plasminogen activator system and telomerase 
reactivation are thought to be crucial steps in the development of the ability of a 
malignant cell to invade and become immortal. There are no published reports of 
the relation between these two events and human carcinogenesis. The results 
show there is a complex relationship between invasion and immortality during 
the progression of Barrett's oesophagus to adenocarcinoma. It is very probable 
that the processes work independently. Plasminogen activator and its receptor 
levels in the later stages of progression were associated with telomerase 
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negativity. This indicated that cells with an invasive phenotype are not capable 
of cellular immortality. Interestingly, the highest levels of inhibitor type-2 were 
also found in these late stage telomerase negative samples, implying that the 
invasive capacity of non-immortal cells maybe held in check by the activity of the 
plasminogen activator inhibitors. The expression of the components of the 
plasminogen activator system may still be controlled in mortal cells. 
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6 The Molecular Characterisation of Two Oesophageal 
Cell-Lines 
6.1 Introduction 
It is currently possible to take immortal human cells from tumours and culture 
them successfully in the laboratory for many generations. In some cases the cells 
proliferate indefinitely and become what is known as a cell-line. These cultured 
immortal cells are useful controls in the assessment of new treatments and 
diagnostic tools for human cancer. Cultured human cells can also be used as 
experimental model systems for the development of in vitro models of the 
diseases from which they are derived. 
As mentioned previously there are two main types of oesophageal tumours, 
squamous cell carcinoma and Barrett's associated adenocarcinoma. In order to 
produce in vitro models of these tumours two oesophageal cell-lines were 
characterised according to molecular changes known within the diseases. These 
cell-lines were, 
" OE21, a human oesophageal squamous cell carcinoma cell-line established in 
1993 from a squamous carcinoma of the mid oesophagus of a 74 year-old male 
patient. Also known as JROECL21. 
9 OE33, a human oesophageal adenocarcinoma cell-line established from the 
adenocarcinoma of the lower oesophagus (Barrett's metaplasia) of a 73 year- 
old female patient. Also known as JROECL33 (Rockett 1997). 
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This chapter describes the molecular characterisation of these experimental 
model systems utilising a range of molecular biological techniques previously 
studied in clinical samples from squamous cell carcinoma and Barrett's 
associated adenocarcinoma. The molecular characteristics assessed included 
cellular adhesion, proliferation, the presence of an immortal phenotype, and 
invasiveness, all of which have been extensively studied in clinical cases. 
6.2 Materials and Methods 
6.2.1 Cell Culture 
Human oesophageal cell-lines OE21 and OE33 (Rockett 1997) were cultured as 
described in section 3.2, in RPM1-1640 modified medium supplemented with 10% 
foetal bovine serum, 5m1 stabilised penicillin-streptomycin solution and 1ml 
amphotericin B solution per 500ml (all regents from Sigma cell culture, Poole, 
Dorset, England). 
Once established the growth media was replaced every 2 days. Cells were grown 
in either T25 culture flasks (for Tri-reagent extraction) or slide flasks (for 
immunohistochemistry). Once the cells were 75-80% confluent they were 
detached from the T25 flask surface using lx trypsin-EDTA solution (Sigma cell 
culture, Dorset, England) and treated for protein extraction. The growth media 
was removed and the cells washed once in sterile PBS, then 5m1 of trypsin 
solution was added and the flask left to stand for 1 minute. Gentile tapping on 
the side of the flask helped to detach the cells. Trypsin was inhibited using 5m1 of 
growth medium and the cells pelleted by centrifugation at 100 xg for 5 minutes 
at 4°C. The pellet of cells could then be used for splitting into further flasks or 
protein extraction. 
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6.2.2 Immunocytochemistry on Slide Flasks 
Cell-lines were grown on both glass and polystyrene slide flasks (Merck, Poole, 
Dorset, England). Once the flasks were 70-80% confluent the cells were washed 3 
times in PBS and fixed in ice cold methanol for 10 minutes. The slides were then 
wrapped in foil and stored at -20°C. Slides were removed from the freezer as 
required and left on the bench for 30 minutes to reach room temperature. The 
slide was divided up into a grid using a "Dako" pen (Dako Ltd. Cambridge UK) 
prior to the blocking of non-specific reactions. 
Immunocytochemistry was then carried out as described in section 3.9 with the 
following modifications. Non-specific reactions were blocked using rabbit serum 
(1: 5) (v/v) in PBS. The blocking serum was removed without washing and the 
primary antibody (see table 6.1 for details of the antibodies and working 
concentrations) added diluted with PBS containing 1% serum and left in a humid 
atmosphere at 4°C overnight. 
Once bound the antibodies were detected with the ABComplex and washed. The 
slides were then incubated with DAB Solution for 5 minutes. The slides were 
then washed in tap water and counterstained with heamatoxylin. Once the slides 
had been counterstained in haematoxylin they were mounted using Ultramount 
aqueous mounting medium (Dako Ltd, Cambridge, UK) and were ready for 
viewing under the light microscope. 
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Table 6.1 Antibodies used for immunocytochemistry on slide flasks. 
Antibody Type Working Company 
Concentrations 
CD44 Monoclonal mouse 12µg/ml Dako Ltd. Cambridge, 
anti-human UK 
Cytokeratin 8 Monoclonal mouse 10µg/ml Dako Ltd. Cambridge, 
anti-human (low UK 
molecular weight) 
Cytokeratin 18 Monoclonal mouse 6µg/ml Dako Ltd. Cambridge, 
anti-human UK 
CEA Monoclonal mouse 6µg/ml Dako Ltd. Cambridge, 
anti-human UK 
P-Cadherin Monoclonal mouse 2.5µg/ml Affiniti Research 
anti-human Products Ltd. Exeter, UK 
ß-Catenin Monoclonal mouse 2.5µg/ml Affiniti Research 
anti-human Products Ltd. Exeter, UK 
p53 Monoclonal mouse 500µg/ml Pharmingen 
anti-human International, 
p63 Polyclonal mouse No data available - Provided by P. Hall 
anti-human dilution 1/1000 
uPA Polyclonal goat anti- 4µg/m1 American Diagnostica 
human Inc. Greenwich USA 
uPA Monoclonal mouse 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
uPAR Monoclonal mouse 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
PAI-1 Monoclonal mouse 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
PAI-2 Polyclonal goat anti- 4µg/ml American Diagnostica 
human Inc. Greenwich USA 
CD44 (Hermes) Monoclonal mouse No data available Provided by A. C. 
anti-human -dilution 1/50 Woodman 
E-Cadherin Monoclonal mouse 2µg/ml Alexis Biochemicals, 
anti-human Nottingham, UK 
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6.2.3 Production of cDNA (RT-PCR) 
Using total RNA samples produced by Tri-reagent extraction (section 3.5) a 
reverse transcription reaction (RT-PCR) was made as described in section 3.11 
with the following modifications. The Promega RT System (Promega Corporation, 
Southampton, UK) was again utilised using AMV Reverse Transcriptase to 
synthesise single-stranded cDNA. 
The resulting cDNA was then transferred to a PCR reaction and cycling 
conditions were one cycle of 94°C for 5 minutes when the DNA polymerase was 
added. This was followed by 30 cycles of 94°C for 1 minute, 1 minute at the 
appropriate annealing temperature calculated by the TM of each primer and a 
72°C extension step varying between 30 seconds and 2 minutes. The primers and 
annealing temperature are summarised in table 6.2. 
6.2.4 Gel Electrophoresis 
PCR products were visualised on agarose gels the percentage of which varied 
according to the size of PCR product. A 1.8% agarose gel was used for PCR 
products approximately 200 - 400bp in size. See section 3.8 for further details. 
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Table 6.2 Primers and specific conditions for PCR. 
Further details of these primers are given in appendix 4. 
Target Primer Conditions Size of Product 
gene 
ß-Actin F and R Annealing at 55°C for 1 minute -500bp 
and extension of 2 minutes 
E-Cadherin 4F and 5R Annealing at 60°C for 1 minute 380bp 
exons 4 and and extension of 30 seconds 
5 
ß-Catenin 1F and 1R Annealing at 55°C for 1 minute -250bp 
and extension of 1 minute 
ß-Catenin 3F and 3R Annealing at 55°C for 1 minute 228bp 
exon 3 and extension of 30 seconds 
6.2.5 TRAPEZETMELISA Telomerase detection kit. 
For non-quantitative detection of telomerase activity in cells the TRAPEZETM 
ELISA telomerase detection kit (Intergen Company, Oxford, UK) was utilised. 
The kit contains all the reagents necessary to perform the Telomeric Repeat 
Amplification Protocol (TRAP) and Enzyme-Linked Immunosorbent Assay 
(ELISA). The assay was carried out according to the manufacture's protocol and 
as described in section 4.2. 
Cultured cells were detached from the bottom of T25 flasks when approximately 
75-80% confluent using trypsin/EDTA as mentioned in the cell culture section 
3.2. The pellet of cells was then washed once in PBS and all the PBS removed. 
The pellet was then resuspended in 2O0µ1 (3-[(3-Cholamidopropyl) 
dimethylammonio]-1-propane-sulfonate) CHAPS Lysis buffer. The sample 
suspensions were incubated on ice for 30 minutes and then spun at 12,000 xg for 
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20 minutes at 4°C. The supernatant (160µ1) was transferred to a fresh tube and 
6µl set aside for determination of protein concentration (see section 3.3.6). The 
kit recommended diluting the sample extracts with CHAPS lysis buffer prior to 
use according to the following: cell extracts (0.01µg/µ1- 0.75µg/µl) using less than 
1.5µg per assay. Titre experiments were also carried out to find the optimum 
concentration of protein required for the assay. The TRAP assay was set up for 
each sample as described in section 4.2 with no modifications. 
6.2.6 ELISA for the detection of the components of the Plasminogen 
Activator system 
The quantitative analysis of the components of the urokinase Plasminogen 
Activator system were carried out on the same cell-line protein extracts as were 
analysed using the TRAPEZETM ELISA. The kits utilised were the IMUBINDO 
uPA ELISA kit, the IMUBIND® Total uPAR ELISA kit, the IMUBIND®Tissue 
PAI-1 ELISA kit and the IMUBIND® PAI-2 ELISA kit (American Diagnostica 
Inc. Greenwich, USA). Analysis was carried out as described in section 5.3 with 
no modifications. 
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6.3 Results 
The overall results are shown in table 6.3. To characterise the cell-lines various 
techniques were used. These were: 
" Telomerase Repeat Amplification Protocol (TRAP), 
" Immunocytochemistry (ICC), 
" Reverse Transcription-Polymerase Chain Reaction (RT-PCR), 
" Enzyme-Linked Immunosorbant assay (ELISA). 
From the table it can be seen that there were differences in some of the results 
for each cell-line and some of the experiments resulted in no differences between 
the cell-lines at all. Differences were seen in some of the components of the 
plasminogen activator system between the cell-lines. Most of the cadherin and 
catenin results were the same for both cell-lines, the only difference was in the 
IHC for ß-catenin, OE21 was positive and OE33 was negative. There were also no 
differences in CD44 expression between the cell-lines. Differences were seen in 
the expression of the cytokeratins, CEA, p63 and p53. 
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Table 6.3. Summary of cell-line characterisation results. 
Abbreviations: TRAP = Telomerase Repeat Amplification Protocol, ELISA = Enzyme- 
Linked Immunosorbent Assay, ICC = Immunocytochemistry, and RT-PCR = Reverse 
Transcription-Polymerase Chain Reaction. 
Molecule/Test OE21 (squamous cell OE33 (Barrett's Different? 
carcinoma) adenocarcinoma) 
Telomerase/TRAP Activity Activity NO 
p63/ICC Nuclear staining Nuclear staining NO 
p53/ICC Weak nuclear staining in Strong nuclear staining YES 
odd cells in all the cells 
ß-actin/RT-PCR Strong band at -500bp Strong band at '-500bp NO 
E-Cadherin/ICC Strong staining in all Strong staining in all NO 
membranes membranes 
E-Cadherin/RT-PCR 4F + 511 4F +5R NO 
Clear band at 380bp Clear band at 380bp 
P-Cadherin/ICC Negative Negative NO 
ß-catenin/ICC Staining in cell Negative YES 
membranes 
ß-catenin/RT-PCR 1F and 1R strong band at 1F and 1R strong band at NO 
240bp 240bp 
ß-catenin/RT-PCR 3F and 3R two bands at 3F and 3R two bands at NO 
200bp and >1000bp 200bp and >1000bp 
CEA/ICC Negative Staining in membranes of YES 
half the cells 
CD44/ICC Very strong staining all Very strong staining all NO 
over the membranes over the membranes 
Cytokeratin 8/ICC Negative Strong staining of the YES 
membranes in half of the 
cells 
Cytokeratin 18/ICC Weak staining of Strong staining of the YES 
membranes in most cells membranes in a few of 
the cells 
Urokinase-type Strong staining in the Strong staining in the NO 
plasminogen cytoplasm around the cytoplasm 
Activator/ICC nucleus of the largest cells 
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Molecule/Test OE21 (squamous cell OE33 (Barrett's Different? 
carcinoma) adenocarcinoma) 
Urokinase-type Weak staining in the Weak staining in the NO 
plasminogen cytoplasm cytoplasm 
Activator 
receptor/ICC 
Plasminogen Moderate staining in the Moderate staining in the NO 
Activator Inhibitor cytoplasm cytoplasm 
type-1/ICC 
Plasminogen Weak staining in the Strong staining in the YES 
Activator Inhibitor cytoplasm cytoplasm 
type-2/ICC 
Urokinase-type 3.25ng/mg protein >10ng/mg protein YES 
Plasminogen 
Activator/ELISA 
Urokinase-type 5.417ng/mg protein 3.934ng/mg protein NO 
Plasminogen 
Activator 
Receptor/ELISA 
Plasminogen >200ng/mg protein 0.984ng/mg protein YES 
Inhibitor type- 
1IELISA 
Plasminogen 42. ing/mg protein >200ng/mg protein YES 
Inhibitor type- 
2/ELISA 
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The TRAP assay was initially optimised using cell lysates derived from the 
oesophageal cell-lines, OE21 and OE33. The optimum protein concentration for 
the cell-lines was found to be 0.015µg/µ1, but the assay was sensitive enough to 
detect telomerase in dilutions of a hundred times less. All the other cell-line 
protein extracts were diluted to a similar concentration before use in the assay. 
The cell-lines were grown on both polystyrene and glass slide flasks (Merck Ltd. 
Poole, Dorset, UIQ for the immunocytochemical techniques. It was observed that 
OE33 did not grow very well on the glass slide flasks. When the cells were 
washed in PBS before fixing with methanol they fell off the slides whereas 0E21 
grew well on both the glass and plastic slide flasks. 
Examples of the immunoreactivity for CD44, E-cadherin, uPA, uPAR, PAT-1 and 
PAI-2 in OE21 and OE33 are shown in figures 6.1 and 6.2 respectively. 
Immunocytological staining for CD44, E-cadherin, and cytokeratin 18 was 
localised to the membranes of both cell-lines, although the staining for 
cytokeratin 18 was weaker in OE21 compared to OE33. There was membranous 
staining for CEA and cytokeratin 8 in OE33, but OE21 was negative for these 
markers. There was membranous staining for ß-catenin in OE21 whereas OE33 
was negative. Both cell-lines were negative for P-Cadherin. There was nuclear 
staining for both p53 and p63 in both cell lines, but staining for p53 was weaker 
in OE21 compared to OE33. There was strong cytoplasmic staining for the 
components of the plasminogen activator system in both cell-lines. The only 
difference in staining was for PAI-2, staining was weaker in OE21 compared to 
OE33. 
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Figure 6.1. Examples of immunocytochemical staining of the squamous cell 
carcinoma cell-line OE21 with: A. CD44, B. E-Cadherin, C. uPA, D. uPAR, E. PAI-1, 
and F. PAI-2. (Magnification x40). 
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Figure 6.2. Examples of immunocytochemical staining of the Barrett's 
associated adenocarcinoma cell-line OE33 with: A. CD44, B. E-Cadherin, C. uPA, 
D. uPAR, E. PAI-1, and F. PAI-2. (magnification x40). 
185 
Telomerase activity was present in both cell-lines as expected because they are 
both immortal cell-lines that have been cultured in the laboratory for many 
years. The ELISA assays for the components of the plasminogen activator system 
resulted in different levels between the cell-lines. 0E21 had the following levels: 
uPA 3.25ng. mg protein, uPAR 5.417ng/mg protein PAI-1 >200ng/mg protein and 
PAI-2 42.1ng/mg protein. OE33 had the following levels: uPA >10ng/mg protein, 
uPAR 3.934ng/mg protein, PAI-1 0.984ng/mg protein and >200ng/mg protein. 
There was a much higher level of PAI-1 in OE21 compared to OE33 and a much 
lower level of PAI-2 in OE21 compared to OE33. Levels of uPA and uPAR were 
similar in both cell-lines. 
The RT-PCR experiments showed that mRNA for both E-cadherin and ß-catenin 
were present in both the cell-lines. No differences were seen in the gels, the 
resulting bands were identical for both cell-lines (results not shown). 
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6.4 Discussion 
The cell-lines, 0E21 and 0E33, used for this part of the work were developed in 
1997. Molecular and cellular analysis was carried out on the lines and clones 
derived from them. These included chromosome analysis, flow cytometric 
analysis, transforming growth factor ßl (TGF-ßl) sensitivity and production were 
tested and RT-PCR carried out for the detection of TFG-01 mRNA. Both the cell 
lines were found to show epithelial morphology and to express epithelial 
cytokeratins and are also tumourigenic in nude mice (Rockett 1997). Both the 
oesophageal cell-lines are held in the European Collection of Cell Cultures. 
In order to characterise the cell-lines various methods of analysis were used 
these included RT-PCR, immunocytochemistry (ICC), the TRAPEZETM ELISA 
telomerase detection kit and ELISA kits for the detection of the components of 
the plasminogen acticator system. In order to characterise the cell-lines to 
produce ex vivo models of oesophageal adenocarcinoma and oesophageal 
squamous cell carcinoma molecular markers were selected that have previously 
been analysed in clinical samples. 
6.4.1 p53 and p63 
The expression of p53 has been widely studied in Barrett's oesophagus. Wild type 
p53 appears to be a regulator of cell kinetics. When a cell sustains DNA damage 
p53 may either repair it or induce cell death. Abnormal p53 represents two 
defects: deletion of one allele in the short arm of chromosome 17 and a 
functionally inactivating mutation of the other allele. The abnormal p53 protein 
has a longer half-life than the wild type protein, due to an amino acid 
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substitution causing over expression allowing the protein to be detected by IHC. 
The p53 abnormality occurs in less than 50% of Barrett's adenocarcinomas, 
therefore malignant progression is possible without the involvement of the p53 
gene (Kubba 1999). 
This study has shown that there was strong nuclear staining in all the cells for 
p53 in the cell-line OE33, the Barrett's adenocarcinoma, whereas the squamous 
carcinoma cell-line, OE21, had weak nuclear staining in some of the cells. In the 
past, p53 abnormalities have been used as a measure of genetic instability in 
Barrett's metaplasia, but their use is far from well established or accepted 
(Kubba 1999). From these results it could be concluded that OE33 is more 
genetically unstable than OE21. 
The tumour protein p63 was cloned by Yang et al in 1998 and was shown to have 
strong homology to the tumour suppresser p53 and the p53-related protein p73. 
p63 has been detected in a variety of human and mouse tissues, but unlike p53 
the p63 gene encodes multiple isotypes with the ability to transactivate p53 
reporter genes and induce apoptosis (Yang 1998). p63 is also known as KET, 
p73L and p51. As p63 has strong homology to p53 it is thought that 
abnormalities in expression will be found in cancer cells, although very little 
research into this area has been carried out. 
A study by Hall et al has looked at the expression of p63 in the neoplastic 
sequence of Barrett's oesophagus and correlated the results with the expression 
of p53 protein. It was found there was exact concordance between the expression 
of p53 and p63 in the advanced stages of neoplastic progression in Barrett's 
oesophagus. In the proliferative compartment of non-neoplastic oesophageal 
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tissues p63 was detectable whereas p53 was not (Hall 2001). The Barrett's 
associated adenocarcinoma cell line (OE33) IHC results mimic the results seen in 
tissue samples. The nuclear staining of p53 and p63 were similar in this cell line. 
If p63 activates p53 and induces apoptosis it would be expected the protein would 
be expressed in the nucleus of the cells as seen in this study. 
6.4.2 Cadherins and catenins 
Epithelial cadherin (E-cad) is the primary regulator of cell adhesion in epithelial 
tissues. There is reduced expression of E-cad during the progression of Barrett's 
oesophagus to adenocarcinoma (Bailey 1998). No differences were seen in E-cad 
protein and mRNA expression in either of the oesophageal cell-lines. There was 
strong staining in the membranes and cytoplasm of both OE21 and OE33 cells. 
E-Cad mRNA expression was the same for both the cell-lines as shown by RT- 
PCR. A PCR product of 380bp was seen for each reaction. As E-cad is a cell 
adhesion molecule it would be expected that it would be expressed on the surface 
of the cell as seen in both the IHC results. According to research into Barrett's 
adenocarcinoma the level of E-cad expression should be lower in cancer when 
compared to Barrett's metaplasia, but the levels of expression seemed to be high 
for both cell-lines. Research has also shown reduced levels of cadherin in poorly 
differenticated invasive oesophageal carcinomas (Sanders 1999). 
Placental cadherin (P-cad) has 58% homology to E-cadherin. P-cadherin 
expression has been found to be absent in Barrett's metaplasia, but was present 
in some adenocarcinomas (Bailey 1998). Both the cell-lines showed no presence of 
P-cadherin protein. 
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Cadherin function is regulated in part by interactions with cytoplasmic proteins 
called catenins. ß-Catenin binds to E-cadherin, but may also bind to the tumour 
suppresser protein APC. Expression of ß-catenin is also found to decrease in 
cancers. Expression of ß-catenin mRNA was the same for each cell-line, a PCR 
product of 240bp was amplified in each case. Strangely the IHC results for the 
presence of ß-catenin protein were different for each cell-line. OE21, the 
squamous cell carcinoma, had strong staining in the cytoplasm and cell 
membrane, but no staining was seen in the Barrett's adenocarcinoma cell-line, 
OE33. 
It was expected that the results for E-cad and ß-catenin expression for each cell- 
line would be the same as E-cad binds to ß-catenin. ß-Catenin and E-cad mRNA 
were present in all the cell-lines, but ß-catenin protein was not detected by IHC 
in OE33. When the cell-lines were grown on glass slide flasks instead of 
polystyrene the cell-line OE33 did not adhere properly to the glass and the 
monolayer became dislodged during the fixing procedure. This implies that the 
adhesion properties of the cell-line OE33 differ from OE21 as the results show. 
The OE33 cells were also observed to grow much slower on glass than they did on 
polystyrene. 
6.4.3 CEA 
Carcinoembyonic antigen (CEA) is a complex immunoreactive glycoprotein 
comprising of 60% carbohydrate. CEA is an adhesion molecule, which is found in 
adenocarcinomas of endodermally derived digestive system epithelia and in foetal 
colon. CEA immunoassay is useful in the diagnosis and monitoring of cancer 
patients for recurrent disease or response to therapy, particularly in colonic 
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cancer (Oikawa 1987). The presence of CEA in the progression of Barrett's 
oesophagus to adenocarcinoma has been established by immunohistochemistry 
by Ferrando et al. CEA was found in 100% of oesophageal adenocarcinoma 
samples tested (Ferrando 1998). In oesophageal carcinoma CEA levels have been 
found to be significantly increased when compared to normal volunteers and the 
localisation changed from mainly membranous to cytoplasmic. (Sanders 1994). 
Staining was seen in the membranes and cytoplasm of approximately half the 
cells of OE33, whereas no staining was seen at all in the OE21 cells. It is thought 
that the over expression of CEA disrupts normal adhesive forces allowing more 
cell movement and adoption of a less organised tissue structure (Benchimol 
1989). As OE21 was negative you would expect the cells to still possess full 
adhesive properties. As mentioned previously OE33 cells appear to be less sticky 
than the OE21 cells, this could be due to expression of CEA in some of the cells. 
The CEA results seem to confirm the theory that OE33 has less adhesion 
properties than 0E21. 
6.4.4 CD44 
CD44 is an integral cell membrane protein, which is thought to have a role in cell 
adhesion. The CD44 protein is encoded by a gene comprising of 20 exons, which 
has been mapped to the short arm of chromosome 11. Numerous isoforms are 
generated by molecular mechanisms of mRNA alternative splicing and post 
translational modifications. The standard form detected here is encoded by the 10 
consecutively expressed exons (exons 1-5 and 16-20) is an 80-9OkDa protein that 
has been implicated mainly in cell-cell and cell-matrix binding. 
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A study by Lagorce-Pages et al into the expression of the standard form of CD44 
in Barrett's associated adenocarcinoma tissue showed immunohistochemical 
staining was localised to the cellular membrane in 70% of adenocarcinoma 
samples analysed (Lagorce-Pages 1998). As expected the results discussed in this 
chapter show very strong staining for CD44 which was also localised to the cell 
membrane in both cell lines. No differences were seen between the staining 
pattern for either cell-line. 
6.4.5 Cytokeratins 
Cytokeratins are subunit proteins of epithelial cell intermediate filaments which 
are genetically determined (Salo 1996). Squamous cell carcinoma of the 
oesophagus has been found to express CK6, CK14, CK17, CK19 in high amounts 
and CK8 in weak to moderate amounts, whereas Barrett's adenocarcinoma has 
been found to express CK8, CK18 and CK19 in high amounts (Moll 1982). It has 
been suggested that CK18 and CK8 expression are diagnostic markers for 
Barrett's metaplasia (Salo 1996). 
OE21 the carcinoma cell-line was found to be negative for CK8 protein and have 
weak staining for CK18. OE33 the Barrett's adenocarcinoma cell-line was found 
to be strongly positive for both CK8 and CK18 as expected. As CK8 and 18 have 
been used to identify Barrett's adenocarcinoma in the past the IHC results seem 
to confirm that the cells are in fact derived from a Barrett's adenocarcinoma. The 
fact that OE21 was negative for CK8 and weakly positive for CK18 may call into 
question the exact cell type of OE21 as it does not match the cytokeratin 
distribution found by Moll et al. 
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6.4.6 Telomerase 
Telomerase is expressed in 85% of human cancers (Shay 1997b and Mackenzie 
1999). It is a sign of immortality and allows the cells to divide without end 
replication problems. Both Barrett's adenocarcinoma (Morales 1998) and 
squamous cell carcinoma (Koyanagi 1999) have been found to be telomerase 
positive from analysis of clinical samples. Both oesophageal cell-lines were found 
to be telomerase positive. This is as expected, as both are immortal cell-lines that 
have been growing in laboratories for many years and were derived from 
oesophageal tumours in 1993. 
6.4.7 Components of the Plasminogen System 
The localisation of the protein and mRNA of uPA, uPAR and the PA inhibitors 
varies from tumour type to tumour type. A study by Shiomi et al used 
immunohistochemistry and in situ hybridisation to investigate the expression of 
uPA, uPAR and PAI-2 in oesophageal squamous cell carcinoma found uPA and 
PAI-2 was expressed in cancer cells as well as in adjacent fibroblasts. In contrast 
uPAR was only expressed in cancer cells at the periphery of the tumours (Shiomi 
2000). The carcinoma cell-line, OE21, has strong staining of uPA, moderate 
staining of inhibitor type-1 and weak staining of uPAR, and inhibitor type-2. 
From these results there is no way of telling exactly what type of cancer cells the 
cell-lines are, but to some extent the IHC results of the cell-line mirror those of 
the tissues, strong staining of the activator and inhibitors and weaker staining of 
the receptor. 
Nekarda et al carried out a study in 1998 to assess the level of expression and 
significance of uPA and PAM in resected adenocarcinoma of the oesophagus 
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using ELISA techniques. This study found that uPA and PAM levels were 
significantly elevated when compared with the normal mucosa (Nekarda 1998). 
The adenocarcinoma cell-line, 0E33, showed strong staining for uPA and PAM 
similar to the results found by Nekarda et al. 
There is a difference in the amount of staining for PAI-2 in the cell-lines. In 
oesophageal carcinoma it has been shown levels of PAI-2 decreased compared to 
normal mucosa (Hewin 1994). PAI-2 levels also decrease in oesophageal 
adenocarcinoma, but to a lesser extent than squamous cell carcinoma. The level 
of staining in the cell-lines follows a similar pattern to the findings in tissue 
samples. 
A resent study by Morrissey et al shows that co-expression of uPA and uPAR is 
required for maximum invasiveness of oesophageal carcinoma cell-lines in vitro 
(Morrissey 1999). There is evidence of co-expression of the activator and receptor 
in both cell-lines when comparing the cells under the microscope, although there 
is less staining of the receptor than the activator. 
In chapter 5 of this report the levels of the components of the PA system in tissue 
were assessed using the same ELISAs as used here to study the cell lines. The 
results are summarised in table 6.4 compared to the results of a previous study 
into the levels of the components of the PA system in the two oesophageal 
tumours. 
There is good concordance in the levels of both uPA and its receptor in the cell- 
line OE33 and adenocarcinoma tissues. Levels of PAT-i were not detected in the 
previous study although high levels were found in the adenocarcinoma cell-line 
and adenocarcinoma tissues. There is an anomaly in PAI-2 levels. In the cell-line 
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OE33 the level is significantly higher than in the adenocarcinoma samples and 
previous studies. 
Table 6.4. Comparison of levels of components of the PA system in 
oesophageal tumours. 
Red rows are the results from the cell-line characterisation. 
uPA uPAR PAI-1 PAI-2 
OE21 Carcinoma ; 3.25ng/mg 7.41 ng/nig >2OOug/iug 12.1 ng/mg 
cell-line protein protein protein protein 
Hewin et al 1994 20.7ng/mg Not in study Not detected 8.2ng/mg 
Carcinoma protein protein 
OE 33 >ing/mg 3.93ng/mg 0.98ng/mg >200ng/mg 
Adenocarcinoma protein protein protein protein 
cell-line 
Values from 0.93ng/mg 3.87ng/mg 6.67ng/mg 8.09ng/mg 
chapter 5 protein protein protein protein 
Adenocarcinoma 
Hewin et al 1994 6.2ng/mg Not in study Not detected 2.4ng/mg 
Adenocarcinoma protein protein 
The differences in the results from the previous study, the cell-lines and results 
from chapter 5 could be explained by the small number of samples assessed in a 
previous study by Hewin et al. Only five resected squamous cell carcinoma cases 
and five adenocarcinoma cases were studied. In chapter 5, thirty adenocarcinoma 
cases were analysed for all the components of the Plasminogen Activator system 
and the cell-lines were analysed with every experiment carried out as a control 
and the median value of these results expressed here. 
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Overall the cell-line results seem to correspond to the molecular 
characterisation of the tumours they are primarily derived from. The cell-line 
OE33 seems to be a good in vitro model of Barrett's associated 
adenocarcinoma. The results are not as conclusive for the squamous cell 
carcinoma cell-line, OE21. There are some differences in the molecules 
expressed in the cell-line when compared to those found in the studies of 
clinical samples. OE33 has more of the expected characteristics of an 
invasive cancer, whereas OE21 seems to be partway through the neoplastic 
change. 
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7 The Effect of Bile Salts on Two Cultured Oesophageal 
cell-lines 
7.1 Introduction 
Experimental work using animal models has implicated a role for bile salts in the 
pathogenesis of Barrett's oesophagus and adenocarcinoma of the oesophagus. 
Duodenogastric reflux has been shown to occur in normal individuals, especially 
at night. Whereas duodenogasro-oesophageal reflux probably occurs infrequently 
in normal individuals, but evidence is strong that it plays a role in Barrett's 
oesophagus and adenocarcinoma (Marshall 1997). Duodenogastro-oesophageal 
reflux is suggested as a cause of Barrett's oesophagus. The duodenal contents 
suspected of causing oesophageal damage include bile acids, lysolecithin secreted 
in bile and the pancreatic enzyme trypsin. Conjugated bile acids are an 
important constituent of duodenal refluxate and can cause oesophageal damage. 
Mucosal damage by bile salts depends on the conjugation state of the bile acids as 
well as the pH of the solution. Conjugated bile acids cause damage at an acidic 
pH, whereas unconjugated bile acids as well as the pancreatic enzyme trypsin 
cause damage at a pH higher than 7 (Buttar 2001). 
Previous studies have looked at the effects of bile salts and pH on both ex vivo 
oesophageal tissue samples and cultured cells. A study by Kaur et al (2000) 
looked at the effects of bile salts with and without acid on cell proliferation in 
biopsies of oesophageal mucosa. This study concluded that brief exposure to bile 
salts in the absence of acid increased proliferation, whereas exposure to a 
combination of acid and bile salts together inhibited proliferation (Kaur 2000). 
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Shirvani et al studied the expression of Cyclo-oxygenase 2 (COX-2) in Barrett's 
oesophagus using biopsies of Barrett's epithelium exposed to acid alone, acid and 
bile or bile alone. This showed COX-2 expression increased significantly when 
exposed to acid or bile salts (Shirvani 2000). The effects of bile salts and acid on 
the apoptotic and proliferative activity of cultured oesophageal cell-lines was 
studied by Whittles et al (1999). It was found that bile salts effected apoptosis 
during acidic conditions. 
In order to assess the effects of conjugated bile salts and acidic conditions on the 
expression of telomerase, the components of the urokinase-type Plasminogen 
Activator system and the adhesion molecules CD44 and E-Cadherin, two 
oesophageal cell-lines were cultured in growth media of varying pH and treated 
with conjugated bile salts. 
7.2 Methods 
7.2.1 Cell Culture 
As mentioned previously in chapter 6 two oesophageal cell-lines were cultured as 
an ex vivo model of two types of oesophageal cancer, Squamous cell carcinoma 
and Barrett's associated adenocarcinoma. These cell-lines were, OE21, a human 
oesophageal squamous cell carcinoma cell-line established in 1993 from a 
squamous carcinoma of the mid oesophagus of a 74 year-old male patient, and 
OE33, a human oesophageal adenocarcinoma cell-line established from the 
adenocarcinoma of the lower oesophagus (Barrett's metaplasia) of a 73 year-old 
female patient (Rockett 1997). 
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The cells were cultured as described in section 3.2 with the folowing 
modifications. Human oesophageal cell-lines OE21 and OE33 were cultured in 
RPM1-1640 modified medium supplemented with 10% foetal bovine serum, 5ml 
stabilised penicillin-streptomycin solution and iml amphotericin B solution per 
500m1 (all regents from Sigma cell culture, Poole, Dorset, England). The cells 
were cultured in both the original pH of the growth media, which was 
approximately 7.4, and also in media altered to an acidic pH of 5 with HCl. The 
cells were also cultured in RPMI-1640 supplemented with 0.1mM concentrations 
of various conjugated bile salts. 
The bile salts used were: 
" Deoxycholic acid (DCA) C24H39O4Na 
" Glycocholic acid (GCA) C26H42NOGNa 
" Glycodeoxyxholic acid (GDC) C2GH42NO5Na 
" Glycochenodeoxycholic acid (GCDA) C26H42NOs Na 
" Taurocholic acid (TCA) C26H44NO"SNa 
9 Taurodeoxycholic acid (TDC) C26H44NOGSNa 
" Taurochenodeoxycholic acid (TCDA) C2GH44NOGSNa 
Prior to treatment with bile salts or acidified growth media the cells were grown 
for a day in either slide flasks for immunocytochemistry for the detection of the 
components of the plasminogen system or T25 flasks for protein extraction 
utilised for the TRAPEZE ELISA Telomerase detection kit and the Plasminogen 
ELISAs. The cultured cells were exposed for one hour to either acidified media, 
media treated with 0.1mM bile salts or 0.1mM bile salts in acidified media. The 
cells were then either, fed without rinsing and grown for a further 18 hours 
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(samples B) or prepared for further analysis (samples A). Slide flasks were 
washed three times in PBS before they were fixed in ice cold methanol for 10 
minutes. The slides were then dried and stored at -20°C wrapped in foil. The cells 
grown in T25 flasks were rinsed in PBS before the cells were scraped off into a 
5m1 solution of sterile PBS. The cells were detached using a cell scraper instead 
of trypsin solution as trypsin has been implicated as a causal factor for Barrett's 
oesophagus and therefore may have effected the cells. The PBS solution 
containing the cells was placed in a 1m1 eppendorf tube and centrifuged at 1000 x 
g for 5 minutes to produce a pellet of cells. The pellet was then rinsed in lml PBS 
and transferred to a 2m1 eppendorf and spun again. All the PBS was removed 
before the pellet was quick frozen and stored at -80°C for protein extraction. 
7.2.2 TRAPEZE ELISA Telomerase detection kit. 
The TRAPEZETM ELISA telomerase detection kit as described in section 4.2 was 
utilised again to assess telomerase activity in the protein samples extracted from 
oesophageal cell-lines treated with both acid and bile salts. 
Cultured cells were detached from the bottom of T25 flasks once treated with bile 
salts or acid using a cell scraper. The pellet of cells was then washed once in PBS 
and all the PBS removed. The pellet was then quick frozen and stored at -80°C 
until sufficient samples were ready for protein extraction. The pellets were 
removed from the freezer and each resuspended in 2O00 CHAPS Lysis buffer 
without defrosting. The sample suspensions were incubated on ice for 30 minutes 
and then spun at 12,000 xg for 20 minutes at 4°C. The supernatant (160µl) was 
transferred to a fresh tube and 6µl set aside for determination of protein 
concentration (see section 3.6). 
200 
The TRAP assay was then carried out as described previously in section 4.2 and 
6.2.5 without any modifications. 
7.2.3 Immunocytochemistry on Slide Flasks 
To assess the effects to treatment with bile and acid on oesophageal cell-lines 
immunocytochemistry was carried out using methods previously described in 
sections 3.9 and 6.2.2. Cell-lines were grown on polystyrene slide flasks (Merck, 
Poole, Dorset, England). Once the cells had been treated with bile or acid they 
were washed 3 times in PBS and fixed in ice cold methanol for 10 minutes. The 
slides were then wrapped in foil and stored at -20°C. Slides were removed from 
the freezer as required and left on the bench for 30 minutes to reach room 
temperature. The slide was divided up into a grid using a "Dako" pen (Dako Ltd. 
Cambridge UK) prior to the blocking of non-specific reactions. 
The primary antibodies used on slides flasks treated with bile salts and varying 
pH are described in table 7.1. 
Once the immunocytochemistry method had been carried out and the slides 
counter stained in haematoxylin they were mounted using Ultramount aqueous 
mounting medium (Dako Ltd, Cambridge, UK) and were ready for viewing under 
the light microscope. 
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Table 7.1 Antibodies used for immunocytochemistry on slide flasks. 
Antibody Type Working Company 
Concentrations 
uPA Polyclonal goat anti- 4µg/ml American Diagnostica 
human Inc. Greenwich USA 
uPA Monoclonal mouse 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
uPAR Monoclonal mouse 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
PAI-1 Monoclonal mouse 4µg/ml American Diagnostica 
anti-human Inc. Greenwich USA 
PAI-2 Polyclonal goat anti- 4µg/ml American Diagnostica 
human Inc. Greenwich USA 
CD44 (Hermes) Monoclonal mouse No data available Provided by A. C. 
anti-human -dilution 1/50 Woodman 
E-Cad Monoclonal mouse 2µg/ml Alexis Biochemicals, 
anti-human Nottingham, UK 
7.2.4 Detection of the components of the Plasminogen Activator system 
using ELISA Techniques. 
The same protein samples from the cultured cells as used for the TRAPEZE- 
ELISA Telomerase detection kit were used to analyse if the cellular 
concentrations of the components of the plasminogen system (uPA, uPAR, PAI-1 
and PAI-2) were altered with exposure to bile salts and acidic conditions. The kits 
utilised were the IMUBIND® uPA ELISA kit, the IMUBIND® Total uPAR 
ELISA kit, the IMUBIND®Tissue PAM ELISA kit and the IMUBIND® PAI-2 
ELISA kit (American Diagnostica Inc. Greenwich, USA). Analysis was carried 
out according to the manufacturer's protocol and detailed methods are described 
in sections 5.3 and 6.2.6. 
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7.3 Results 
The oesophageal cell-lines OE21 and OE33 were exposed to seven different 
conjugated bile salts in growth media of both acidic and neutral pH. The cells 
were exposed to bile salts, acidic growth media or bile salts in acidic growth 
media for 1 hour and either analysed (samples A) or grown for a further 18 hours 
before analysis (samples B). This resulted in 32 protein samples for each cell-line. 
These were used in ELISA experiments to assess the components of the 
Plasminogen Activator system and in the TRAPEZETM ELISA to detect telomerase 
activity. 
Cells cultured in the different conditions were also analysed using 
immunocytochemistry to detect the components of the plasminogen system (uPA, 
uPAR, PAI-1 and PAI-2) and the adhesion molecules CD44 and E-Cadherin. 
These results are summarised in table 7.2. 
7.3.1 Immunocytological Results 
The expression of two adhesion molecules, CD44 and E-Cadherin, were analysed 
using immunocytochemistry on two cell-lines OE21 and OE33 after treatment 
with various bile salts and acidified growth media. Examples of the 
immunoreactivity of the cell-lines to these are molecules are shown in figures 7.1 
to 7.4. The immunocytological staining for both CD44 and E-Cad was localised to 
the plasma membrane of the cells. The staining was strongest in the untreated 
cells and cells treated with bile salts alone. In the presence of acidified media and 
acidified bile salts the staining for CD44 and E-cad was significantly less. 
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The expression of the components of the plasminogen activator system, uPA, 
uPAR, PM-1 and PAI-2 were analysed using immunocytochemistry in two cell- 
lines OE21 and OE33 after treatment with various bile salts and acidified growth 
media. Examples of the immunoreactivity of the cell-lines to these molecules are 
shown in figures 7.5 to 7.12. The staining for the components of the plasminogen 
system was localised to the cytoplasm of the cells. In OE21 the staining for uPA 
was localised around the nucleus of the largest cells. This was not seen in OE33. 
There was some staining for the inhibitors within the nucleus of the cells. There 
were no significant differences in the staining for the components of the 
plasminogen activator system with exposure to bile salts, acidified media or the 
combination of both in either cell-line. 
There were less of both types of cells on the slides exposed to acidified media and 
bile salt compared to the non-treated controls and cells exposed to bile salts 
alone. Also of note is the fact that exposure to bile salts alone appeared to 
increase the number of the cells on the slide a day after treatment compared to 
the non-treated controls. The exposure of cells to DCA and acidified media, TDC 
and acidified media, and GCA and acidified media caused the nuclei of both 
OE21 and OE33 to stain differently in heamatoxylin. The nuclei appeared 
transparent and pale compared to non-treated controls and other treated cells. 
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Table 7.2. Results of immunocytochemistry on cells treated with bile 
salts and grown in acidified media. 
Abbreviations: DCA = Deoxycholic acid, GCA = Glycocholic acid, GDC - Glycodeoxyxholic 
acid, GCDA = Glycochenodeoxycholic acid, TCA = Taurocholic acid, TDC = 
Taurodeoxycholic acid and TCDA = Taurochenodeoxycholic acid. 
A= Samples analysed directedly after exposure. B= Samples analysed 18 hours after 
exposure. 
Grading of staining: -= Negative, +/- = Weak, += Moderate, ++ = Strong and +++ = Very 
Strong. 
OE21 
Treatment uPA uPAR PAI-1 PAI-2 CD44 E-Cad 
Control ++ +/- + +/- ++ ++ 
ACID A + + - - 
ACID B +/- - + + - - 
GDC A ++ +/- + +++ +++ +++ 
GDC B ++ +/- +++ +++ ++ +++ 
GDC+ ACID A +/- +/- + ++ +/- - 
GDC+ ACID B + + + + +/- +/- 
DCA A ++ + ++ ++ ++ ++ 
DCA B ++ ++ + ++ +++ +++ 
D CA + ACID A +/- +/- + + +/- +/- 
D CA + ACID B +/- +/- + ++ + +/- 
GCA A ++ +/- + + +/- +/- 
GCA B + +/- ++ +/- + +/- 
G CA + ACID A +/- +/- + + +/- - 
GCA + ACID B +/- + + +/- +/- - 
TCA A ++ +/- ++ + + ++ 
TCA B ++ +/- + + + ++ 
TCA + ACID A + +/- + + +/- - 
TCA + ACID B +/- +/- ++ + +/- - 
TDC A + + ++ ++ ++ ++ 
TDC B + + +++ ++ +++ +++ 
TDC + ACID A + + ++ + + - 
TDC + ACID B + + ++ + - - 
GCDA A + +/- + ++ ++ ++ 
GC DA B + +/- + ++ ++ ++ 
GC DA + ACID A + +/- + + +/- - 
GC DA + ACID B + +/- + + +/- +/- 
TCDA A + +/- +/- ++ ++ ++ 
TCDA B + +/- + + ++ ++ 
TCDA + ACID A +/- +/- + + +/- - 
TC DA + ACID B +/- +/- + + + +/- 
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OE33 
Treatment uPA uPAR PAI-1 PAI-2 CD44 E-Cad 
Control ++ +/- + ++ ++ ++ 
ACID A ++ +/- + ++ +/- +/- 
ACID B ++ + ++ ++ + +/- 
GDCA ++ + ++ ++ +++ +++ 
GDCB ++ ++ ++ ++ +++ +++ 
GDC+ ACID A + - + + + +/- 
GDC+ ACID B +/- +/- + + +/- +/- 
DCA A ++ + ++ ++ +++ +++ 
DCA B ++ + ++ +++ +++ +++ 
DCA + ACID A + +/- + + + +/- 
DCA + ACID B +/- + ++ + + +/- 
G CA A ++ +/- ++ ++ +++ +++ 
G CA B + +/- ++ ++ ++ +++ 
G CA + ACID A +/- +/- + + + +/- 
GCA+ACID B + +/- + + + ++ 
TCA A + +/- + + ++ + 
TCA B + +/- + + +++ +++ 
TCA + ACID A +/- +/- + + +/- +/- 
TCA + ACID B + +/- + ++ ++ + 
TDC A ++ + +++ ++ +++ +++ 
TDC B ++ + ++ ++ ++ +++ 
TDC+ ACID A + +/- + +/- + +/- 
TDC + ACID B + - + + + - 
GCDA A ++ + ++ ++ ++ +++ 
GC DA B + + + ++ ++ ++ 
GCDA+ACIDA + +/- + ++ + +/- 
GCDA + ACID B + +/- + + + +/- 
TCDA A + + + ++ ++ ++ 
TCDA B + +/- + + + ++ 
TCDA + ACID A + + + +/- 
TC DA + ACID B + + +/- 
206 
lltlw 
4 
A. .` At B. 
* It 
# APO 1 
C. 02 .. D. dak 
Ir s 
,b 
wý 
4 *If .01 
E. F. Alt 
G. H. 
74 
I. 't. 
Figure 7.1 CD44 immunoreactivity in the oesophageal cell-line OE21 treated 
with: A. Nothing day two Control, B. pH 5 day one, C. pH 5 and GCDA day two, D. 
GCDA day one, E. TCA day one, F. pH 5 and TCA day 2, G. TCDA day two, H. pH 5 and 
TCDA day 2 and I. pH 5 and DCA day 2. (Magnification x10) 
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Figure 7.2. CD44 immunoreactivity in the oesophageal cell-line OE33 
treated with: A. Nothing day one control, B. pH 5 day one, C. DCA day one, D. 
pH 5 and DCA day 2, E. GDC day one, F. pH 5 and GDC day two, G. pH 5 and 
TCA day one and H. pH 5 and TCDA day 2. (Magnification x40) 
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Figure 7.3. E-Cadherin immunoreactivity in the oesophageal cell-line 
OE21 treated with: A. nothing day two Control, B. pH 5 day one, C. pH 5 and 
DCA day one, D. DCA day one, E. GDCA day one, and F. pH 5 and GDC day 
one. (Magnification x40). 
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Figure 7.4. E-Cadherin immunoreactivity in the oesophageal cell-line 
OE33 treated with: A. nothing day one Control, B. pH 5 day one, C. TDC day 
one, D. pH 5 and TDC day one, E. GDC day one, F. pH 5 and GDC day one, G. 
TCDA day one, and H. pH 5 and TCDA day one. (Magnification x40) 
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Figure 7.5. uPA immunoreactivity in the oesophageal cell-line OE21 
treated with: A. Nothing day one control, B. pH 5 day one, C. TDC day two, D. 
pH 5 and UCA day two, and E. GCA day 2. (Magnification x40). 
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Figure 7.6. uPA immunoreactivity in the oesophageal cell-line OE33 
treated with: A. nothing day one control, B. pH 5 day one, C. pH 5 and TDC day 
two, D. p11 5 and GC DA day two, and E. TCA day one. (Magnification x40). 
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Figure 7.7. uPAR immunoreactivity in the oesophageal cell-line OE21 
treated with: A. Nothing day one control, B. pH 5 day one, and C. pH 5 and 
TDC day two. (Magnification x40). 
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Figure 7.8. uPAR immunoreactivity in the oesophageal cell-line OE33 
treated with: A. Nothing day one control, B. pH 5 day one, C. DCA day one, D. 
pH 5 and DCA day two, E. pH 5 and TCDA day two, and F. pH 5 and TDC day 
one. (Magnification x40) 
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Figure 7.9. PAI-1 immunoreactivity in the oesophageal cell-line OE21 
treated with: A. Nothing day one control, B. pH 5 day one, C. DCA day one, D. 
pH 5 and GCI)A (lay two, E. GCA day two, F. pH 5 and GCA day one, G. pH 5 
and TCA day 2, and H. pH 5 and TDCA day one. (Magnification x40). 
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Figure 7.10. PAI-1 immunoreactivity in the oesophageal cell-line OE33 
treated with: A. Nothing day two control, B. pH 5 day one, C. DCA day one, D. 
pH 5 and GCDA day two, E. pH 5 and TCDA day one, and F. pH 5 and TDC day 
two. (Magnification x40). 
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Figure 7.11. PAI-2 immunoreactivity in the oesophageal cell-line OE21 
treated with: A. Nothing day 2 control, B. pH 5 and GDC day two, C. TCA day 
one, D. pH 5 and TCA day one, and E. TDC day two. (Magnification x40) 
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Figure 7.12. PAI-2 immunoreactivity in the oesophageal cell-line OE33 
treated with: A. Nothing day one control, B. pH 5 day one, C. TCA day one, and 
D. pH 5 and DCA day two. (Magnification x40). 
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Figure 7.13. Graphical representation of immunohistochemistry results 
of the cell-line OE33 treated to bile salts and acidic growth media. 
Levels of staining: 1= negative, 2= weak, 3= moderate, 4= strong and 5= very strong. 
A= initial exposure and B= one days growth after exposure. 
A. Cell-line OE33 grown in acidic media. 
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B. Cell-line OE33 grown in acidified media and treated with glycodeoxycholic acid. 
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C. Cell-line OE33 grown in acidified media and treated with glycocholic acid. 
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D. Cell-line OE33 grown in acidified media and treated with taurocholic acid. 
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E. Cell-line OE33 grown in acidified media and treated with taurodeoxycholic acid. 
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F. Cell-line OE33 grown in acidified media and treated with deoxycholic acid. 
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G. Cell-line OE33 grown in acidified media and treated with glycochenodeoxycholic acid. 
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H. Cell-line OE33 grown in acidified media and treated with taurochenodeoxycholic acid. 
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Graphs comparing the amount of staining of each component with treatment in 
the oesophageal cell-line OE33 can be found figure 7.13. In the cell-line OE33 
grown with acidified media there was a decrease in staining for the adhesion 
molecules CD44 and E-Cad compared to the normal control. The components of 
the PA system remained the same. There were no real differences between 
samples from day 1 and day 2. 
In the cell-line OE33 grown treated with the bile salt GDC there was an increase 
in staining for the plasminogen activator receptor, inhibitor type-1 and the 
adhesion molecules. In acidified growth media there was a decrease in all the 
markers. There were no differences between samples from day 1 and day 2. 
In the cell-line 0E33 treated with the bile salt DCA there was a slight increase in 
expression of all the adhesion molecules on the second day. There was an 
increase in the staining for plasminogen activator receptor, inhibitor type-1 and 
the adhesion molecules on exposure to the bile salt alone. There was a decrease 
in the expression of all the components in acidic growth media. There were no 
changes between samples from day 1 and day 2 when treated with acidified 
growth media. 
In the cell-line OE33 treated with the bile salt GCA alone there were no 
significant changes in any of the molecules. There was a decrease in all the 
molecules when grown in acidified growth media. There were no changes 
between samples from day 1 and day 2. 
In the cell-line OE33 treated with the bile salt TCA there were no differences in 
the components of the plasminogen activator system even in acidified growth 
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media. There was decreased staining for the adhesion molecules CD44 and E-cad 
in acidified media. When exposed to bile alone there was an increase in staining 
for CD44 and E-cad in samples from day two. 
In the cell-line OE33 treated with the bile salt TDC there was an increase in the 
expression of the adhesion molecules, plasminogen activator receptor and 
inhibitor type-1. The levels of staining for all the molecules decreased when 
grown in acidified growth media. There was a decrease in staining for the 
plasminogen activator inhibitors and the adhesion molecules on day 2. 
In the cell-line OE33 treated with the bile salt GCDA there was an increase in 
staining for plasminogen activator receptor, inhibitor type-1 and E-cad. There 
was a decrease in staining for CD44 and E-cad in acidified growth media. There 
were no changes between samples from day 1 and day 2. 
In the cell-line OE33 treated with the bile salt TCDA there was a decrease in 
staining in all the samples except plasminogen activator inhibitor type-1 from the 
second day. There was a decrease in staining for plasminogen activator, CD44 
and E-cad in acidified growth media. 
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Figure 7.14. Graphical representation of immunohistochemistry results 
of the cell-line OE21 treated to bile salts and acidic growth media. 
Levels of staining: 1= negative, 2= weak, 3= moderate, 4= strong and 5= very strong. 
A= initial exposure and B= one days growth after exposure. 
A. Cell-line OE21 grown in acidified media. 
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B. Cell-line OE21 grown in acidified media and treated with deoxycholic acid. 
OE21 
5 
4 
CD 
C 
1 
0 
OE21 
Q Control 
 DCAA 
1111 Ith 
DCA B 
Q DCA + ACID A 
uPA uPAR PAl-1 PAI-2 CD44 E -Cad  0+ 
ACID B 
Antigen 
C. Cell-line OE21 grown in acidified media and treated with glycodeoxycholic acid. 
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D. Cell-line OE21 grown in acidified media and treated with glycocholic acid. 
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E. Cell-line 0E21 grown in acidified media and treated with taurocholic acid. 
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F. Cell-line OE21 grown in acidified media and treated with taurodeoxychohc acid. 
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Graphs comparing the amount of staining of each component with treatment in 
the oesophageal cell-line OE21 can be found figure 7.14. In the cell-line OE21 
grown in acidified media there is a decrease in staining for the plasminogen 
activator inhibitor, its receptor and the adhesion molecules CD44 and E-cad. 
There are no changes for inhibitor type-1, but an increase in staining for type-2. 
There were no difference between samples from day 1 and day 2. 
In the cell-line OE21 treated with the bile salt DCA there were was an increase 
in staining for the adhesion molecules and plasminogen activator receptor. The 
staining for the adhesion molecules decreased when the cells were grown in 
acidified media. 
In the cell-line OE21 treated with the bile salt GDC there was an increase in 
staining for the plasminogen activator inhibitors and the adhesion molecules. 
These levels decreased when the cells were grown in acidified media. 
In the cell-line OE21 treated with the bile salt GCA there was a decrease in 
staining for the adhesion molecules. With exposure to acidified growth media 
there was a decrease in staining for all the molecules. There were no differences 
between samples from day 1 and day 2. 
In the cell-line OE21 treated with the bile salt TCA there was no change in the 
staining for any of the molecules. There was decrease staining for plasminogen 
activator and the adhesion molecules in acidified growth media. There were no 
significant differences in staining between samples from day 1 and day 2. 
In the cell-line OE21 treated with the bile salt TDC there was an increase in 
staining for the plasminogen inhibitors. There was an increase in staining for the 
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adhesion molecules on the second day. Levels of staining for the adhesion 
molecules decreased in acidified growth media. 
In the cell-line 0E21 treated with GCDA there was no change in the staining for 
any of the molecules except plasminogen activator inhibitor type-2, which 
increased. The levels of the adhesion molecules and PAI-2 decreased with 
exposure to acidified growth media. There were no differences between day 1 and 
day 2. 
In the cell-line OE21 treated with TCDA there was a decrease in the staining for 
plasminogen activator and an increase in staining for its inhibitor type-2. There 
is a decrease in staining for the adhesion molecules and plasminogen activator 
with exposure to acidified growth media. 
7.3.2 ELISA and TRAP Results 
The cellular concentration of the components of the plasminogen activator system 
and telomerase activity were also analysed using TRAP and ELISA techniques 
the results of this are summarised in table 7.3. There were no differences in the 
activity of telomerase in either cell-line with exposure to acidified media or bile 
treatment of the cells. 
Some differences can be seen in the results from the plasminogen ELISA 
experiments on exposure to bile and acid treatment, but no real patterns appear 
in the results. In some cases of the cell-line OE33 there appeared to be an 
increase in expression of uPA (treatment with GDC, DCA, TDC, and TCDA) and 
uPAR (treatment with all bile salts) on cells grown in acidified media with bile 
salts compared to the non-treated control and cells treated with bile salts alone. 
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A 
No significant difference in the amount of either of the inhibitors can be seen 
with the various treatments. 
A proportion of the treated cells from cell-line 0E21 had to be excluded from this 
study as the extracted protein concentrations were too low for successful 
completion of the test. Although the cells were washed before the addition of 
CHAPS lysis buffer the lowered pH seemed to effect the detergent and extraction 
process. 
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Table 7.3. Results of ELISA on cells treated with bile salts and grown in 
acidified media. 
Abbreviations: DCA = Deoxycholic acid, GCA = Glycocholic acid, GDC - Glycodeoxyxholic 
acid, GCDA = Glycochenodeoxycholic acid, TCA = Taurocholic acid, TDC = 
Taurodeoxycholic acid, TCDA = Taurochenodeoxycholic acid, Y= yes and N= no. 
A= Samples analysed directedly after exposure. B= Samples analysed 18 hours after 
exposure. 
*= Samples with a protein concentration that was too low for analysis. 
Antigen levels in ng/mg protein. 
OE21 
Treatment uPA uPAR PAI-1 PAI-2 Telomeras 
e 
Control 5 5.417 >200 17.5 Y 
ACID A 1 5.833 320 20 Y 
ACID B 4.889 7.222 >200 23.333 Y 
GDC A 2.727 6.364 338.182 67.273 Y 
GDC B 3.487 4.615 297.436 28.718 Y 
GDC+ ACID A 3.75 215 5 Y 
GDC + ACID B 6 256 0 N 
DCA A 8.533 10 >100 26.667 Y 
DCA B 8.533 10 >100 26.667 Y 
DCA + ACID A 146.667 Y 
DCA + ACID B 182.857 Y 
GCA A 3.6 4 242 20 Y 
GCA B 17.647 7.059 >200 24.706 Y 
GCA + ACID A 480 y 
GCA + ACID B 293.333 Y 
TCA A 6.375 4.063 >200 15.625 Y 
TCA B 6.537 4.878 >200 24.39 Y 
TCA + ACID A 28.571 217.143 34.286 Y 
TCA + ACID B 18.75 162.5 17.5 Y 
TDC A 0.842 2.105 >200 58.333 Y 
TDC B 2.247 3.146 >200 54.762 Y 
TDC + ACID A 15 360 0 Y 
TDC + ACID B 14.444 275.556 0 Y 
GCDA A 4.875 8.125 >200 21.359 Y 
GCDA B 2 2.241 >200 68.571 Y 
GCDA + ACID A 22.5 325 5 N 
GCDA + ACID B 14 296 0 Y 
TCDA A 3 0 66.667 0 Y 
TCDA B 6.271 2.712 >200 51.186 Y 
TCDA + ACID A 0.75 9.375 246.25 0 Y 
TCDA + ACID B 1.556 11.111 340 0 Y 
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OE33 
Treatment uPA uPAR PAI-1 PAI-2 Telomeras 
e 
Control >25 3.934 0.984 58.142 y 
ACID A 3.888 4.673 2.243 99.065 Y 
ACID B 7.143 18.571 0 57.143 Y 
GDC A 7.403 4.328 0.896 57.91 Y 
GDC B 7.429 3.429 0 6 Y 
GDC+ ACID A 26.429 43.571 0 81.111 Y 
GDC + ACID B 29 11.667 10 0 Y 
DCA A 5.767 3.023 1.395 30.233 Y 
DCA B 5.608 2.941 0.392 45.098 Y 
DCA + ACID A 15.333 44.444 0 37.778 Y 
DCA + ACID B 10.133 30 0 9.333 Y 
GCA A 6.7 4 3.5 107 Y 
GCA B 6.36 2.36 2.236 57.143 Y 
GCA + ACID A 17.875 35.625 0 52.5 Y 
GCA + ACID B 6.476 42.857 0 20.952 N 
TCA A >25 1.553 1.279 23.196 Y 
TCA B >25 2.847 0.694 36.389 Y 
TCA + ACID A 18.235 54.118 0 58.824 Y 
TCA + ACID B 5.333 23.333 0 14.667 Y 
TDC A 4.932 3.609 1.203 11.579 Y 
TDC B 6.19 4.167 0.952 10.787 Y 
TDC + ACID A 16.111 27.778 0 90 Y 
TDC + ACID B 25.538 11.538 6.154 0 Y 
GCDA A >25 3.214 0.714 20 Y 
GCDA B >25 1.748 0 14.655 Y 
GCDA + ACID A 24.444 32.771 0 91.111 Y 
GCDA + ACID B 35.111 16.667 8.889 0 y 
TCDA A 10.222 0.556 4.444 137.778 Y 
TCDA B 11.619 1.429 1.905 101.905 Y 
TCDA + ACID A 18.571 38.571 0 0 Y 
TCDA + ACID B 23.714 13.571 5.714 0 Y 
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7.4 Discussion 
Bile acid toxicity has been extensively studied, but there is a wide variation in 
the reporting of the relative toxicity of the individual bile acid fractions. Much 
information is based on the toxic effects of bile on gastric mucosa, colonic mucosa 
and hepatocytes, but little information is available on the toxicity of bile on 
oesophageal mucosa in gastro-oesophageal reflux disease and Barrett's 
oesophagus. The concentration of bile acids and toxicity is known to change with 
pH depending on the degree of ionisation of the molecules. 
Bile salts have been implicated as having a causal influence in the pathogenesis 
of Barrett's oesophagus and adenocarcinoma of the oesophagus. Duodenogastro- 
oesophageal reflux is thought to occur infrequently in normal individuals, but 
evidence is strong that it plays a role in causing oesophageal damage in Barrett's 
oesophagus and adenocarcinoma (Marshall 1997). The duodenal contents 
suspected of causing oesophageal damage include bile acids, lysolecithin secreted 
in bile, and trypsin. Oesophageal mucosa damage induced by bile salts depends 
on the conjugation state of the bile salts as well as the pH of the solution. A study 
by Buttar et al found conjugated bile acids cause damage at an acidic pH, 
whereas unconjugated bile acids as well as the pancreatic enzyme trypsin cause 
damage at a pH higher than 7 (Buttar 2001). 
It has been found that patients with oesophagitis had greater acid reflux than 
those without, but patients with stricture and Barrett's oesophagus had similar 
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acid reflex to those with uncomplicated erosive oesophagitis. Pepsin 
concentrations were highest in patients with stricture and Barrett's oesophagus 
especially at night (Gotley 1991). 
Here the oesophageal cell-lines, 0E21 and 0E33, which have been characterised 
as in vitro models of oesophageal cancer, have been analysed to see if exposure to 
conjugated bile salts in both acidic and neutral pH alters the expression of 
telomerase, the components of the plasminogen system and adhesion molecules. 
It has been shown that conjugated bile salts cause the most damage in acidic 
conditions, therefore the bile salts used were all conjugated and included: 
" Primary bile acids 
1. Taurocholic acid (TCA) 
2. Glycocholic acid (GCA) 
" Secondary bile acids 
1. Deoxycholic acid (DCA) 
2. Taurodeoxycholic acid (TDC) 
3. Glycodeoxycholic acid (GDC) 
4. Taurochenodeoxycholic acid (TCDA) 
5. Glycochenodeoxycholic acid (GCDA) 
The main constituents of reflux bile have been found to be taurocholic, glycholic 
and cholic, therefore the most easily available of these bile acids have been used. 
Gotley et al tried to assess the concentration of bile acids in oesophageal 
aspirates. He found that chromatograms of oesophageal aspirates contained six 
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bile acid peaks including, GDA, GCDA, TCDA, TDA, GCA and TCA. It was found 
that the median concentration of bile acids was <20µmol/1, which was 
significantly lower than during the night-time period (median 51pmol/1) (Gotley 
1988). 
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7.4.1 Morphology 
The overall morphology of the cultured cells treated in the various different ways 
was assessed during treatment using an inverted phase contrast microscope 
before harvesting. The cells were also assessed once stained 
immunocytochemically. Cultured cells treated with conjugated bile salts alone 
appear no different to the untreated control cells when viewed under the 
microscope. There does seem to be an increase in cell number in flasks treated 
with bile and grown on overnight compared to untreated controls. Previous 
studies have shown that exposure of oesophageal tissues to bile salts increased 
the proliferation of cells (Kaur 2000), but rates of proliferation have not been 
assessed here. 
Examination of cells under the microscope that were exposed to bile salts in 
acidic conditions revealed morphological changes characteristic of apoptosis, 
including loss of adhesion, rounding and membrane blebbing. Cells grown in 
acidic media appear to shrink in size and gaps appear between cells within the 
monolayer (see figures 7.1 - 7.12 for examples). This can be seen after the hour 
treatment and is still evident the following day. Cells treated to conjugated bile 
salts in acidic conditions also show this shrinkage, and cells become detached 
from the surface of the flask. This is evident from the small size of the pellets of 
harvested cells from flasks treated with bile salts in acidic media. In some cases 
the protein extracted from these pellets was too low for ELISA analysis for the 
components of the plasminogen activator system. Also significant numbers of 
loose/nonadherent cells were lost during the fixation and staining steps of the 
immunocytochemistry. It could also be possible that the acid conditions effected 
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the detergent based lysis method used here to extract proteins from the cells. All 
harvested cells grown in acid conditions yielded a low concentration of proteins. 
In these experiments protein samples were extracted from the cells using CHAPS 
lysis buffer. CHAPS is an ionic detergent. Ionic detergents are strongly 
amphiphilic and therefore tend to denature proteins. Amphiphilic substances are 
both hydrophobic and hydrophilic and breakdown these interactions in 
macromolecules. This could effect the ELISA detection methods for the 
components of the plasminogen system as the samples were also extracted for 
telomerase detection using CHAPS lysis buffer, which could denature the 
proteins and alter the antibody epitopes. A neutral detergent Triton X-100 could 
be used instead to confirm this. 
Slide flasks containing OE33 that were treated with bile salts in acidic conditions 
yielded less cells than corresponding OE21 flasks. In some cases more than 60% 
of the monolayer of cells became detached from the surface of the flask during the 
washing and fixing stages of preparation for immunocytochemistry. This could 
limit the results of the immunocytochemistry as very few cells were left for 
analysis compared to OE21. 
Treatment of both cell-lines with the bile salts DCA, TDC and GCA in acidified 
media resulted in a change to the appearance of the cell nuclei once counter 
stained with heamatoxylin. This change was still apparent after a day's growth 
in normal media. The nuclei appeared to be pale and transparent compared to 
the non-treated controls and other treated cells. 
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7.4.2 Effects of bile and acid treatment on molecular markers 
Previous studies have looked at the effects of bile salts and pH on both ex vivo 
oesophageal tissue samples and cultured cells. A study by Kaur et al (2000) 
looked at the effects of bile salts with and without acid on cell proliferation in 
biopsies of oesophageal mucosa. This study concluded that brief exposure to bile 
salts in the absence of acid increased proliferation, whereas exposure to a 
combination of acid and bile salts together inhibited proliferation (Kaur 2000). 
Shirvani et al studied the expression of Cyclo-oxygenase 2 (COX-2) in Barrett's 
oesophagus using biopsies of Barrett's epithelium exposed to acid alone, acid and 
bile or bile alone. COX-2 is a membrane bound glycoprotein that functions as a 
rate limiting enzyme that is induced by various stimuli. Increased COX-2 
expression has been demonstrated in human inflammatory diseases. It has been 
implicated in colorectal and oesophageal carcinogenesis including Barrett's 
oesophagus and adenocarcinoma. Shirvani showed COX-2 expression increased 
significantly when exposed to acid or bile salts (Shirvani 2000). 
The effects of bile salts and acid on the apoptotic and proliferative activity of 
cultured oesophageal cell-lines was studied by Whittles et al (1999). It was found 
that bile salts effected apoptosis during acidic conditions. Exposure to the bile 
salt DCA caused the most apoptosis in the oesophageal cell-lines and also caused 
the most disruption to intergrins within the cells. It is thought that compared to 
normal controls, patients with Barrett's oesophagus have high levels of DCA in 
oesophageal aspirates. Bile salts such as TDC cause extensive damage to the 
oesophageal mucosa barrier (Whittles 1999). 
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The expression of the components of the plasminogen activator system, uPA, uPA 
receptor and the inhibitors PAI-1 and PAI-2 were assessed using 
immunocytochemistry in oesophageal cell-lines treated with bile salts and 
acidified growth media. Staining for the components of the plasminogen system 
was localised to the cytoplasm of the cells. In OE21 the staining for uPA was 
localised around the nucleus of the largest cells in the treated samples as well as 
the non-treated controls. Staining for uPA in OE33 was seen universally 
throughout the cytoplasm of both the treated and non-treated cells. There was 
some staining for the inhibitors in the nuclei of the cells, but no significant 
changes were seen with exposure of the cells to either bile salts or acidic 
conditions. 
It has been shown in chapter 5 that changes in the expression of the components 
of the plasminogen system are a late event during the progression of Barrett's 
oesophagus to adenocarcinoma. These molecules are expressed when a large 
amount of oesophageal damage has occurred and dysplasia or in situ carcinoma 
is already present/ in the mucosa. Gastro-oesophageal and duodenogasro- 
oesophageal reflux are thought to cause the epithelial changes seen in patients 
with Barrett's oesophagus. The oesophageal cell-lines are derived from tumour 
samples from patients who have undergone resection (Rockett 1997). There is 
increased expression of the components of the plasminogen system in tumours 
and therefore the levels are high in the cell-lines. Exposure to bile and acid 
conditions appears to have little effect on these molecular markers. 
In cells treated with acidified growth media and bile salts the expression of two 
adhesion molecules, CD44 and E-Cad, were assessed using 
238 
immunocytochemistry. In the non-treated controls the immunocytological 
staining was localised to the plasma membranes of the cells. Once cells had been 
treated with either acidified media or bile salts in acidified media the staining for 
both CD44 and E-cad was significantly less. CD44 and E-cad are adhesion 
molecules and are involved in cell to cell interactions. As mentioned earlier cells 
exposed to acidified media became detached from the surface of the flask. This 
was most obvious in the cell-line OE33. Growth media of pH5 disrupted the 
adhesion molecules on the surface of the cells causing the cells to shrivel and 
shrink. As discussed previously (Chapter 6) levels of E-cad are low in OE33 and 
in some cases cells have lost adhesion properties before treatment with bile and 
acidic growth media. 
Cell membranes are made of a lipid bilayer matrix. Their lipid fractions consist of 
complex mixtures of lipids and proteins that vary according to the type of cell 
they are part of. Membrane proteins carry out dynamic processes associated with 
membranes and therefore vary from cell to cell. Membrane proteins are classified 
according to how tightly they are associated with the membrane. Intrinsic 
proteins are tightly bound to the membrane by hydrophobic interactions and can 
only be separated by treatment with agents that disrupt the membranes such as 
detergents, (e. g. CHAPS). Extrinsic proteins are dissociated from the membrane 
by relatively mild procedures that leave the membrane intact (e. g. changes to 
pH). 
In this study changes to the pH of the growth media alters the levels of the 
membrane bound proteins CD44, E-cad, and uPAR. It is possible that in the 
normal mucosa of the oesophagus gastro-oesophageal and duodenogasro- 
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oesophageal reflux causes the membrane bound proteins such as CD44, E-Cad 
and integrins (Whittles 1999) to become dissociated from the membrane. 
Proteins bear numerous functional groups such as carboxyl and amino groups 
that can undergo acid-base reactions, therefore many properties of these 
molecules vary with the acidity of the solutions into which they are immersed. 
The exposure of cells to acidic conditions in the oesophagus and in these 
experiments could effect the way the proteins tested function in ways that could 
not be detected with immunocytochemistry and ELISA techniques. 
The effects of free bile acids (cholic, deoxycholic and chenodeoxycholic acids) have 
been studied in the small intestine. These bile acids inhibit the main active 
transport system for glucose, amino acids and sodium in the small intestine and 
cause extensive damage with loss of villi (Nehra 1999). 
It has been suggested that bile acids damage the mucosa not by a detergent effect 
on the surface membrane, but by being adsorbed into the epithelial cells, causing 
disorganisation of the intracellular membranes and interfering with cellular 
metabolism (Marshall 1997). 
The role that the various components of duodenal juice play in the development 
of oesophageal injury has been the subject of may experimental animal studies. 
Attempts have been made to define the roles of hydrochloric acid, pepsin, bile 
salts and trypsin alone and in combination (see table 7.4). 
These studies show that more oesophageal damage is induced by bile acids in the 
presence of acidic conditions or the presence of HC1. Incidence of the damaging 
effects of duodenal contents on the oesophageal mucosa in humans remains less 
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clear-cut as there is no reliable technique for detecting duodenogastro- 
oesophageal reflux. Various direct and indirect methods have been used, but all 
have their drawbacks. pH monitoring is the most widely used method to detect 
reflux from the duodenum, but the results are full of contradiction. 
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Table 7.4. Summary of animal studies investigating the effect of gastric 
and duodenal contents on oesophageal mucosa. 
Abbreviations: HC1= hydrochloric acid, TCA = taurocholic acid, TDCA taurodeoxycholic 
acid, CA cholic acid, DCA = deoxycholic acid, CDCA = chenodeoxycholic acid. 
(Adapted from Marshall et al 1997). 
Reference Year Substances Extent of damage 
tested 
Henderson et al 1972 HC1, TCA, TDCA, HC1+ bile salt > HCl or bile salt 
GCA alone 
Kivilaakso et al 1980 TCA, DCA, CDCA, TCA at pH 3.5 and DCA or 
Pepsin, CDCA at pH7 > pepsin at pH 
Lysolecithin 3.5 > lysolecithin. 
Harmon et al 1981 TDCA, TCA, CA, HC1 alone damages at pH1, 
DCA, HC1 TDCA and TCA at pH 2, DCA 
and CA at pH 7. 
Salo et al 1983 HCI, Pepsin, TCA, Pepsin or TCA + HCl > pepsin 
DCA or TCA alone. 
Kiroff et al 1987 TCA, HCl TCA + HC1 > TCA alone. 
Gotley et al 1992 "Bile acid Bile acids + pepsin = pepsin > 
mixture", pepsin bile acids alone. 
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A study by Nehra et al tried to determine the spectrum of bile acids refluxed in 
patients with GORD and its relation to oesophageal pH using combined 
oesophageal aspiration and pH monitoring. It was found that the predominant 
bile acids detected were cholic, taurocholic and glycocholic, but there was 
significantly greater proportion of secondary bile acids, deoxycholic and 
taurodeoxycholic acids in patients with erosive oesophagitis and Barrett's 
oesophagus/stricture (Nehra 1999). A consistent finding of secondary bile acids in 
patients with Barrett's oesophagus suggests that these bile salts may contribute 
to the metaplastic change. 
The overall results of this small study into the effects of bile acids and pH on 
molecular markers for Barrett's oesophagus back up those of previous studies. 
There were more morphological and molecular changes in cells treated with both 
bile acids and lowered pH than those treated to bile salts alone. The most 
changes were seen in cells treated with taurocholic bile acids (TDC, TCA and 
TCDA). Changes were also seen in cells treated with DCA. These bile salts have 
been detected in patients with GORD, oesophagitis and Barrett's oesophagus and 
therefore could be implicated in causing the oesophageal damage associated with 
these disorders. 
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8 General Discussion and Future Direction 
8.1 Adenocarcinoma of the oesophagus in patients with Barrett's 
oesophagus 
The diagnosis of oesophageal cancer carries a dismal prognosis with an overall 
five year survival of less than 10%. The incidence of oesophageal squamous cell 
carcinoma has remained constant over the past 20 years, whereas the incidence 
of oesophageal adenocarcinoma is increasing rapidly. The reasons for this change 
from a predominance of one histological type of cancer to another are largely 
unknown. It has been suggested that all oesophageal adenocarcinomas arise in 
areas of metaplastic epithelium in which the normal squamous mucosa is 
replaced by specialised intestinal like columnar epithelium known as Barrett's 
oesophagus. It is thought that there is a progression in this abnormal epithelium 
through various degrees of dysplasia to neoplasia. The factors influencing this 
progression are poorly understood. 
Barrett's oesophagus is usually diagnosed in patients undergoing endoscopy for 
gastro-oesophageal reflux symptoms. The diagnosis can only be carried out in 
these biopsy samples using histological techniques. As mentioned earlier 
Barrett's metaplasia can be easily identified by endoscopic surveillance, but the 
detection of dysplasia alone by endoscopy is difficult, because it has no 
distinguishing endoscopic characteristics. A better understanding of the 
molecular characteristics of Barrett's metaplasia, dysplasia and adenocarcinoma 
could generate more sensitive diagnostic methods for malignant change. 
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8.2 Molecular Markers for the Progression of Barrett's 
Associated Cancer. 
The current knowledge of the molecular characteristics of Barrett's oesophagus 
are summarised in section 1.15 and include various molecules such as tumour 
suppresser genes, markers of cellular proliferation, oncogenes, growth factors, 
enzymes and adhesion molecules. As yet no single molecular marker or group of 
markers have been found to reliably diagnose the neoplastic progression in 
Barrett's oesophagus. Therefore dysplasia in biopsy samples can only be 
diagnosed using histological techniques. This study has focused upon two 
molecular markers; the components of the plasminogen activator system as a 
measure of invasiveness and telomerase as a measure of cellular immortality. 
Over the last 20 years extensive research has been carried out to investigate the 
role of proteolytic enzymes in tumour cell biology. The serine protease system 
consists of plasminogen, which is converted to plasmin by two activators; 
urokinase-type plasminogen activator and tissue-type plasminogen activator. The 
urokinase-type activator is thought to have a greater role in the mechanism of 
tissue invasion and is active at a cell surface receptor. Two naturally occurring 
inhibitors, PAI-1 and PAI-2 inhibit the activity of this binding. There are no 
published reports of the levels of the components of the PA system in Barrett's 
oesophagus or associated cancers. 
Another characteristic feature of many tumours is the absence of programmed 
cell death and the resultant cellular immortality. The activity of telomerase is 
critical in the prevention of DNA damage and cell death. In most normal somatic 
tissues telomerase expression is suppressed, but it is reactivated during tumour 
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development and is thought to be a potential marker of the development of a 
malignant phenotype. There are currently no extensive studies of telomerase 
activity in the progression of Barrett's oesophagus to adenocarcinoma. 
This work has investigated several areas of cancer biology relevant to 
oesophageal adenocarcinoma where there is no previously published work. The 
levels of the components of the plasminogen system in the progression of 
Barrett's associated cancer are described for the first time. Also there are no 
other studies of the relationship between telomerase activity and the 
plasminogen activator system in any tumour type. 
8.3 Telomerase and Barrett's Associated Adenocarcinoma 
Here a study has been carried out into the activity of telomerase during the 
metaplasic-dysplasic-neoplastic progression of Barrett's oesophagus utilising the 
TRAP method of analysis. Telomerase activity increases as the disease 
progresses. Telomerase reactivation appears to be an early event during the 
progression of Barrett's associated adenocarcinoma. Telomerase activity is 
present in intestinal metaplasia, but not in the other non-dysplastic Barrett's 
metaplasia. It has been suggested that it is the intestinal metaplasia that 
progresses to dysplasia and adenocarcinoma and therefore telomerase activity 
could be a useful molecular marker for finding patients who's disease is starting 
to progress. 
The diagnostic tool utilised here (the TRAPEZETM ELISA) is a simple test that 
could in the future detect telomerase in exfoliated cells from the oesophagus. In 
some institutions an endoscopic brush or balloon is used during surveillance to 
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collect cells from the surface of the oesophagus of patients with minimal 
discomfort. Currently two studies have looked at the possibility of diagnosing 
Barrett's oesophagus using balloon cytology (Fennerty 1995 and Falk 1997). Both 
studies observed the abrased cells microscopically for abnormalities and the 
results were disappointing, although the potential cost savings of balloon 
cytology compared to endoscopic cancer surveillance in Barrett's oesophagus 
support further studies into this technique. In the future Balloon abrasion for the 
collection of oesophageal cells and the use of molecular rather than cytological 
analysis may become a central procedure in the surveillance strategy for 
Barrett's oesophagus. 
The main disadvantage of using the TRAP method for analysing telomerase in 
clinical tissue samples is there is no way of telling exactly which cells within the 
tissue are expressing telomerase. Some of the resected tissue samples assessed 
during this study contained a range of tissue types. In order to get a complete 
picture of telomerase activity within the progression of Barrett's metaplasia to 
adenocarcinoma a non-isotopic method of in situ hybridisation for the detection of 
the RNA component of telomerase was developed. 
Three methods of in situ hybridisation for the detection of the RNA component of 
telomerase were investigated. The most successful of these was Method 3 loosely 
based on that described by Chang et al 1999 and utilised DIG labelled RNA sense 
and anti-sense probes detected by the reaction of the enzyme alkaline 
phosphatase with BCIP/NBT. In the future this method of non-isotopic in situ 
hybridisation could easily be utilised to carry out a full assessment of the 
localisation of telomerase in the metaplasia: neoplastic progression of Barrett's 
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oesophagus and its correlation with telomerase activity detected with the TRAP 
assay. 
8.4 The Components of the Plasminogen Activator System and 
Barrett's Associated Adenocarcinoma 
No previous studies have assessed the levels of the components of the 
plasminogen activator system during the progression of Barrett's oesophagus to 
adenocarcinoma. Here patterns have been shown in the cellular localisation and 
levels of the components of the plasminogen activator system. Changes appear as 
a late event during the progression of the disease showing the invasive phenotype 
of Barrett's oesophagus allowing cells to invade the basement membrane does not 
appear until severe dysplasia or neoplasia is present in the oesophagus. 
The components of the plasminogen system were detected using an ELISA based 
technique, so again these molecules could be detected in abrased cells from brush 
or balloon endoscopy. In the future detection of the components of the 
plasminogen system could be used as a diagnostic tool to assess patients with a 
poor prognosis and increased risk of metastasis. 
When plasminogen activator binds to its receptor or inhibitors it is incorporated 
into the cytoplasm of the cell (Naitoh 2000). Therefore even if the plasminogen 
activator antigen is detected in a certain location within the cell it does not mean 
it was produced there. This could be true for all the other components of the 
plasminogen system. For this reason identification of the mRNA of the 
components of the plasminogen activation system is needed. Messenger RNA can 
be detected within the cell utilising an in situ hybridisation method. In the future 
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this could be used to further enhance the knowledge of the expression and 
localisation of the components of the plasminogen activator system during the 
progression of Barrett's oesophagus to adenocarcinoma. 
8.5 Potential Clinical Benefits 
This study offers three main groups of potential clinical benefits for patients with 
or at risk of developing oesophageal cancer. These are diagnostic, prognostic and 
therapeutic. 
8.5.1 Diagnostic 
As mentioned there is considerable controversy over the way in which patients 
with Barrett's oesophagus should be managed within the NHS. Some hospitals 
use surveillance programs where patients undergo repeated endoscopy and 
biopsy in the hope of identifying the progression of the metaplasia to dysplasia, to 
allow early intervention before the development of malignancy. As a vast 
majority of patients with non-dysplastic Barrett's metaplasia do not go on to 
develop cancer the yield of these surveillance programs is very low. The analysis 
of telomerase activity and the components of the plasminogen activator system in 
biopsy samples may help to identify patients whose disease is starting to 
progress and maybe used in conjunction with standard pathological examination 
to provide a more accurate estimate of the risk of progression to cancer. 
8.5.2 Prognostic 
Many studies have been carried out relating the levels of expression of the 
components of the plasminogen system to prognosis in a variety of solid tumours. 
It is thought that tumours possessing the ability to overcome the extracellular 
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matrix and metastasise will behave more aggressively and give patients a poor 
prognosis. In the future the analysis of telomerase activity and measurement of 
the components of the plasminogen system in samples taken by biopsy or after 
resection may add to the prognostic accuracy and act as a guide to the clinician to 
recommend treatment for the patient. 
8.5.3 Treatment 
A novel technique in cancer therapy is proteolysis inhibition. There have been 
several phase three clinical trials of inhibitors of proteolysis in patients with a 
variety of cancers. The main target for inhibition with drugs is the matrix 
metalloproteinases system, which shows varying degrees of success. There are an 
increasing number of inhibitors of the plasminogen activator system under 
development some of which it is hoped will provide some therapeutic benefit to 
patients in limiting or preventing metastasis in tumours. The results presented 
here will add strength to the idea that Barrett's associated cancer should be 
included in the list of potential targets for these therapies. 
8.6 The Analysis of Immortal Cell-lines as in vitro Models of 
Oesophageal Cancers 
In order to produce in vitro models of the two main types of oesophageal tumours 
two oesophageal cell-lines were characterised, these were OE21 (squamous cell 
carcinoma) and OE33 (Barrett's associated adenocarcinoma). In order to 
characterise the cell-lines various methods of analysis were used to detect a 
number of previously studied molecular markers for these diseases. 
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Overall the molecular characteristics of the cell-lines correspond to those of the 
tumours from which they were derived. The cell-line OE33 seems a valid ex vivo 
model of Barrett's associated adenocarcinoma. The molecular characteristics of 
the squamous cell carcinoma cell-line OE21 were not as conclusive. There were 
differences in the molecules expressed in the cell-line when compared to those 
found in the studies of clinical cases. OE33 has more of the expected 
characteristics of an invasive cancer, whereas OE21 seems to express different 
characteristics to the related tumour. 
In the future these cell-lines could be utilised in studies for the treatment and 
diagnosis of oesophageal tumours, either as controls or for initial analysis of 
techniques. OE21 and OE33 could also be used as described in chapter 7 as in 
vitro models of oesophageal tumours analysing the effects of environmental 
changes on the molecular characteristics of oesophageal tumours. 
8.7 The Effect of Bile and Acid Exposure in Barrett's Oesophagus 
Both animal and human studies have suggested that hydrochloric acid is a major 
factor in oesophageal mucosa damage, but that bile acids and trypsin in synergy 
with each other and with hydrochloric acid play a significant role in the 
pathogenesis of Barrett's oesophagus. Here a small study into the effects of bile 
acids and pH on molecular markers for the progression of Barrett's oesophagus 
was carried out in two oesophageal cell-lines OE21 (derived from squamous cell 
carcinoma) and 0E33 (derived from Barrett's associated adenocarcinoma). 
The overall results of this small study back up those of previous studies. There 
were more morphological and molecular changes in cells treated with both bile 
251 
acids and lowered pH than those treated to bile salts alone. Most changes were 
seen in cells treated with taurocholic bile acids (taurodeoxycholic acid, 
taurocholic acid and taurochenodeoxycholic acid). Changes were also seen in cells 
treated with deoxycholic acid. These bile salts have been detected in patients 
with gastro-oesophageal reflux disease and Barrett's oesophagus and therefore 
could be implicated in causing the oesophageal damage associated with these 
disorders. 
The incidence of the damaging effects of duodenal contents on the oesophageal 
mucosa in humans remains unclear, as there is currently no reliable technique 
for detecting duodenogastro-oesophageal reflux. Various direct and indirect 
methods have been used previously, but all have their shortcomings. In this 
study human derived oesophageal cell-lines were used as an ex vivo model of the 
human oesophagus to analyse the effects of bile salts and pH on the oesophageal 
mucosa, but in the future in vivo studies will be needed to decipher the exact 
effects of acid and bile on the human oesophagus. 
In this study cells were only exposed to the environmental changes for a short 
period of time (1 hour) and either analysed then or grown for a further 18 hours. 
In the future this study could be extended using multiple exposures to the 
conditions or exposure for longer periods. Also the length of time after exposure 
could be extended to see if the bile acids or acidified growth media have long term 
effects to the cells. The effects of trypsin, pepsin and lysolecithin could also be 
assessed in cell-lines exposed to bile acids and lowered pH. 
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9 Conclusions 
The aim of this study was to investigate molecular markers for the progression of 
Barrett's oesophagus to adenocarcinoma with reference to the components of the 
urokinase-type Plasminogen Activator system and the reactivation of telomerase. 
The molecular characterisation of two oesophageal cell-lines was also carried out 
with the aim of producing ex vivo models of oesophageal cancer. 
Investigation into both telomerase activity and the plasminogen activator system 
have provided new information concerning the nature and timing of molecular 
changes which occur during the Barrett's metaplasia/dysplasia/adenocarcinoma 
sequence. 
The expression of the components of the plasminogen activator system is altered 
in Barrett's associated adenocarcinoma when compared to non-involved 
oesophageal and gastric mucosa. The progression of Barrett's oesophagus to 
adenocarcinoma is characterised by an increase in levels of urokinase-type 
plasminogen activator and its receptor and a slight decrease in its inhibitors 
type-1 and -2. 
The development of an immortal phenotype during the progression of Barrett's 
oesophagus to adenocarcinoma has been assessed. Telomerase appears to be 
reactivated early in disease progression in 50% of the intestinal type Barrett's 
metaplastic tissue assayed. Telomerase was detected in 76% of adenocarcinoma 
tissues assayed. A non-isotopic method of in situ hybridisation for the detection of 
the RNA component of telomerase has been successfully developed and utilised 
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on a small scale to investigate the cellular localisation of telomerase in Barrett's 
associated adenocarcinoma. 
The human oesophageal cell-lines OE21 and OE33 have been shown to have 
molecular characteristics similar enough to the malignant diseases to be used as 
ex vivo models of squamous cell carcinoma and Barrett's associated 
adenocarcinoma respectively. The treatment of these cell-lines with bile acids 
and acidified growth media demonstrated morphological and molecular 
alterations to their malignant characteristics. 
The aim of this thesis was the study of molecular markers for the progression of 
Barrett's oesophagus to adenocarcinoma, to identify markers that can be used as 
diagnostic tools. To some extent this aim has been achieved in that telomerase 
reactivation and the plasminogen system have been assessed as possible 
molecular markers for the progression of Barrett's oesophagus, but only 
telomerase detection has the potential to be used as a diagnostic tool for 
progression. In the future a randomised clinical trial of patients with intestinal 
metaplasia could be carried out to assess whether this potential is really relevent 
for diagnosing patients likely to progress to dysaplasia and adenocarcinoma of 
the oesophagus. 
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10 Publications Arising from this Study 
10.1 Abstracts 
Hewin D. F., Cadd V. A., Barr H., Warner P. J., Woodman A. C., Shepherd N. A., 
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junction. Association of Upper GI surgeons Meeting, Edinburgh. 
Cadd V. A., Shepherd N. A., Vipond M. N., Barr H., Warner P. J., and Woodman 
A. C. (May 2001). Telomerase and the plasminogen system during the 
metaplastic: neoplastic sequence of Barrett's oesophagus. Clinical Chemistry and 
Laboratory Medicine Vol. 39 S165 PO"F031. 
Cadd V. A., Licchesi J., Morgan S. L., Warner P. J., and Woodman A. C. (March 
2001). Putting molecular diagnosis into practise. Set for Britain, presentations by 
Britain's young scientists, The House of Commons, London. 
Cadd V. A., Shepherd N. A., Hewin D., Warner P. J., and Woodman A. C. 
(November 2000). Cellular distribution of urokinase-type plasminogen activator, 
its receptor, plasminogen inhibitor type-1 and -2 in the metaplastic neoplastic 
sequence of Barrett's oesophagus. Reporting back the results of R&D, NHS 
Executive South West. Abstract #19. 
Cadd V. A., Shepherd N. A., Barr H., Warner P. J., and Woodman A. C. (July 
2000). Development of an immortal phenotype in the metaplastic neoplastic 
sequence of Barrett's Oesophagus. Pathological Society of Great Britain and 
Ireland 181st Meeting Abstract #45. 
10.2 Papers 
None published at present, some papers in progress. 
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GLOUCESTERSHIRE 
HEALTH AUTHORITY 
Our Ref: k; r&d/Irecs/1999/wglrec/Outcome99_1OW(10.6)a 
Please ask for: Hazel Moynihan 
11 June 1999 
Professor Hugh Barr 
Consultant Surgeon 
Ward 9 
Gloucestershire Royal Hospital 
Great Western Road 
GL1 3NN 
Dear Professor Barr 
VICTORIA WAREHOUSE 
THE DOCKS 
GLOUCESTER GL1 2EL 
TEL: (01452) 300222 
FAX: (01452) 318800 
TEL: (Direct) 
" (01452) 
FAX: (Direct) 
(01452) 
99/10w: Investigation of cancerous and pre-cancerous changes in Barrett's 
Oesophagus using optical and microbiological techniques to advance the early 
diagnosis of malignancy 
Thank you for responding to the points that were made. We are satisfied that these meet 
the committee's requirements and I am therefore happy to grant you full approval to 
proceed subject to terms and conditions set out in our previous letter. 
Yours sincerely 
1 CA-/, UL-ýI 
Jane Maxwell 
Vice Chair, West Gloucestershire LREC 
cc Catherine Fulljames, Cranfield University, GRH 
11 
GLOUCESTERSHIRE 
"ýN40OAb- HEALTH AUTHORITY 
Our Ref: " 
k: r&d/Irecs/1999/wglrec/Outcome99_1OW(IO_6) 
Please ask for: Hazel Moynihan 
10 June 1999 
Professor Hugh Barr 
Consultant Surgeon 
Ward 9 
Gloucestershire Royal Hospital 
Great Western Road 
GL1 3NN 
Dear Professor Barr 
VICTORIA WAREHOUSE 
THE DOCKS 
GLOUCESTER GL1 2EL 
TEL: (01452) 300222 
FAX: (01452) 318800 
TEL: (Direct) 
" (01452) FAX: (Direct) 
(01452) 
99/1OW: Investigation of cancerous and pre-cancerous changes in Barrett's 
Oesophagus using optical and microbiological techniques to advance the early 
diagnosis of malignancy 
Thank you for attending the West Gloucestershire LREC yesterday with your colleagues. 
The committee gives you full approval to proceed subject to your submitting revisions to the 
Patient Information Sheet, Consent Form and Protocol. 
Specifically, the committee asked: - 
" That the protocol includes details of what the samples will be used for. 
" That the Patient Information Sheet be in a larger type face, and that some of the 
technical details of what happens to the samples be left out of the Patient Information 
Sheet. ' 
" That the Patient Information Sheet and Consent Form are on headed note paper. 
" The Consent Form should have provision for the subject to answer Yes or No to each of 
the sentences. 
The Committee draws your attention to: 
a) The responsibility of the investigator to notify the LREC immediately of any 
information received by him/her of which he/she becomes aware which would cast 
doubt upon, or alter, any information contained in the original application, or a later 
amendment application, submitted to the LREC and/or which would raise questions 
about the safety and/or continued conduct of the research. 
b) The need to comply with the Data Protection Act 1984. iii 
Chairman: Chris Creswick Chief Executive: Jeff James 
c) The need to comply, throughout the conduct of the study, with good clinical research 
practice standards. 
d) The need to refer proposed amendments to the protocol to the LREC for further 
review and to obtain LREC approval there to prior to implementation (except only in 
cases of emergency where the welfare of the subject is paramount). 
e) The requirement to furnish the LREC with details of the progress of the research 
project periodically (usually annually) and failure to do this could result in 
approval to continue with the study being withdrawn. Please also inform us of 
the conclusion and outcome of the research project and inform the LREC should the 
research be discontinued or any subject withdrawn altogether 
A list of the members of the West Gloucestershire LREC may be supplied if required. 
Yours sincerely 
Jane Maxwell 
Vice Chair, West Gloucestershire LREC 
cc Catherine Fulljames, Cranfield University, GRH 
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THE INSTITUTE OF MEDICAL SCIENCES 
CranUeld UNIVERSITY 
PROTOCOL 
GLOUCESTERSHIRE 
ROYAL NHS TRUST 
DONATION OF SAMPLES TO INVESTIGATE OPTICAL & 
MOLECULAR BIOLOGY TECHNIQUES TO ADVANCE THE 
EARLY DIAGNOSIS OF MALIGNANCY 
The samples must be processed as soon as is practically possible. 
Samples Required 
Samples of non-involved, inflammatory, Barrett's, dysplastic and malignant oesophagus. 
Equipment 
Cryogenic vials, liquid nitrogen, pathology cards (for biopsy samples) and logbook (for 
resection material) will be provided. A password-protected database will be used to store 
patient details and assign a unique patient identification number, which is then used in the 
labelling of the samples. 
Collection of biopsy samples 
1. Inform the patient about the project and tissue donation. 
2. Obtain signed consent to obtain tissue samples for research. 
3. Fill in patient details on a pathology card (or use a sticker from their notes), the 
assigned patient identification number and the date of collection. 
4. Take the samples during routine surveillance endoscopy. Place the biopsies on card in 
the cryovials. These are labelled with the patient identification number, tissue type 
and sample name. 
5. Place the vials in liquid nitrogen at once to snap freeze the samples. Retain the 
samples in the liquid nitrogen store until required. 
6. When the samples are used frozen H&E sections will be cut for histopathological 
analysis. 
Collection of resection samples 
1. Inform the patient about the project and tissue donation. 
2. Obtain signed consent to obtain tissue samples for research. 
3. Fill in patient details in log-book (or use a sticker from their notes), the assigned 
patient identification number and the date of collection. 
4. Take the samples during routine pathological analysis. Place the biopsies on card in 
the cryovials. These are labelled with the patient identification number, tissue type 
and sample name. 
5. Place the vials in liquid nitrogen at once to snap freeze the samples. Retain the 
samples in the liquid nitrogen store until required. 
6. When the samples are used frozen H&E sections will be cut for histopathological 
analysis. 
The samples collected as detailed above will be used in the following ways: - 
Optical Investigation of Samples 
Optical analysis will involve the measurement of samples using Raman, Infrared and 
other spectroscopic techniques. The spectra will be correlated with the pathology as 
determined from the H&E stained frozen sections. A spectral library will be built and its 
validity tested. 
Molecular Biology Investigation of Samples 
Molecular characterisation of oesophageal cell lines and human tissue from each of the 
stages in the Barrett's adenocarcinoma sequence will be carried out using molecular and 
cellular techniques. These include immunoassay, PCR, immunohistochemistry, in situ 
hybridisation. Markers to be examined include oncogenes, adhesion molecules, tumour 
supressors and telomerase. 
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THE INSTITUTE OF MEDICAL SCIENCES 
Cranfield NIVLRSITY 
GLOUCESTERSHIRE 
ROYAL NIIS TRUST 
PATIENT INFORMATION 
DONATION OF SAMPLES TO INVESTIGATE OPTICAL & 
MOLECULAR BIOLOGY TECHNIQUES TO ADVANCE THE 
EARLY DIAGNOSIS OF MALIGNANCY 
Background 
The staff of Gloucestershire Royal Hospital and scientists at Cranfield University are 
working together to find new ways of providing advanced clinical support for the local 
community. 
An area where we feel we can make major advances is in improving our ability to detect 
oesophageal disease, pre-cancer and cancer. Using advanced rapid tests we hope to be 
able to easily detect this disease without the need to bring patients into hospital or 
undergo long uncomfortable procedures. 
Before these investigations can be carried out on patients, it is necessary to assess its 
suitability with human tissue in the laboratory. 
Please help us. 
Your doctor has explained to you that he/she will be removing some oesophagus tissue 
during the course of your care. Specialist staff within the hospital will examine this tissue 
and your care guided by what they find. After all these examinations have been 
undertaken there may be a small amount of tissue remaining. If you are willing to allow 
us, we'can use this tissue to help us develop new diagnostic tests. 
Your care, treatment or method of assessment will not be altered in any way by your 
decision to donate or otherwise. Furthermore no additional procedures will be undertaken 
as a result of your consent. 
We will be collecting samples from many people under surveillance for Barrett's 
oesophagus. Therefore this request does not mean that your diagnosis is unsure. 
Thank you for your help and co-operation. If you have any questions please ask 
your doctor or contact Professor II. Barr, Ward 9, Gloucestershire Royal Hospital. 
Tel: (01452) 394679 
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THE INSTITUTE OF MEDICAL SCIENCES 
CranUeld 
NIvERsrrv 
GLOUCESTERSHIRE 
ROYAL NHS TRUST 
CONSENT FORM 
DONATION OF SAMPLES TO INVESTIGATE OPTICAL & 
MOLECULAR BIOLOGY TECHNIQUES TO ADVANCE THE 
EARLY DIAGNOSIS OF MALIGNANCY 
"I have read the attached information leaflet, discussed it with 
my doctor and fully understand what is required. YES / NO 
"I request that any. tissue samples taken during the course of my 
care at Gloucestershire Royal Hospital, may be made available 
for research after all procedures required for my clinical 
management have been completed. YES / NO 
"I understand that my care will be unaffected by my consent. 
YES / NO 
.......................................................... 
Name of Patient 
.......................................... 
Hospital Number 
........................................................... 
Signature 
Your doctor will retain this form. 
............................................. 
Date 
CONFIDENTIAL 
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Appendix 2: Suppliers and Equipment 
A) Suppliers 
Ambion, Austin, Texas, USA 
American Diagnostica Inc. Greenwich, CT. USA 
Amersham Life Sciences Ltd. Rainham Essex 
BDH, Poole, Dorset 
BioRad Laboratories Ltd. Hemel Hempstead, Herts 
Dako Ltd, High Wycombe, Bucks 
Gibco BRL/Life Technologies, Paisley 
Intergen Company, Purchase, NY, USA 
Invitrogen, Leek, The Netherlands 
Perkin Elmer, Warrington, Cheshire 
Promega, Madison, WI, USA 
Roche Molecular Biochemicals, Mannheim, Germany 
Sigma-Aldrich, Poole, Dorset 
Transduction Laboratories, Lexington, KY, USA 
Vector Laboratories Inc. Burlingame, CA, USA. 
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B) Equipment 
Balances - Sartorius Analytical BP110S and Salter Todd Oertling HC22 
Cell culture Incubator - Napco Environment controller 
Centrifuges - ALC Multispeed Refidgerated Centrifuge PK 131R 
Electroblotter - Hoefer Semiphor 
Electrophoresis - EmbiTech OneRun and Mini Protean II 
Hybridisation oven - Hybaid minioven MKII 
Laminar flow cabinet - Microflow Biological Safety cabinet MS 1425/2 
Microfuge - MSE Microcentur 
Microscopes - Nikon TMS Inverted Microscope and Zeizz Axioscope with 
Axiocam digital camera 
pH Meter - Orion Model 410A 
Plate reader - Dynex Technologies MRX 
Power packs - Hoefer EPS 2A200 
Rocking table - Stuart Scientific Platform Shaker STR6 
Stirrers - Bibby Scientific Magnetic Stirrer and Hotplate HB502. 
Thermal Cyclers - Hybaid Touchdown and Techne Genius 
UV Spec - WPA Lightwave 
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UV Visualisor - WP Transluminator and Syngene Gene Genius bio-imaging 
system. 
Waterbaths - Grant 
C) Consumables 
Consumable Source/Catalogue number 
ECL Western Blotting Detection 
Reagents 
Amersham Pharmacia Biotech RPN 
2106 
Polystyrene slide flasks BDH Merck (NUNQ 402/0333/04 
Tissue culture flasks T25 BDH Merck 402/0311/04 
Tissue culture flasks T75 BDH Merck 402/0311/08 
Protein Dye Concentrate Bio-Rad 500-0006 
Glass Slide flasks BDH Merck 402/0333/02 
RPMI 1640 medium Fwith L-glutamine, 
sodium bicarbonate) 
Sigma R-8758 
Amphorericin B 250gg/ml Sigma A-2942 
Foetal Calf Serum Sigma F-7524 
10,000units/ml penicillin/10mg/ml 
streptomycin 
Sigma P-4333 
10x solution trypsin/EDTA Sigma T-4174 
Glycocholic acid (GCA) Sig a G-7132 
Deoxycholic Acid (DCA) Sigma D-6750 
Glycochenodeoxycholic acid (GCDA) Sigma G-0759 
Glycodeoxycholic acid (GDC) Sigma G-3258 
Taurodeoxycholic acid (TDC) Sigma T-0875 
Taurochenodeoxycholic acid (TCDA) Sigma T- 6260 
_ TRAPEZE ELISA Telomerase detection 
kit 
Intergen S7750 
IMUBIND uPA ELISA kit American Diagnostica #894 
IMUBIND uPAR ELISA kit American Diagnostica #893 
IMUBIND PAI- 1 ELISA kit American Diagnostica #821 
_ IMUBIND PAI-2 ELISA kit American Diagnostica #823 
Precision molecular mass standard BioRad 170-8207 
Trireagent Sigma T-9424 
PBS Tablets GibcoBRL 18912-014 
_ RNase Zap Ambion #9780 
RNase Zap Wipes Ambion #9786 
NucAwayTm Spin Columns Ambion #10070 
mRNAlocatorTm-Hyb Kit Ambion #1800 
mRNAlocator; Tm-Biotin Ambion #1805 
_ MAXIscriptTm SP6/T7 Kit Ambion #1308 
_ Nuclear Fast Red Vector Laboratories H-3403 
_ VectaMountTm Vector Laboratories H-5000 
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Alkaline Phosphatase Substrate kit IV 
BCIP/NBT 
Vector Laboratories SK-5400 
Ultramount Dako S1964 
Histoclear Fisher Chemicals H/0468/17 
HybriSlips Plastic coverslips Sigma H-0784 
DIG RNA Labeling kit (SP6/T7) Roche 1175 025 
DIG Wash and Block Buffer Set Roche 1585 762 
DIG Easy Hyb Roche 1603 558 
BM Purple AP Substrate Roche 1442 074 
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Appendix 3: Solutions 
Solutions for Immunohistochemistry 
Tris Buffered Saline (TBS) 
0.05M Tris; 0.15M Sodium Chloride pH 7.6 
Phosphate Buffered Saline 
Made with sterile tablets (GibcoBRL Life Technologies). One tablet per 
500m1 RO water. 
Rabbit Serum Block 
1 part rabbit serum to 5 parts PBS 
Antibody Diluent 
1% Rabbit serum in PBS 
Endogenous peroxidase blocker 
3% Hydrogen peroxide in methanol. 
DAB Solution 
50mg DAB plus 100µl Hydrogen Peroxide in 100ml TBS. 
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Solutions for Western Blotting 
Run buffer 
25mM Trzma Base; 250mM lycine; 0.1% (w/v) SDS 
Sample Buffer 
100mM Tris-HC1, pH 6.8; 4% (w/v) SDS; 20% (v/v) Glycerol; 2% (w/v) 
Bromophenol Blue. 
Transfer Buffer 
10mM Tris-HCI; 10mM Glycine; 0.1% (w/v) SDS; 20% (v/v) Methanol 
Block Buffer/Antibody Diluent 
5% (w/v) Marvel /TBS 
Wash buffer 
0.5% Tween 20/TBS 
Solutions for Nucleic acid electrophoresis 
TAE Buffer 
50X Stock TAE: 605g Trizma Base; 36.5g EDTA (acid free); 125m1 glacial 
Acetic Acid made up to 2.5litres with RO water. 
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Solutions for in situ Hybridisation 
20X SSC 
3M Sodium Chloride; 0.3M Sodium Citrate pH 7.0 
Solutions for bacterial cloning 
LB Broth 
1% (w/v) tryptone; 0.5% (w/v) Yeast Extract; 1% (w/v) Sodium Chloride, 
pH to 7.5 with Sodium Hydroxide. Antibiotic (Ampicillin) added 100µg/m1 
after autoclaving 
LB Agar plates 
15g11 agar was added before autoclaving and antibiotic (ampicillin) added 
at 100µg/ml when cooled to approximately 50°C before pouring onto 10cm 
plates. 
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Appendix 4: PCR Primers 
F= Forward (sense) primer; R= Reverse (anti-sense) primer; all written 5' to 3' 
E-Cadherin Primers 
4F: AGG CCT CCG TTT GTG GAA TC 
5R: CTT CAG CCA TCC TGT TTC TC 
,ß -Catenin Primers 
3F: AGC TGC TTT GAT GGA GTT GG 
3R: GCT ACT TGT TCT TGA GTG AAG G 
1F and 1R unknown gift from T Bailey. 
Actin Primers 
F: TGA CGG GGT CAC CCA CAC TGT 
R: CTA GAA GCA TTT GCG GTG GAC 
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Appendix 5: Plasminogen IHC Raw Data 
Abbrieviations: uPA = urokinase-type plasminogen activator, uPAr, urokinase-type 
plasmingeon activator receptor, PAM plasminogen activator inhibitor type-1, PAI-2 
plasminogen activator inhibitor type-2, and E-cad = Epithelial Cadherin. 
Grading of staining., -= negative, 4/- = weak, += moderate, ++ = strong and +++ = very 
strong. 
Sample Diagnosis PuPA MuPA uPAR PAM PAI-2 CD44 E-Cad 
1 Barretfs + + ++ + 
2 Barreft's + ++ + ++ 
3 Barreft's + 
4 Barreft's ++ ++ + + 
5 Barreft's + ++ + + ++ 
6 Barretfs + + 
7 Barreff's + + + 
8 BarreWs + + + + 
9 Barrett's + + +/- +/- +/. 
10 Barreft's + + 
11 Barreft's 
12 Barreft's + + 
13 Barreft's 
14 Barreft's 
15 Barreff's 
16 Barrett's 
17 Barreft's- + ++ ... ... 
18 Barreft's + + ++ + 
19 Barreft's + + + 
20 Cancer well diff ++ + ++ ++ 
21 Cancer lymph node + + ++ + ++ 
22 Cancer poorly diff + +/- - ... ++ ++ 
23 Cancer well diff ++ ++ ... ... ++ ++ 
24 Cancer Lymph node ++ ++ + ... ... + 
25 Cancer well diff ... ... ... 
26 Cancer Lymph node + +++ ++ 
27 Cancer poorly diff + ++ + + 
28 Cancer poorly diff + ++ 
29 Cancer mod diff ++ ++ ++ ++ ++ 
30 Cancer poorly diff ++ ++ ++ + ++ 
31 Cancer Lymph node ++ + ++ + 
32 HGD 
33 HGD + 
34 LGD 
35 HGD + ++ + ++ + 
36 HGD ++ ++ + ++ 
37 HGD ++ 
38 Barreft's + + 
39 HGD + 
40 HGD + + 
41 HGD + 
42 LGD + 
43 LGD 
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44 LGD + 
45 HGD 
46 LGD 
47 HGDILGD + + + ++ 
48 LGD + + + + + 
49 LGD + + + + 
50 HGD +/- + /- +/. 
51 HGD + + + - +/. ++ 
52 HGD + + + + +/- 
53 HGD +/- + +/- 
54 HGDILGD ++ ... ... 
55 LGD + + + + + 
56 HGD ++ ++ + + ++ + 
57 HGD + ++ ++ + ++ 
59 Barrett's +/- +/- +/- + + 
60 Barreft's + + + ++ + 
61 Barreft's + + + + 
62 Barreft's +/- + + 
63 Barreft's + + 
64 Barreft's + + + 
65 Barreft's ++ + + 
66 Barreft's + + + 
67 BarretCs + + 
68 Barreft's ++ 
69 BarretVs + 
70 Normal Oesophagus ++ 
71 Barreft's +/- 
72 BarretVs ++ 
73 Barreft's + 
74 Barreft's + 
75 Barreft's +/- 
76 Barreft's + 
77 BarretVs + + ++ + 
78 Barreft's ++ + + 
79 Barreft's + + + 
80 Cancer well diff + ++ ++ ++ 
81 Cancer Lymph node ++ ++ + 
82 Cancer pooriv diff ++ ++ ++ ... ... 
83 Cancer well diff + ++ ++ ++ 
84 Cancer Lymph node ... ... + ++ 
85 Cancer poorly diff ... ++ ++ ++ 
86 Cancer mod diff + +/- + + 
87 Cancer poorly diff ++ ++ ++ ++ ++ 
88 Cancer + + + 
89 Cancer + ... ... + 
90 Cancer Lymph node + ++ ++ ++ 
91 Cancer well diff + + ++ ++ ++ 
92 Cancer Lymph node + + ++ ... ... 
93 aancer poorly diff + + + ... ... 
94 Cancer poorly diff ... ... ... ... ++ 
95 Cancer poorly diff ++ ++ ++ + ++ 
96 Cancer poorly diff ++ ++ ++ ++ 
97 Cancer well diff ++- +++ ++ +++ 
98 Cancer poorly diff ++ ++ ++ - ++ 
_ 99 Cancer poorly diff ... ++ ++ ++ ++ 
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100 Cancer Lymph node + ++ ++ ++ 
101 Cancer poorly diff ++- ++ ++ ++ 
102 Cancer Lymph node ++ ++ ++ ++ ++ 
103 Cancer poorly diff + + + + 
104 ancer poorly diff ++ + ++ 
105 Cancer well diff ... ++ ++ 
106 Cancer Lymph node + ++ + + 
107 Cancer poorly diff + ++ ++ 
108 Cancer mod diff + + + ... ... + 
109 Cancer well diff ... .. ... ... ... 
110 Cancer ++ . + + ++ 
ill Cancer poorly diff +/- ++ ++ + 
112 Cancer well diff ++ ++ ... ++ 
113 Cancer +/- ++ ++ ++ 
114 Cancer mod diff ++ ++ + +++ ++ 
115 Cancer Lymph node ++ ++ 
116 Cancer + ++ ++ 
117 Cancer poorly diff ++ ++ 
118 Cancer Lymph node + ++ ++ 
119 Cancer well diff + + ++ ++ 
120 HGD +/- +/- +/. 
121 HGD ++ ++ + + 
122 HGD +/- +/. +/- + + 
123 Cancer poorly diff ++ ++ ++ ++ 
124 Cancer lymph node + + + ++ ++ 
125 Cancer well diff + ++ + ++ 
12-6 Normal Stomach + + + ++ 
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Appendix 6: Plasminogen ELISA Raw Data 
Antigen Levels in ng/mg protein 
Non-Involved Stomach 
uPA uPAR PAM PAI-2 
1 0.10 0.36 1.52 0.50 
2 0.09 0.61 2.80 0.50 
3 0.07 0.12 2.35 0.47 
4 0.16 9.00 1.00 34.00 
5 0.57 18.10 16.19 22.86 
6 0.07 0.03 1.97 22.30 
7 0.05 0.37 0.82 0.65 
8 0.11 0.03 3.16 0.50 
9 0.15 0.03 2.64 3.77 
10 0.16 0.16 3.22 0.66 
11 0.11 0.06 4.20 0.86 
12 0.13 6.88 2.50 2.50 
13 0.09 0.58 1.89 0.93 
14 0.08 0.62 0.93 2.17 
15 0.10 0.40 1.82 0.50 
16 0.17 1.38 2.90 10.73 
17 0.08 0.65 2.34 0.78 
18 0.17 0.72 2.27 0.41 
19 0.20 0.98 1.31 200 
20 0.13 0.62 2.00 0.50 
21 0.19 0.86 1.89 3.78 
22 0.08 0.98 3.68 0.79 
23 0.18 2.21 2.21 1.48 
24 0.15 2.30 0.81 1.84 
25 0.32 2.53 1.80 3.37 
26 0.25 1.86 2.19 3.58 
27 0.13 1.03 0.49 1.22 
28 0.14 1.42 2.75 2.28 
29 0.21 0.91 1.67 2.42 
30 0.15 0.99 2.04 1.79 
31 0.30 1.77 1.69 4.90 
Non-involved Oesophagus 
uPA uPAR PAT-1 PAI-2 
0.07 0.74 0.74 200 
0.05 1.12 0.81 200 
0.05 0.27 0.81 200 
0.24 1.87 1.33 3.5 
0.07 0.03 1.05 39.6 
0.10 0.138 1.72 62.1 
0.11 0.03 3.33 200 
0.05 0.94 1.62 200 
0.11 0.98 1.43 200 
0.04 0.26 0.71 200 
0.32 4.02 5.37 200 
0.08 0.34 1.17 200 
0.05 0.38 2.28 200 
0.12 0.25 1.18 200 
0.17 0.64 1.74 200 
0.46 1.57 2.29 200 
0.46 0.25 2.32 200 
0.11 0.75 10.97 200 
0.21 1.03 2.89 200 
0.31 1.39 1.54 75.1 
0.22 1.36 0.81 200 
0.28 1.88 1.50 200 
0.47 2.33 1.86 4.70 
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Non-dysplastic Barrett's Metaplasia 
uPA uPAR PAI-1 PAI-2 
1 0.20 0.03 3.00 4.00 
2 0.17 0.03 1.67 0.50 
3 0.16 1.35 1.08 1.62 
4 0.05 1.19 0.95 0.50 
5 0.27 1.71 1.42 1.65 
6 0.69 2.41 4.14 50.35 
7 1.13 3.75 157.5 95.00 
8 0.83 5.00 6.67 1.67 
9 0.10 0.34 1.68 0.50 
10 0.60 0.03 3.00 2.00 
11 0.21 0.03 3.45 1.38 
12 0.59 5.19 5.93 0.50 
13 0.62 3.08 6.15 35.39 
14 0.39 2.40 1.15 2.31 
Low Grade Dysplasia 
uPA uPAR PAI-1 PAI-2 
0.17 0.03 2.50 0.50 
0.36 0.03 3.03 0.50 
0.23 0.03 1.54 0.50 
0.17 0.53 1.28 0.85 
0.27 0.33 0.67 14.00 
0.25 1.67 3.33 5.83 
0.30 4.55 3.64 0.5 
0.82 0.91 3.64 6.36 
0.22 1.80 1.71 0.63 
0.63 2.11 4.21 200 
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High Grade Dysplasia 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
uPA uPAR PAI-1 PAI-2 
0.46 1.54 3.08 4.62 
0.28 0.35 2.76 2.07 
0.77 1.70 2.98 5.96 
0.48 0.03 2.40 9.60 
0.4 0.03 8.00 112 
0.39 0.39 3.08 9.23 
0.86 2.57 5.14 200 
0.75 0.51 2.29 67.43 
0.51 2.18 2.91 200 
0.71 2.86 7.14 200 
Adenocarcinoma 
uPA uPAR PAI-1 PAI-2 
0.28 0.90 0.30 3.40 
1.21 3.23 12.93 5.25 
1.19 5.17 4.79 200 
1.00 3.75 6.67 10.83 
2.37 5.05 38.45 33.01 
1.54 0.03 6.15 7.69 
1.55 4.78 13.22 3.65 
0.96 0.01 3.95 2.47 
0.64 2.03 5.8 5.80 
0.57 1.42 3.27 17.14 
1.39 2.38 6.96 17.39 
2.20 10.67 12.14 200 
0.59 5.08 2.30 1.64 
0.56 2.00 3.60 8.80 
1.03 5.59 89.39 4.69 
0.17 1.43 4.00 12.57 
0.26 1.07 2.42 3.18 
0.26 0.75 4.37 68.39 
1.28 3.99 11.28 200 
0.80 3.20 17.60 13.60 
1.97 12.28 11.93 14.04 
2.35 4.94 44.56 3.21 
0.87 6.51 6.79 2.83 
0.58 2.84 6.56 6.18 
0.93 4.51 5.13 10.77 
1.03 7.35 6.67 8.49 
0.94 8.51 20.43 1.70 
0.55 4.85 3.64 6.06 
0.79 5.56 21.17 4.62 
0.60 3.00 7.00 130 
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Appendix 7: Statistical Analysis of Plasminogen ELISA 
Standard Deviation reflects the varience of the data from the 
mean. 
Varience square of the standard deviation. 
Median middle value. 
Urokinase-type Plasminogen Activator 
N Stom N Oes Barrett's LGD HGD Cancer 
Number 31 23 14 10 10 30 
Mean 0.158 0.180 0.429 0.342 0.561 1.015 
Median 0.140 0.110 0.330 0.260 0.495 0.935 
Lower 
Quartile 
0.090 0.07 0.170 0.220 0.400 0.580 
Upper 
Quartile 
0.180 0.28 0.620 0.360 0.750 1.280 
Varience 0.010 0.02 0.102 0.046 0.038 0.366 
Standard 
Deviation 
0.100 0.141 0.320 0.214 0.196 0.605 
Standard 
Error of 
the mean 
0.018 0.029 0.086 0.068 0.062 0.110 
Urokinase-type Plasmingen Activator Receptor 
N Stom N Oes Barrett's LGD HGD Cancer 
Number 31 23 14 10 10 30 
Mean 1.359 1.035 1.896 1.199 1.216 3.569 
Median 0.790 0.940 1.530 0.720 1.025 3.490 
Lower 
Quartile 
0.400 0.270 0.30 0.03 0.350 1.715 
Upper 
Quartile 
1.420 1.390 3.080 1.800 2.180 5.065 
Varience 3.753 0.833 2.003 2.003 1.172 4.873 
Standard 
Deviation 
1.937 0.913 1.415 1.415 1.082 2.208 
Standard 
Error of 
the mean 
0.354 0.190 0.448 0.448 0.342 0.417 
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Plasminogen Activator Inhibitor Type-1 
N Stom N Oes Barrett's LGD HGD Cancer 
Number 31 23 14 10 10 30 
Mean 2.842 2.151 3.099 2.555 3.978 10.172 
Median 2.190 1.540 3.000 2.765 3.030 6.670 
Lower 
Quartile 
1.690 1.050 1.420 1.540 2.760 4.000 
Upper 
Quartile 
2.800 2.290 4.140 3.640 5.140 12.140 
Varience 8.800 4.792 4.222 1.427 4.233 104.261 
Standard 
Deviation 
2.967 2.189 2.005 1.195 2.057 10.211 
Standard 
Error of 
the mean 
0.533 0.456 0.570 0.378 0.651 1.896 
Plasminogen Activator Inhibitor Type-2 
N Stom N Oes Barrett's LGD HGD Cancer 
Number 31 23 14 10 10 30 
Mean 4.435 164.591 14.098 3.297 81.091 10.669 
Median 1.635 200 0.500 0.630 38.515 6.120 
Lower 
Quartile 
0.650 200 0.500 0.500 5.960 3.40 
Upper 
Quartile 
3.580 200 4 5.830 200 12.570 
Varience 62.597 4914.207 774.343 21.843 7952.423 185.195 
Standard 
Deviation 
7.912 70.101 27.827 4.674 89.176 13.609 
Standard 
Error of 
the mean 
1.444 14.617 7.437 1.558 28.2 2.669 
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